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Abstract 
 Numerous clinical and experimental studies have implicated tumour necrosis 
factor (TNF) as a central mediator of acute lung injury (ALI). TNF signals through two 
cell surface receptors, TNFR1 and TNFR2, which initiate distinct signalling pathways and 
cellular responses. Using a novel, highly selective TNFR1 domain antibody GSK1995057 
allied with TNF-receptor (TNFR) specific muteins, the work in this thesis investigated the 
roles of differential TNFR signalling in a range of human in vitro models of ALI using 
human lung microvascular endothelial cells (HMVEC-L), human alveolar type 2 cells 
(hAT2) and human neutrophils.  In particular we focused on the cascade of events, which 
lead to neutrophil migration into the alveolar space during ALI. The TNFR1 signalling 
pathway mediated HMVEC-L activation (neutrophil adhesion molecule expression and 
chemokine / cytokine release) and injury (trans-endothelial resistance). These effects were 
associated with an amelioration of neutrophil migration through HMVEC-L monolayers. 
TNFR1 signalling also played key roles in neutrophil priming, activation, and cell fate. 
TNFR1 signalling mediated TNF-induced alterations in neutrophil cell surface molecule 
expression and reactive oxygen species production. TNFR1 antagonism also reversed 
TNF induced late survival (20 hours) of human neutrophils. In an attempt to generate 
translational data investigating the effects of differential TNFR1 signalling, we 
established a human ex vivo model of ALI. Using an LPS method of injury we 
demonstrated release of the pro-inflammatory cytokines TNF, interleukin (IL-)-8, IL-6 
and IL-1β in the alveolar space. This was associated with a significant influx of healthy 
donor neutrophils and pulmonary oedema in LPS injured lung compared to control treated 
contralateral lung.  These data suggest a central role for TNFR1 signalling in ALI. 
Translation of these in vitro data in our human ex vivo lung model may provide the basis 
for future clinical trials of selective TNFR1 antagonism in ALI. (Words 295) 
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1 Chapter 1: Introduction 
1.1 Acute lung injury 
1.1.1 Clinical perspective 
 Despite almost 40 years of scientific research, outcomes in acute respiratory 
distress syndrome (ARDS) are comparable to breast cancer or HIV (Camporota, 2006; 
Rubenfeld et al., 2005) and no specific pharmacotherapy exists. ARDS, which was first 
described in by Ashbaugh and Petty in 1967 (Ashbaugh et al., 1967),  is characterised by 
acute inflammation that affects the function of the gas exchange surface of the lung, 
presenting clinically with acute onset of breathlessness and hypoxaemia in the presence of 
diffuse pulmonary oedema on the chest radiograph. A working definition of ARDS was 
established in 1994 by the American European Consensus Conference (AECC) (Bernard 
et al., 1994). This definition identified patients with bilateral pulmonary infiltrates and 
hypoxaemia (PaO2:FiO2 ratio of less than 300mmHg) as having acute lung injury (ALI). 
Those with more severe derangements of hypoxaemia (PaO2:FiO2 ratio of less than 
200mmHg) were given a diagnosis of ARDS. A recent report - called the Berlin definition 
(Ranieri et al., 2012) - recommends the use of three categories of ARDS, mild, moderate 
and severe based on the degree of hypoxaemia (table 1.1). Additionally, the exclusion of 
pulmonary oedema secondary to cardiac failure is now not mandated, positive end 
expiratory pressure (PEEP) is accounted for as an indicator of severity and a known risk 
factor for ARDS has to be present at onset.  Whether stratification of patients based on 
these revised descriptions will enhance clinical detection of ARDS remains to be 
determined. For the purposes of this thesis, the umbrella term acute lung injury will be 
used to encompass clinical and experimental definitions of ARDS. 
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Table 1.1 Berlin Definition of ARDS 
 Mild ARDS Moderate ARDS Severe ARDS 
Gas exchange PaO2:FiO2  201-300 mmHg PaO2:FiO2  ≤200 mmHg PaO2:FiO2  ≤100 mmHg 
PEEP PEEP≥ 5cm H20 PEEP≥ 5cm H20 PEEP≥ 10 cm H20 
Chest x-ray Bilateral opacities Bilateral opacities Bilateral opacities 
PaO2/FiO2: arterial partial pressure of oxygen/ inspired oxygen fraction PEEP: positive end 
expiratory pressure 
 
 Many conditions are associated with the onset of ALI. The risk factors for ALI can 
be divided into two groups depending on whether injury to the lung is direct such as 
pneumonia, or indirect blood-borne insults – for example, severe sepsis (Ware, 2006). 
Indirect injury, via blood-borne inflammatory mediators, is more common. Sepsis 
(including pneumonia) is the commonest risk factor (Hudson et al., 1995), as well as 
being the risk factor most likely to cause ALI. Risk of progression to ALI varies 
according to the type, number and severity of predisposing conditions, as well as the 
genetics and other characteristics of the patient (Marshall et al., 2002). Diagnosing and 
treating conditions that mimic or are associated with ALI is the first principal of 
successful management of these patients. 
 A prospective, population-based, cohort study in 21 hospitals in the USA over 14 
months in the late 1990s identified 1113 adults who met AECC criteria for ALI 
(Rubenfeld et al., 2005). The age-adjusted incidence of ALI was 86.2 per 100,000 person-
years. The in-hospital mortality rate was 38.5%; mortality was 24% for teenagers and 
60% for patients 85 years of age or older. More recent data collected between 2001 and 
2008 demonstrated that that the incidence of ALI in hospitalized adults declined from 
82.4 to 38.9 per 100,000 person-years during the study period (Li et al., 2011). A fall in 
hospital-acquired ALI was responsible for the observed decline as there was no change in 
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incidence of ALI on hospital admission during the study period. Improvements in 
healthcare delivery and process such as adherence to low-tidal volume ventilation and 
conservative use of blood products were sighted as possible reasons for the observed 
decline. Based on the most recent ARDS Network trials, a 60-day mortality of 22% has 
been reported despite higher severity of illness scores and a higher incidence of shock at 
enrollment compared with previous trial data (National Heart et al., 2011).  
 Once treatment of the precipitating condition and patient support has begun, 
prognostic factors relate to the patient’s response to therapy. Severe arterial hypoxemia 
(PaO2/FiO2 < 100mmHg) and an increase in the pulmonary dead space fraction (>0.60) 
are associated with higher mortality (Nuckton et al., 2002). Mortality rates correlate with 
the number of organ system failures, increasing to 83% when three or more are present. 
Complications appearing during the course of ARDS, including circulatory shock, acute 
renal failure and liver dysfunction, allied with age over 60 years are associated with a 
higher mortality (Liu et al., 2007; Cooke et al., 2008; Brown et al., 2011). The majority of 
late deaths are related to sepsis syndrome, present in 73% of ALI patients, in whom the 
predominant site of infection is the lung (Bachofen and Weibel, 1982). Several 
investigators have indicated that sepsis rather than respiratory failure is the leading cause 
of death in patients with ARDS (Montgomery et al., 1985; Luhr et al., 2000; Fein et al., 
1983; Doyle et al., 1995).  
 Most ALI patients either die or are weaned from supportive treatment within 1-2 
weeks, although up to 10% of patients require prolonged (30 days or more) mechanical 
ventilation. Lung function in most survivors returns to normal over 6-12 months although 
the majority have persistent, abnormal exercise endurance; the six minute walk distance at 
one, three and five years was 66, 67 and 76 percent of predicted respectively in a 
prospective study of 109 ARDS survivors (Herridge et al., 2011).  However, 
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neuromuscular and neurocognitive morbidity can significantly impair longer- term health-
related quality of life (Herridge et al., 2003; Hopkins et al., 1999; Wilcox and Herridge, 
2010). 
1.1.2 Pathogenesis of acute lung injury  
1.1.2.1 Epithelial activation and injury 
 The normal alveolar epithelium is composed of approximately equal numbers of 
flat type I cells (hAT1) which account for 95% of the alveolar surface area but only 8% of 
the total cells in the adult human lung and cuboidal type II cells (hAT2) which comprise 
15% of the total cells of the lung, but only 5% of the alveolar surface area (Crapo et al., 
1982). In contrast to hAT2, hAT1 are susceptible to injury and cell death. hAT2 have 
several critical functions, including surfactant production and ion transport. They also 
function as progenitor cells for regeneration of hAT1 cells after injury. Hence, alveolar 
epithelial injury has critical implications for the pathogenesis of ALI. Indeed, the extent of 
alveolar epithelial damage is an important predictor of outcome (Matthay and Wiener-
Kronish, 1990). Typical histological appearances include extensive necrosis of alveolar 
type I cells and the formation of protein-rich hyaline membranes on a denuded basement 
membrane.  
 Alveolar fluid clearance by hAT2 is primarily driven through sodium uptake on 
the apical membrane, followed by extrusion of sodium on the baso-lateral surface by 
Na+K+- ATPase (Matthay et al., 2000). Loss of alveolar epithelial integrity through 
apoptosis and necrosis of hAT2 results in the accumulation of protein-rich and highly 
cellular oedema fluid in the interstitium and alveoli. Furthermore, in vitro data suggest 
that inflammation further impairs fluid clearance through down-regulation of sodium and 
chloride transporters on epithelial cells (Lee et al., 2007).  
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 Loss of surfactant producing hAT2, allied with the effect of plasma proteins in the 
airspace, impairs surfactant turnover and production contributing to surfactant deficiency 
and dysfunction (Lewis and Jobe, 1993; Gregory et al., 1991). Surfactant is a complex 
mixture of phospholipids and proteins, which reduces alveolar surface tension preventing 
collapse of the airspace. Thus, abnormalities in surfactant production and function may 
contribute to the pathogenesis of ALI through exacerbation of atelectasis and impairment 
of gas exchange, increased oedema formation, and impairment of local host defense. This 
presents clinically with collapse of lung units and reduced lung compliance. 
 Epithelial cells also play a key role in regulating the inflammatory response in the 
alveolar space through: 
1. Production of injury-driven pro-inflammatory cytokines, including tumour necrosis 
factor (TNF), interleukins (IL) -1, -4, -6, -13, substance P, and platelet-activating 
factor (PAF) 
2. Release of chemokines including IL-8, monocyte chemotactic protein-1 (MCP-1), 
growth related oncogene-alpha (GRO-α), and epithelial-derived neutrophil-activating 
peptide 78 (ENA-78) 
3. Cell-cell interactions with resident lung cells, in particular alveolar macrophages. 
4. Expression of adhesion molecules, such as intercellular adhesion molecule 1 (ICAM-
1), to facilitate leukocyte trafficking into the alveolar space 
These processes are central to both the onset and progression of ALI (Bermudez and 
Goodman, 1996; Steinberg et al., 1994; Tate and Repine, 1983). Neutrophil migration into 
the alveolar space, in response to a chemokine gradient, further disrupts epithelial cell 
barrier function, fluid clearance and surfactant production. This occurs through the release 
of oxidants, proteases, leukotrienes, and other pro-inflammatory mediators (discussed in 
chapter 1.4.1).  
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1.1.2.2 Endothelial activation and injury 
 The pulmonary endothelium forms a continuous, tight barrier of squamous 
endothelial cells, which regulate fluid permeability as well as modulating host 
inflammation, vascular tone, angiogeneis and interactions with blood-borne cells. Loss of 
barrier integrity, characterized by the formation of reversible intercellular gaps between 
endothelial cells, is accepted as the ultra-structural basis for the increased permeability 
pulmonary oedema observed in ALI (Hurley, 1982). Hyper-filtration of plasma across the 
lung vascular bed results in the accumulation of protein-rich oedema in the interstitium 
and the alveoli, even in the context of normal lung vascular pressure (Calfee and Matthay, 
2007).  Gap formation is induced by the binding of mediators, including thrombin, 
thromboxane A2 and transforming growth factor beta (TGFβ) to their cognate receptors on 
the endothelial cell surface, which induces cytoskeletal rearrangement and endothelial 
barrier disruption. Sources of these mediators include platelets, leukocytes and epithelial 
cells.  Gap formation may also occur as a result of endothelial cell apoptosis in response 
to specific stimuli, such as endotoxin.  
 Similar to the alveolar epithelium, the lung endothelium orchestrates and 
propagates the inflammatory response. After stimulation by a range of mediators, 
endothelial cells release cytokines and chemokines, and up-regulate the expression of 
neutrophil (and platelet) adhesion molecules, such as ICAM-1, vascular cell adhesion 
molecule 1 (VCAM- 1) and E-Selectin. Leukocytes, attracted via a chemokine gradient 
accumulate in the microcirculation of the lung, where cytokine-induced cytoskeletal 
alterations reduce their deformability, promoting sequestration in the lung 
microvasculature (reviewed in chapter 1.4). Neutrophils, activated by local mediators and 
cytokines subsequently degranulate releasing toxic mediators, which can further increase 
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lung vascular permeability through alterations in focal adhesions, transmembrane 
integrins and the cytoskeleton of endothelial cells.   
 In response to a range of stimuli including hypoxia, cytokines, chemokines, and 
activated platelets and neutrophils, the pulmonary endothelium shifts from an anti-
thrombotic and anti-inflammatory phenotype to an activated state, characterized by pro-
thrombotic and pro-adhesive properties. Central to this transformation is the up-regulation 
and activation of tissue factor and loss of the ability to activate proteins C and S, resulting 
in capillary thrombosis and extra-vascular fibrin deposition, potentiating pulmonary 
dysfunction and the acute inflammatory response (Bastarache et al., 2006; Idell, 2003; 
Wang et al., 2008). It may also contribute to the increased dead-space fraction seen in ALI 
patients (Nuckton et al., 2002). 
Figure 1.1 Pathogenesis of acute lung injury  
Adapted from (Grommes and Soehnlein, 2011), ROS: reactive oxygen species, MMP: matrix 
metalloproteinases 
 
1.1.2.3 Ventilator associated lung injury 
 The application of mechanical ventilation, required in the majority of patients, 
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(VALI). Mechanical forces applied during ventilation cause physical disruption of the 
alveolar-capillary membrane leading to pulmonary oedema, whilst cyclical stretch that is 
insufficient to mechanically disrupt tissues, induces activation of cell-signalling pathways 
in epithelial, endothelial and inflammatory cells. These adverse effects, in the context of 
the injured lung, may result in cell death or the expression of pro-inflammatory and/or 
pro-fibrotic mediators (e.g. TGF β, TNF, IL-1β, IL-6, IL-8) (Stuber et al., 2002; Ranieri et 
al., 1999; Belperio et al., 2006). These pro-inflammatory mediators further propagate 
injury and phagocyte influx into the alveolar space, resulting in a pathophysiology that is 
indistinguishable from ALI of other aetiologies. The precise source, and indeed role of 
individual mediators remains unresolved. 
 The observation that injurious mechanical ventilation could also lead to the 
systemic release of inflammatory mediators into the circulation (Slutsky, 2005; Tremblay 
and Slutsky, 1998) as well as translocation of bacteria (Nahum et al., 1997) or endotoxin 
(Murphy et al., 2000) from the airspace into the bloodstream has led to the biotrauma 
hypothesis of VALI. Thus, in addition to local injury, VALI can drive systemic 
inflammation and extra-pulmonary organ damage. This is reflected in the fact that the 
majority of ARDS patients die from multi-system organ failure, as opposed to 
hypoxaemic respiratory failure (Stapleton et al., 2005; Vincent and Zambon, 2006).  
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Figure 1.2 Pathobiology of ventilator associated lung injury  
Adapted from (Slutsky and Ranieri, 2013), TGF β: transforming growth factor-β, TNF: tumour 
necrosis factor 
 The magnitude of the clinical burden of VALI was demonstrated by the ARDS 
Network study, in which 861 patients with ARDS were randomized to receive either a 
high tidal volume (12ml/kg predicted body weight), or a low tidal volume ventilation 
strategy (6ml/kg predicted body weight) (Network, 2000). The low tidal volume cohort 
demonstrated a 9% absolute reduction in mortality from 39.8 percent in the conventional 
group to 31 percent in the low volume group. There were also more ventilator- and organ 
failure-free days in survivors in the low volume group. 
1.1.2.4 Resolution of inflammation and repair of the injured lung 
 Following the acute inflammatory phase, most patients gradually recover normal 
physiology and lung function. In the alveolar epithelium, which is normally lined by 
approximately equal numbers of type I and type II cells, type II cells proliferate in 
response to stimulation by epithelial growth factors, including keratinocyte (KGF) and 
hepatocyte growth factors. Type II cells are also thought to act as progenitor cells for both 
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daughter type II cells and type I cells (Sannes, 1991), differentiating into type I cells in 
response to specific developmental cues. Local and bone marrow–derived stem cells, 
recruited to the injured lung by soluble factors (Rojas et al., 2005), may also contribute to 
repair (Lee et al., 2009; Kumar et al., 2011; Burnham et al., 2005). Collectively, these 
mechanisms combine to reconstitute the epithelial barrier and restore lung function.  
 However, if epithelial injury is severe, or epithelial repair is impaired, a 
fibroproliferative phase of ALI can ensue either following or in parallel with epithelial 
injury possibly through activation of proteinase-activated receptors (Jose et al., 2014; 
Howell et al., 2005). During this phase, mesenchymal cells proliferate, neovascularisation 
occurs and the alveolar space becomes filled with activated fibroblasts and myofibroblasts 
that synthesise excessive collagenous extracellular matrix. A small proportion of patients 
progress to a chronic phase of respiratory insufficiency characterized by widespread 
pulmonary fibrosis with disordered lung architecture and evidence of sub-pleural and 
intrapulmonary cysts (Gattinoni et al., 1994).  
 Resolution of inflammation in ALI occurs through clearance of alveolar 
neutrophils, monocytes, and necrotic debris from the distal airspaces of the lung. 
Macrophages remove apoptotic neutrophils and monocytes via a process called 
efferocytosis, involving phagocyte migration towards apoptotic cells, receptor adhesion, 
and ingestion (Bratton and Henson, 2011; McCubbrey and Curtis, 2013). Regulatory T 
cells may play an essential role in this process by enhancing neutrophil apoptosis and 
suppressing cytokine secretion, in part by release of TGF-β (D'Alessio et al., 2009). 
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1.1.3 Treatment of acute lung injury 
 Despite over 40 years of research, none of the pharmacological interventions 
developed and investigated in ALI have translated into measurable clinical benefit. 
Current best practice focuses on treatment of the precipitating insult, supportive therapy 
and the avoidance of complications, which add further insult to injury (Slutsky and 
Ranieri, 2013).  
 Owing to the heterogeneity of causes and biology of ALI, efforts to develop 
adjunctive treatments have largely focused on targeting specific aspects of the 
pathogenesis of ALI (reviewed in (Sweeney et al., 2013; Roch et al., 2013), for example, 
anti-inflammatory therapies. Despite promising experimental data supporting their 
potential efficacy, clinical trials of granulocyte-macrophage colony stimulating factor 
(GM-CSF), corticosteroids, antioxidants, and anti-cytokine therapies have failed to 
demonstrate a mortality benefit. Alternatively, agents have been aimed at improving 
physiological abnormalities in ALI; for example, diuretics and β2 agonists to minimise 
pulmonary oedema, vasodilators and anticoagulants to optimise alveolar perfusion, and 
surfactant and neuromuscular blocking agents to limit VALI.  With the exception of one 
recent trial of neuromuscular blockade (Papazian et al., 2010), none of these agents have 
demonstrated clinical benefit. More recently, investigators have focused on cell-based 
therapy to enhance alveolar repair (Matthay et al., 2010; Lee et al., 2009) and modulation 
of signalling pathways to reduce lung vascular permeability (London et al., 2010).  
 Numerous factors explain the failure of pharmacotherapy trials in ALI. Many of 
these issues relate to the logistics of researching and treating a heterogeneous population 
with a range of underlying pathologies and comorbidities, suffering from a syndrome with 
no definitive diagnostic test or biomarker. Nonetheless, there are unquestionably 
deficiencies in the translation of promising experimental data into clinically effective 
35 
 
 
therapies, in part, is due to limitations of the currently available pre-clinical (animal) 
models of ALI (Matute-Bello et al., 2008; Bastarache and Blackwell, 2009).  
1.2 Current experimental modelling of acute lung injury  
1.2.1 Animal models 
 Animal models are invaluable in the study of complex syndromes such as ALI, 
allowing the testing of hypotheses in complex biological systems. Rodent ALI models, in 
particular, have revealed important biologic mechanisms underlying the temporal 
sequence of injury, inflammation and dysregulated repair.  
 In parallel with the aetiologies of human ALI, animal models are broadly divided 
into those inducing direct and indirect injury. Modes of direct injury include noxious 
stimuli (e.g. intra-tracheal or intranasal administration of bacteria, or bacterial products 
such as lipopolysaccharide (LPS)) to model pneumonia, the administration of intra-
tracheal acid to reproduce aspiration pneumonitis, and simulation of VALI using high 
tidal volume ventilation. Indirect injury models include sepsis models such as caecal 
ligation and puncture (CLP) and the administration of intravenous bacteria or LPS or 
intravenous oleic acid model, which simulates the release of bone marrow fats in ALI 
patients following long bone fracture.  
 The injury in these models broadly targets either the capillary endothelium or 
alveolar epithelium (Matute-Bello et al., 2008). Although each can reproduce components 
of the key pathological changes that occur in ALI, none is capable of fully recapitulating 
the clinical features. For example, although LPS administration elicits a neutrophilic 
inflammatory response with an increase in intrapulmonary cytokines, changes in alveolar-
capillary permeability are mild (Wiener-Kronish et al., 1991). In fact, of the currently 
available animal models, only acid aspiration, transfusion associated lung injury (TRALI) 
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and VALI models mimic human aetiologies of ALI to a reasonable extent. Combination 
models using two mechanisms of injury, such as surfactant depletion and high tidal 
volume ventilation, might overcome some of these failings.  Recapitulating the 
coagulation and fibrinolytic abnormalities of ALI, in particular, continues to pose a 
scientific challenge. 
 Despite extensive study in current animal models, none of the pharmacological 
interventions developed has translated into measurable clinical benefit. Additional 
limitations might therefore exist – for example, there are fundamental differences in 
anatomy and physiology between humans and both small and large animals. Indeed, 
comparative proteomic analysis between bronchoalveolar lavage fluid (BALF) from an 
ALI patient and a mouse model of ALI identified only 21 homologous proteins (Gharib et 
al., 2010). In addition, airway architecture and pleural anatomy show marked differences 
(Albertine et al., 1984; Shapiro, 2006), and normal rates of alveolar epithelial fluid 
transport differ markedly across species (Matthay et al., 1985; Sakuma et al., 1997; 
Smedira et al., 1991). Primate studies are more closely representative of human disease 
but are logistically complicated, financially prohibitive and fewer genetic and genomic 
tools are available. A further drawback of animal models is interspecies difference in host 
immune response to epithelial injury and the coagulopathy of ALI (Bastarache and 
Blackwell, 2009). Animal size places limitations on sampling volume of, for example, 
blood and BALF, as well as obtaining accurate physiological measurements. Modelling of 
established, severe ALI presents logistical problems in the provision of prolonged 
intensive care to critically ill rodents; most animals die from shock or hypoxemia. Finally, 
there are no robust biomarkers in animal models of ALI that translate into the human 
syndrome, and vice versa. Despite these limitations, animal models will continue to have 
a considerable role in the study of ALI for the foreseeable future, principally because few 
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alternatives allow investigation (including imaging modalities) and therapeutic testing in a 
complex biological system.  
1.2.2 Human models  
1.2.2.1 In vivo models  
 One lung ventilation (OLV) is a technique used in thoracic surgery describing 
ventilation of a single lung, allowing the other one to collapse. The method optimises 
surgical access during lung resection and oesophagectomy procedures. OLV is associated 
with pulmonary inflammation, reflecting what is defined as subclinical ALI in most 
patients (Moloney et al., 2004). The majority of the pathophysiological features of OLV-
induced ALI, including endothelial and epithelial dysfunction, neutrophil infiltration and 
vascular congestion, are common to ALI of other aetiologies (Carden and Granger, 2000; 
Her and Mandy, 2004; Jordan et al., 2000; Yin et al., 2007). The incidence of ALI after 
lung resection is 2-4% after lobectomy and up to 8% after pneumonectomy, with a 
mortality of 40-60% (Alam et al., 2007; Dulu et al., 2006; Kutlu et al., 2000; Ruffini et al., 
2001). The incidence of ALI after oesophagectomy in a single centre study was 23.8% 
(Tandon et al., 2001).  
 Pulmonary dysfunction following cardiopulmonary bypass (CPB) is common, 
with ALI occurring in 2% of patients. Causative mechanisms include ischaemia-
reperfusion, endothelial dysfunction, systemic inflammation and atelectasis (Dodd-o et al., 
2004; Fan et al., 2006; Syed et al., 2004). Analysis of intra-operative lung specimens 
showed evidence of alveolar oedema, extravasation of erythrocytes and neutrophils, and 
congested alveolar capillaries (Wasowicz et al., 1999). Electron microscopy demonstrated 
swollen and necrotic pneumocytes and endothelial cells (Wasowicz et al., 1999).  
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 The elective nature of surgery affords an opportunity to identify a cohort of 
potentially predictable ALI patients for future study. Indeed, the efficacy of 
hydroxymethylglutaryl-CoA (HMGCoA) reductase inhibitors to modulate physiological 
and biological parameters and beta agonists to improve clinical outcomes in patients 
undergoing oesophagectomy has recently been assessed by investigators in the UK 
(Shyamsundar et al., 2014; Perkins et al., 2014). Whilst, beta agonists had no impact on 
ALI prevention, the study recruited over 350 patients suggesting that the post-
oesophagectomy model is viable and feasible human model for future study of novel 
interventions in ALI. 
 Inhalation of LPS, a component of the outer membrane of gram-negative bacteria, 
results in a local subclinical alveolar inflammatory response with neutrophil recruitment 
and an increase in cytokine and chemokine production (Jagielo et al., 1996; Nick et al., 
2004; O'Grady et al., 2001; Sandstrom et al., 1994), analogous to that which occurs in 
ALI. Notably, the coagulopathic and fibrinolytic abnormalities associated with ALI are 
also replicated in the inhaled LPS model (Maris et al., 2005). Although a mild systemic 
inflammatory response is also observed, neither the pulmonary or systemic effects have 
been associated with significant adverse clinical events.  
 Models of nebulized or bronchoscopically instilled LPS have been applied to test a 
range of putative therapies in ALI, including recombinant human activated protein C, β-
agonists, corticosteroids and phosphodiesterase-4 inhibitors (Chen et al., 2009; Michel et 
al., 2007; Nick et al., 2004; Shyamsundar et al., 2009). More recently the inhaled LPS 
model was used as part of a randomized control trial to investigate monocyte depletion as 
a means of modulating early neutrophil recruitment to inflamed lung (Barr et al., 2013). 
Following LPS inhalation, 30 volunteers were randomised to actual or sham leukapheresis 
to reduce peripheral blood monocytes. Despite failing to detect any clinical or biological 
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effect, this translational study demonstrated the potential of human models to inform later-
phase clinical trials. 
 There are several pathological, ethical and logistical challenges that limit the use 
of in vivo surgical models in humans. First, these are short-term models of low-level 
inflammation and although many of the pathological hallmarks of ALI are re-created, the 
physiological decrements in gas exchange and the levels of pro-inflammatory cytokines 
induced are modest. Second, in vivo studies are inevitably constrained by clinical 
priorities and ethical considerations. Third, it is important to recognise that the 
pathogenesis of ALI after operations involving both OLV and CPB is multi-factorial, and 
patient factors combine with the direct effects of OLV and CPB to compromise 
pulmonary function in the early post-operative phase.  
1.2.2.2 Ex vivo models  
 Ex vivo lung research has been widely used to study lung function in small animals 
and other species (Broccard et al., 2002; Wang et al., 1989; Wisser et al., 1993). Human 
ex vivo research uses consented donor organs that are unsuitable for transplantation based 
on International Society for Heart and Lung Transplant (ISHLT) criteria (Orens et al., 
2006). Organs are maintained in a viable state with established ventilation and perfusion 
systems.  
 Human ex vivo models of ALI involve similar noxious stimuli to those used in 
animals, including live bacteria, which can be either infused into lung tissue via the 
perfused vasculature, or delivered to the airways and distal lung by nebulisation, or 
delivered under direct vision to a targeted area using a bronchoscope. Such models may 
permit testing of disease-modifying therapies in ALI to generate relevant, reliable and 
predictable human pharmacodynamic, pharmacokinetic and toxicology data through 
analysis at the organ, cell, genomic and molecular level, before early phase clinical 
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studies. Ex vivo modelling is superior to tissue and cell-based assays, as the architectural 
integrity of the lung is preserved. For example, type I pneumocytes that cover over 90% 
of the gas exchange surface of the lung and are difficult to culture in vitro; therefore, little 
is known about the response of this cell type to injury and subsequent mechanisms of 
repair. Moreover, ex vivo ALI models might allow recapitulation of severe ALI, 
experimental manipulation and temporal analysis of distal lung tissue, which are not 
achievable using in vivo human models.  
 Currently, there are two main techniques for maintaining lungs ex vivo: The 
isolated perfused lung model and the ex vivo lung perfusion (EVLP) model. In the isolated 
perfused lung model, the lungs, together with the heart, are surgically removed and 
suspended by the trachea in a humidified, jacketed chamber maintained at 36-37°C. The 
lungs are perfused with a buffer solution that enters the lung by the pulmonary artery and 
drains via the pulmonary vein. The buffer solution is then collected or re-circulated. The 
lung is either left unventilated, or continuous positive airway pressure is applied.  
 Ex vivo lung perfusion was developed by Steen (Steen et al., 2003) as a method to 
assess the quality of donor lungs from non-heart beating donors. It is used clinically to 
facilitate reconditioning and subsequent transplantation of unacceptable donor lungs 
(Egan et al., 2006; Steen et al., 2007; Wierup et al., 2006). An elaborate and expensive 
extracorporeal circuit and ventilator system replicate in vivo physiology; lungs are 
ventilated with a low tidal volume strategy, while an extracorporeal circuit with a 
centrifugal or roller pump generates perfusate flow which can be as high as 40% of the 
donor’s cardiac output. An albumin-based perfusate, with or without matched red cells is 
used to optimise oncotic pressure and reduce endogenous lung oedema. Whole lungs have 
been maintained on EVLP for up to 12 hours with preservation of lung function and 
avoidance of additional lung injury (Cypel et al., 2009; Cypel et al., 2008).  Clinically, 
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EVLP has been used as a platform for administration of antimicrobial therapy to reduce 
the burden of bacterial load in lungs that otherwise would be rejected for transplantation. 
Moreover, gene therapy with an adenoviral vector encoding human interleukin-10, 
attenuated inflammation in injured human donor lungs resulting in improved lung 
function after 12 hours of ex vivo perfusion (Cypel et al., 2009).  
                
Figure 1.3 Ex vivo human models of ALI 
The isolated perfused lung model (panel A) is a simplified version of the ex vivo lung perfusion 
model (EVLP, panel B). In the isolated perfused lung model whole human lungs are suspended by 
the trachea in a humidified chamber. The lungs are perfused with a buffer solution, at a low flow 
rate, that drains passively via the pulmonary vein. The lungs are either left unventilated or 
continuous positive airway pressure (CPAP) is applied. The EVLP uses a modified 
cardiopulmonary bypass circuit to perfuse a high oncotic pressure solution with red blood cells. A 
ventilator is connected to the trachea via an endotracheal tube and a protective ventilatory strategy 
(6 ml/kg tidal volume) used. Adapted from (Lee et al., 2009) 
 
 Although ex vivo modelling has many potential benefits, there are several 
limitations. It is important to recognise that most lungs donated for research have been 
declined for transplantation, baseline physiology is often abnormal and there will 
inevitably be a degree of background ALI present prior to use of the tissue for 
experimental modelling. Moreover, donated lungs are unlikely to be homogenous, with a 
wide variation in ischaemic times and donor co-morbidities, including smoking. The 
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direct impact of cold preservation of the lungs for transport on the development of ALI 
remains poorly understood. Available donor lungs are, by necessity, at a premium. Organ 
procurement is further limited by legal, ethical and cultural considerations, which vary 
between states and countries. This process is facilitated by collaboration with donor 
networks and organ procurement organisations. The fact that renal and hepatic 
metabolism are absent in ex vivo models also needs to be taken into consideration when 
interpreting pharmacokinetic data.  
1.3 Tumour Necrosis Factor 
1.3.1 TNF as a pro-inflammatory cytokine 
 TNF is a pleiotropic cytokine regulating many biological processes including 
immune function, inflammation, energy metabolism, cellular fate, proliferation and 
differentiation. In general however, it may be considered to represent a major pro-
inflammatory and immuno-regulatory mediator, with the capacity to induce necrosis and 
apoptosis (MacEwan, 2002). TNF is mainly produced by a range of cells including 
macrophages, dendritic cells, T-lymphocytes, mast cells, endothelial cells, fibroblasts and 
neuronal tissue (MacEwan, 2002; Wajant et al., 2003) and most cells show at least some 
TNF responsiveness.  
 The central role of TNF as a regulator of inflammation was highlighted by the side 
effect profile of recombinant TNF administered to patients as an anti-cancer therapy in the 
late 1980’s. Patients developed a symptom profile that paralleled clinical sepsis including 
headache, nausea, vomiting, fever, rigors, anorexia, hypotension diarrhoea and 
coagulopathy (Bauer et al., 1989; Jakubowski et al., 1989). These symptoms and the 
associated metabolic responses closely mimicked those following systemic LPS 
administration to healthy volunteers (Michie et al., 1988). Furthermore, lethal septic shock 
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does not occur in TNF deficient mice (Ito et al., 2006). Accordingly, TNF is implicated in 
the pathogenesis of many diseases including atherosclerosis, Alzheimer's disease, and 
multiple sclerosis. TNF has a central role in auto-immune diseases including rheumatoid 
arthritis, psoriasis and inflammatory bowel disease, where anti-TNF therapy has 
demonstrated clinical benefit (Klareskog et al., 2004; Breedveld et al., 2006). 
Concomitantly, inhibition of TNF increases susceptibility to infections with bacteria or 
mycobacteria, further emphasizing the essential role of TNF in immune responses and 
inflammation (Feldmann and Steinman, 2005; Galli et al., 2008). 
1.3.2 TNF biology 
 TNF is synthesized as a 34kDa type II transmembrane protein, meaning that it 
crosses the membrane once and is orientated such that its amino terminus is intracellular 
and its carboxy terminus is extracellular. TNF can either function in its membrane-bound 
form, or it can be released as a soluble circulating (cleaved) form of a 17kDa polypeptide 
by a metalloproteinase called TNF alpha converting enzyme (TACE/ADAM17) (Black et 
al., 1997; Moss et al., 1997) and other sheddases (Krunkosky et al., 2005; Wajant et al., 
2003; Aggarwal, 2003). 
 TNF signals through one of two type I transmembrane receptors designated TNF 
receptor-1 (TNFR1, p55) and TNF receptor-2 (TNFR2, p75) (Locksley et al., 2001) to 
initiate distinct signalling pathways and cellular responses (Aggarwal, 2003). The 
extracellular domains of both TNFR are similar and contain four cysteine rich structural 
motifs that form TNF-binding domains. By contrast, intracellular domains are quite 
different. Both receptors are devoid of intrinsic enzymatic activity, and each signal by 
recruiting cytosolic proteins to their intracellular domains as a result of the conformational 
changes induced by ligand binding. Subsequent events are best understood for TNFR1 
and are illustrated in figure 1.4. Cell surface receptor expression is regulated by protein 
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synthesis, the action of sheddases and by receptor internalisation (Higuchi and Aggarwal, 
1994). TNFR1 is predominantly sequestered in the Golgi apparatus and mobilized to the 
cell surface, whereas TNFR2 is typically localized to the plasma membrane. TNFR1 
expression is thought to be ubiquitous, whereas expression of TNFR2 is mainly restricted 
to immune and endothelial cells (Gomez et al., 2006; Ermert et al., 2003). 
 The actions of TNF depend on the relative abundance of these receptors and are 
antagonised by circulating inhibitors (TNF binding proteins) and soluble receptors. Whilst 
both receptors bind soluble TNF with similar affinity, membrane TNF may preferentially 
interact with TNFR2 (Grell et al., 1998; Grell et al., 1995). In addition to responding to 
TNF, both TNFR may be activated by a structurally homologous ligand called 
lymphotoxin. It has also been suggested that TNFR2, which can be more abundantly 
expressed, may engage in a phenomenon called ‘ligand passing’; TNFR2 binds and then 
immediately dissociates from TNF in close proximity to TNFR1, resulting in transfer of 
TNF to TNFR1, and promotion of TNFR1 activation (Tartaglia et al., 1993). This 
phenomenon appears to occur when TNFR2 and soluble TNF levels are low.   
1.3.3 TNF signalling pathways 
1.3.3.1 The TNFR1 signalling pathway 
 The cytoplasmic region of TNFR1 contains a death domain (DD) that couples 
TNFR1 to either of two distinct signalling pathways via binding of the adapter protein 
TNFR-associated death domain (TRADD). In the absence of ligand, TNFR1 is thought to 
associate with silencer of death domain (SODD) to prevent signalling, although genetic 
deletion does not induce constitutive signalling. TNF binding releases SODD and 
promotes the binding of TRADD. In the main signalling pathway, TRADD recruits two 
additional proteins, namely receptor interacting kinase protein-1 (RIPK1) and TNFR-
associated factor 2 (TRAF2). This complex is internalised and released from TNFR1; 
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inhibition of internalisation interferes with endothelial cell signalling (Schutze et al., 
1999). The internalised complex along with other incorporated proteins (called a 
signallosome), then functions through recruitment and activation of cytosolic proteins 
including; mitogen activated protein kinase kinase kinases (MAP3Ks), c-Jun N-terminal 
kinase (JNK), p38 mitogen activated protein kinases (p38MAPK), apoptosis signalling 
kinase (ASK)-1 and the inhibitor of nuclear factor kappa B kinase (IKK) complex. Hence, 
the transcription factors, nuclear factor kappa-B (NF-κB) and activator protein-1 are 
activated culminating in the induction of expression in genes important for cell growth 
and death, development, oncogenesis, immune, inflammatory, and stress responses (Grell 
et al., 1998). Thus, TNFR1 modulates recruitment of inflammatory leukocytes, mediates 
production of pro-inflammatory chemokines and promotes trans-endothelial migration of 
leukocytes of cells (Paleolog et al., 1994; Slowik et al., 1993) and oxidative burst in 
neutrophils (Dri et al., 2000).  
 After several hours, the signallosomes assembled on TRAD may be inactivated by 
a de-ubiquinating enzyme called A20 (induced by activation of NF-κB), or further 
modified by recruitment of Fas associated death domain (FADD). FADD converts the 
signallosome to a death inducing signalling complex (DISC), which can activate caspase-
8, and subsequently caspase-3 to induce apoptosis (Higuchi and Aggarwal, 1994; Micheau 
and Tschopp, 2003; Schneider-Brachert et al., 2004). However, cells lacking FADD are 
also susceptible to cell death via a poorly understood pathway involving receptor 
interacting kinase protein-3 (RIPK3) in a process called necroptosis (Osborn et al., 2010). 
 In addition to activating cell death pathways, TNF can inhibit cell death via the 
caspase and JNK pathways. Activated NF-κB induces transcription of FLICE-inhibitory 
protein (cFLIP), which competes with procaspase-8 for binding to FADD, preventing 
activation of caspase-8 by the TRADD/RIPK1/TRAF2/FADD complex (Hehlgans and 
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Pfeffer, 2005; Naude et al., 2011; Ware, 2005). It has also been suggested that TNF can 
activate mitochondria to sequentially release reactive oxygen species, cytochrome C, and 
Bax, leading to activation of caspase-9 and caspase-3 and thereby causing apoptosis 
(Morgan and Liu, 2010). 
 
 
Figure 1.4 TNF signalling pathways 
Adapted from(Waters et al., 2013) Akt – protein kinase B : ASK 1 - apoptosis signalling kinase; 
AP1 – Activator protein-1 ; cFLIP - FLICE-inhibitory protein; Etk - epithelial/endothelial tyrosine 
kinase; FADD - Fas associated death domain ; IKK - IκB kinase; JNK - c-Jun N-terminal kinase; 
MKK3 – mitogen activated protein kinases kinase 3; NFκB – nuclear factor kappa B; PI3K - 
phosphatidyl inositol 3 kinase ; RIPK1 - receptor interacting kinase protein-1; RIPK3 - receptor 
interacting kinase protein-3; SODD - silencer of death domain; TRADD - TNFR-associated death 
domain; TRAF - TNFR-associated factor 2 
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1.3.3.2 The TNFR2 signalling pathway 
 Significantly less is known about TNFR2 signalling pathways. TNFR2 lacks an 
intracellular DD to recruit TRADD, but can directly interact with TRAF2 via a TRAF 
binding site. Following ligand binding TNFR2 recruits TRAF2, leading to NF-κB 
activation independent of the TNFR1 signalling pathway (Thommesen and Laegreid, 
2005); over-expression of TNFR2 can lead to NF-κB activation via this mechanism, 
although the intracellular signalling mechanisms are unclear (Rothe et al., 1995). 
Moreover, TNFR2 induced NF-κB activation appears to be active in only some cell types 
(Naude et al., 2011). A further downstream signalling pathway of TNFR2 involves 
activation of a cytosolic protein called epithelial/endothelial tyrosine kinase (Etk). Etk 
activation via TNFR2 can partly activate vascular endothelial growth factor receptor 2, 
leading to activation of PI3K and its effector protein called Akt (Zhang et al., 2003). This 
pathway was cytoprotective and promoted cell growth, although it may not be sufficient 
to do so on its own.  In some cell types (including T-cells), TNFR2 can also induce cell 
death although the signalling pathways responsible remain elusive. Some studies suggest 
it may be mediated indirectly by up-regulation of transmembrane TNF, which then 
secondarily stimulates TNFR1 (Grell et al., 1999; Vercammen et al., 1995). 
	  
1.3.4 The roles of differential TNFR signalling in host immunity and repair 
 TNF and its differential signalling pathways, play key roles in host immunity and 
tissue repair mechanisms. Upon release, TNF proceeds throughout the lifecycle to exert 
regulatory roles over immune cells by triggering transcription of genes responsible for 
inflammation, proliferation, differentiation, and apoptosis. To counter invading micro-
organisms, TNF facilitates proliferation of immune cell clones and subsequent 
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differentiation and recruitment of naïve immune cells. Subsequently, TNF orchestrates 
destruction of superfluous immune cell clones to reduce inflammation and tissue damage.  
 The relative contribution of TNFR signalling in these processes is not well 
understood and often contradictory.  Studies using transgenic mice deficient in TNFR1, 
demonstrate that some signalling via TNFR1 is important for controlling infection by 
intracellular pathogens such as Listeria monocytogenes and Mycobacterium tuberculosis 
(Schluter and Deckert, 2000).  Interestingly, TNFR1 deficient animals are resistant to 
TNF and IL-1β-mediated mortality, and to endotoxic shock induced by LPS or D-
galactosamine.  However, there is evidence to support divergence in the role of TNF 
receptors in host immunity. For example, TNFR2 facilitated generation of Fas ligand-
dependent cytotoxic T-cell effector pathways play an important role in antiviral-immune 
responses in the liver and lungs (Kafrouni et al., 2003; Richter and Topham, 2007), and 
TNFR2 may also be involved in the pathogenesis of cerebral malaria (Piguet et al., 2002).  
Finally, TNFR2 may also be important in the control of inflammation, since TNFR2 is 
expressed on a highly suppressive subset of regulatory T cells (Tregs) (Chen et al., 2008). 
Adoptive transfer of TNFR2 deficient CD4+ T cells resulted in more severe inflammation 
and tissue destruction in the CD4+ T-cell transfer murine model of colitis (Dayer 
Schneider et al., 2009). Moreover, an agonist for TNFR2 selectively destroyed 
autoreactive T-cells in blood samples from patients with type I diabetes (Ban et al., 2008), 
whilst TNFR1 could deliver pro-survival signals to these autoreactive T lymphocytes 
(Twu et al., 2011). TNFR2 is an important receptor expressed on regulatory T cells 
necessary for their activation, proliferation and proper functioning (Chen et al., 2007).  
Furthermore, TNFR2 signalling plays a non-redundant role in natural killer cell-dendritic 
cell activation (Xu et al., 2007).  
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 The central role of TNFR2 signalling in tissue repair has been highlighted by 
experimental studies using transgenic mice deficient in TNFR2 and TNFR selective 
muteins. Murine models have demonstrated that TNFR2 is protective in the pathogenesis 
of heart failure (Hamid et al., 2009; Higuchi et al., 2004), renal allograft failure due 
ischaemia-reperfusion injury (Al-Lamki et al., 2005), neuronal injury (Fontaine et al., 
2002), and ischaemic neovascularisation (Goukassian et al., 2007). TNFR2 is also crucial 
for TNF-induced regeneration of oligodendrocyte precursors that make up myelin (Arnett 
et al., 2001), and TNFR2 signalling has a role in angiogenesis; endothelial-specific 
transgenesis of TNFR2 promoted adaptive arteriogenesis and angiogenesis in a femoral 
artery ligation model (Luo et al., 2010). In contrast to the suggested essential role of 
TNFR2 signalling in tissue repair, TNFR1 is required for liver regeneration (Yamada et 
al., 1998), but it nevertheless plays a non-redundant role in hepatitis (Shibata et al., 2008). 
1.3.5 The role of TNF in acute lung injury  
 Although TNFR have been shown to be differentially expressed on both alveolar 
epithelial cells and the pulmonary endothelium (Ermert et al., 2003; Grau et al., 1996), 
many of the pro-inflammatory effects of TNF can be explained based on the effects of 
TNF on vascular endothelium and leukocyte-endothelial interactions.  Endothelial cells 
up-regulate the expression of leukocyte adhesion molecules including ICAM-1, VCAM-1  
(vascular cell adhesion molecule-1) and E-selectin (Mackay et al., 1993; Slowik et al., 
1993; Neumann et al., 1996; Eriksson et al., 2005), in a distinct temporal, spatial and 
anatomical pattern (Petzelbauer et al., 1994; Bradley and Pober, 1996) in response to TNF 
exposure. Similarly, TNF induces release of chemokines including IL-8, MCP-1, GM-
CSF and interferon-gamma induced protein-10 (Rollins et al., 1990; Paleolog et al., 1994), 
leading to leukocyte recruitment, independent of antigen recognition. Finally, TNF 
disrupts adherens junctions in endothelial cells (Angelini et al., 2006; Petrache et al., 
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2001) promoting fluid leak and leukocyte influx. Given that the pulmonary vascular bed 
(including the lung capillaries, the site of pulmonary neutrophil recruitment) is unique in 
receiving the body’s entire cardiac output, and that gap formation in lung endothelium is 
the primary cause of fluid leak in ALI, the lungs would seem to be exquisitely sensitive to 
TNF-induced inflammation and lung injury. 
 TNF has been strongly implicated in the pathogenesis of ALI, initiating the 
inflammatory cytokine cascade by inducing up-regulation of pro-inflammatory neutrophil 
chemokines including IL-8 (Matsushima et al., 1989). Levels of TNF and its soluble 
receptors are elevated in BALF (Armstrong and Millar, 1997; Pugin et al., 1999) and 
blood of patients with ALI (Hyers et al., 1991), and levels of downstream TNFR1 
signalling products (e.g. IL- 6, IL-8, TNFR1 and TNFR2) in blood have been associated 
with a poor outcome (Calfee et al., 2009; Parsons et al., 2005) and sequential organ failure 
in ALI patients (Liu et al., 2007). Alveolar macrophages from ALI patients express higher 
levels of bioactive cell-surface TNF, with a trend for increased soluble TNF production 
(Armstrong et al., 2000; Armstrong and Millar, 1997).  
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Figure 1.5 The central role of TNF in the pathogenesis of ALI 
ROS: Reactive oxygen species, VALI: Ventilator associated lung injury, ICAM-1: Intracellular 
adhesion molecule-1, VCAM-1: vascular cell adhesion molecule -1, MCP-1 Monocyte 
chemotactic protein-1 
 TNF has similarly been implicated in the pathogenesis of both experimental and 
clinical VALI. Indeed, in a clinical study, BALF and plasma levels of TNF and its soluble 
receptors fell after 36 to 40 hours in patients with ALI receiving protective ventilation, 
compared to those ventilated using a conventional strategy (Ranieri et al., 1999). Early 
experimental studies yielded conflicting results (Imai et al., 1999; Murphy et al., 2000; 
Ricard et al., 2001; Tremblay et al., 2002), however recent work has demonstrated that the 
complexities of differential TNF signalling may underlie some of the confusion.  In 
genetically modified mice, pulmonary oedema formation in the early phases of VALI was 
mediated through the TNFR1 receptor, whilst TNFR2 was protective (Wilson et al., 
2007). The mechanism of this divergent effect is unclear, although TNFR1 may increase 
alveolar-capillary membrane permeability via p38 mediated cytoskeletal rearrangement in 
endothelial cells (Ferrero et al., 2001), whereas TNFR2 activation may maintain epithelial 
Leukocyte)ac+va+on)
&)recruitment)))
)
VALI)
Indirect)injury)eg.)
sepsis)
TNF$
Inﬂamma*on$
Release)of):)
IL?1β,)IL?6,)IL?8,)MCP?1)
Up?regula+on)of:)
ICAM?1,)VCAM?1,)E?
Selec+n)
$
Lung$Injury$Direct)injury))
eg.)pneumonia) Proteinases)
Ca+onic)polypep+des)
Cytokines)
ROS)
Macrophage)
)ac+va+on)
)
52 
 
 
barrier function through the endothelial/epithelial tyrosine kinase (Etk/Bmx) (Hamm-
Alvarez et al., 2001).   
1.3.6 TNF antagonism 
1.3.6.1 Currently available therapies 
 Over the past decade, the use of TNF antagonists, has led to substantial 
improvements in the quality of life of patients with several autoimmune diseases 
including rheumatoid arthritis and Crohn’s disease. In these diseases and others, anti-TNF 
therapy interferes with disease pathogenesis at multiple levels, inhibiting inflammatory 
cell recruitment, inducing inflammatory cell death and lowering cytokine production by 
multiple cell types, thus limiting aberrant inflammatory damage and promoting functional 
recovery of the affected tissues. Over two million patients have been treated with anti-
TNF therapy to date, and three of the commercially available TNF-blockers are among the 
top ten best-selling drugs in the world.  
 Different compounds targeting TNF are available, the mouse-human chimeric 
antibody Infliximab, the fully human antibodies Adalimumab and Golimumab, a fusion 
protein composed of the extracellular part of two TNFR2 molecules coupled to the 
fragment crystallisable (Fc) region of an Immunoglobulin-G1 (IgG1) molecule, 
Etanercept and a PEGylated fragment antigen-binding (Fab) fragment lacking an Fc 
region, Certolizumab. These compounds differ in composition, mechanism of inhibition, 
dosing, and route of application.  For example, whilst they all inhibit soluble TNF with 
comparable efficiency (Kaymakcalan et al., 2009), they have different binding kinetics to 
membrane bound TNF (Scallon et al., 2002) which may account for their varying 
efficacies in different auto-immune diseases. 
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 Despite the promising clinical outcomes, anti-TNF therapy has been associated 
with important complications, most notably an increased risk of infection from 
intracellular bacteria and certain viruses (Gardam et al., 2003). Moreover, anti-TNF 
therapy has been associated with the development of de-novo auto-immune diseases such 
as systemic lupus erythematosus and multiple sclerosis, and a propensity towards a higher 
incidence of malignancies and lymphoma. These effects may relate to unwanted effects on 
TNFR2 signalling in host immunity, particularly T-regulatory cells (chapter 1.3.4). 
 Based on these data and the data suggesting a role for TNFR2 signalling in tissue 
repair and regeneration (chapter 1.3.3.2), a variety of compounds that selectively block 
TNFR1 have been developed including monoclonal antibodies and antagonistic TNF 
mutants with specificity for TNFR1. Ideally these would reduce the pro-inflammatory 
effects of TNFR1 induced NF-κB signalling in the relevant tissues and cells whilst 
maintaining the putative benefits of TNFR2 signalling.  
1.3.6.2 TNF blockade in acute lung injury 
 Despite anti-TNF therapy or TNF receptor blockade ameliorating the severity of 
lung injury in animal models (Windsor et al., 1993; Van Zee et al., 1996; Tracey et al., 
1987; Imai et al., 1999; Goldman et al., 1990) clinical studies of a recombinant TNF 
neutralizing fusion protein in sepsis, which included subgroup analysis of patients with 
ALI, yielded largely disappointing results (Abraham et al., 1998; Abraham et al., 1995; 
Fisher et al., 1996), culminating in a large (1340 patients) phase III study demonstrating 
no 28-day mortality benefit (Abraham et al., 2001). The failure of this trial may be 
explained by the kinetics of TNF release in sepsis. Despite targeting early sepsis in the 
trial (<4 hours of vasopressor dependent shock), in animals serum TNF peaked 
90 minutes after endotoxin injection having a circulating half-life of just 14–18 minutes 
(DeForge et al., 1990). Indeed, in experimental sepsis models, neutralizing antibody to 
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TNF was protective only when it was administered during a window beginning before, 
and ending very soon after, injection of endotoxin (Beutler et al., 1985) or E. coli  (Tracey 
et al., 1987). Moreover, in patients with severe meningococcal sepsis, TNF release 
occurred early but was absent in the mid- and later- phases of fatal infections (Waage et 
al., 1987). Alternatively, accumulating data in a range of experimental models (chapter 
1.3.4) suggest that the complexity of differential TNFR signalling in host inflammation 
and immunity, may account for the lack of clinical efficacy of TNF blockade. For 
example, patients with Gram-positive infection tended to have an increased mortality 
whereas those with Gram-negative infection were unaffected (Fisher et al., 1996). 
1.3.6.3 GSK1995057 
1.3.6.3.1 Domain antibodies  
 Domain antibodies (dAb) are an emerging class of drug comprising the variable 
domains of either the heavy (VH) or light chain (VL), and are thus the smallest functional 
antigen-binding portions of the immunoglobulin-G (IgG) molecule. Each dAb therefore 
contains three of the six naturally occurring complementary determining regions from an 
antibody, which are the diversified loop regions that bind to target antigen. They were 
discovered in the late 1980s by a group from Cambridge when a repertoire of isolated 
murine VH domains was screened for binding to lysozyme (Ward et al., 1989). Given that 
they only comprise the VH domain of an antibody, they are one quarter the size of a 
fragment antigen-binding region and half the size of single chain fragments. Variable 
domains bind a wide range of antigens from small molecules to large proteins and inhibit 
enzymatic activity by penetrating into enzymatic active sites. dAbs are readily expressed 
in bacteria and are therefore suitable for isolation by in vitro selection via phage display 
(Holt et al., 2003).  Thus, the potential exists to generate fully human dAbs with high 
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target affinity and specificity with the advantages of conventional antibodies but 
considerably greater ease of manufacturing. 
 
Figure 1.6 Variable domain antibodies 
A human Immunoglobulin-G (IgG) molecule has both variable and constant regions. An IgG 
contains two variable regions (each composed of a VH and VL domain) that confer antigen- 
binding specificity on the antibody, and an Fc fragment in the constant region that recruits the 
effector functions of the immune system. A domain antibody (dAb) is an isolated antibody VH 
(shown here) or VL domain. Taken from (Holt et al., 2003). MW: molecular weight (kilodaltons), 
CH: heavy chain, CL: light chain, Fc: fragment crystallisable portion.  
 Domain antibodies offer multiple advantages over conventional antibody 
technology: they bind monovalently to their targets, avoiding the potential for receptor 
cross-linking; they lack the Fc portions and do not induce Fc effector responses such as 
complement- or antibody-dependent cytotoxicity; their small size (~12 kD) enables better 
tissue penetration and delivery at much higher concentrations per unit mass and 
potentially fewer long-term adverse effects (e.g. immunosuppression) due to more rapid 
excretion; and they are thermodynamically and potentially proteolytically stable. 
1.3.6.4 Selective TNFR1 antagonism using GSK1995057 
 A number of antibodies have been described that bind specifically to TNFR1, 
however, several of these cross-link the receptor resulting in activation of downstream 
What is a dAb?
A dAb is either the variable domain of an antibody heavy
chain (VH domain) [2] or the variable dom in of an
antibody light chain (VL domain) [15]. Each dAb therefore
contains three of the ix naturally occurring com lemen-
tarity determining regions (CDRs) from an antibody,
which are the highly div rsified loop regions that bind to
the target antigen. Although it might seem surprising that
three CDR regions are sufficient to confer antigen-binding
specificity and high affinity, Darwinian evolution has itself
arrived at that very solution in camelids, which p oduc
antibodies comprising only a heavy chain. The antigen-
binding site of these antibodies consists of a single
unpaired variable domain (referred to as VHH).
The crystal [16,17] and solution [18–20] structures of
several dAbs have been solved and show that isolated
human VH and camelid VHH dAbs adopt a b-sheet
structure similar to a VH or VL immunoglo ulin fold in a
conventional antibody. By contrast, some of the CDR
structures seen in camel VHH dAbs ar different from
those in naturally paired VH domains. A comparison of
the structures of camelid CDRH1 and CDRH2 with the set
of loops found in human and mouse antibodies has
revealed significant differences in their main chain
conformations [21]. In addition, the CDRH3 regions of
naturally occurring camelid VHH antibodies are, on
average, longer than the CDRH3 regions of naturally
paired VH domains. Camelid VHH sequences also contain
amino acid substitutions in the framework regions that
are not observed in paired VH domains [22] and which
might have evolved to accommodate the absence of the
VL and constant CH1 domains or the differences in the
loop conformations.
Irrespective of the precise driving force behind the
emergence of heavy chain antibodies in camelids, their
variable domai s bind awide range of antigens, from small
molecules such as haptens [23] to large proteins [7], and
they inhibit enzymatic activity [8] by penetrating into
enzyme active sites [24,25]. The potential to create fully
human dAbs with high affinity and specificity for
numerous targets raises the possibility of creating a
completely new clas of therapeutic drug with all the
advantages of conventional antibodies but without the
drawbacks encountered in manufacturing and formatting.
Biophysical properties
As with any protein of commercial value, dAbs need to be
manufactured in high yield and must be extremely soluble
and resistant to proteolysis, aggregation, denaturation
and chemical degradation. The first murine VH domain
antibodies that were cloned, however, had relatively low
expression levels and solubility [2]. Because the VH
domain was selected for binding (in the mouse) in the
presence of a cognate VL molecule, the removal of that VL
domain presumably resulted in a significant reduction in
stability and/or the exposure of hydrophobic residues that
would normally form part of the VH–VL interface.
Hence, when camelid VHH domains were first cloned
[22], their improved solubilities were attributed to a tetrad
of highly conserved hydrophilic mutations, Val37! Tyr
(or Phe), Gly44! Glu (or Gln), Leu45! Arg (or Cys), and
Trp47! Gly (or Ser, Leu or Phe), at the former VL
interface [22,26]. This led to the idea of ‘camelisation’,
which involved the replacement of the residues at
positions 44, 45 and 47 in human VH domains with those
frequently found in camel VHH domains [18]. This process
Figure 1. A human IgG molecule has both variable and constant regions. An IgG contains two variable regions (each composed of a VH and VL domain) that confer antigen-
binding specificity on the antibody, and an Fc fragment in the constant region that recruits the effector functions of the immune system. Conventional recombinant anti-
body fragments contain one antigen-binding VH–VL pairing. At ,57 kDa, a Fab fragment comprises a VH–CH1 polypeptide disulphide-bonded to a VL–CL polypeptide. At
,27 kDa, a scFv fragment contains only the VH domain fused to the VL domain via a polypeptide linker. By contrast, the domain antibody, or dAb, of 11–15 kDa is either an
isolated antibody VH domain [2], as s own here, or an isol ted antibody VL domain [15]. E ch dAb thus contains thr e of the six naturally ccurring complementarity deter-
mining regions (CDRs) from a VH–VL pairing. The side chains of the CDRs are highlighted in red.
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signalling cascades (Menegazzi et al., 1994; Weingartner et al., 2002). Therefore, 
investigation of the role of TNFR1 is largely limited to studies in knockout mice or over-
expression systems.  
GSK1995057 is a variable domain antibody developed by GlaxoSmithKline 
(GSK) that comprises a single heavy chain variable domain of ~13kDa.  It was selected 
from a phage display dAb library comprising the framework sequences of the human 
germline gene 3-23; gene 3-23 is the most commonly used in human antibodies.  
GSK1995057 is expressed as a recombinant protein from E. coli and is purified by a 
multi-step sequential chromatography process. Degradation testing confirmed that it 
remains monomeric and stable during storage and during nebulisation (personal 
communication from GSK). The biological consequences of GSK1995057 pharmacology 
appear similar to monoclonal antibody TNF antagonists with subtle differences predicted 
based on differential signalling through TNFR1.  
 GSK1995057 specifically binds TNFR1 with high affinity  (assessed by both 
Biacore™ assay and ELISA, table 1.2) and inhibits the binding of TNF and subsequent 
signal transduction via TNFR1.  Surface plasmon resonance studies and immunoassay 
studies demonstrated that GSK1995057 does not show evidence of binding to other TNFR 
superfamily receptors including TNFR2, nerve growth factor receptor (NGFR), 
recombinant lymphotoxin beta-receptor, TNF-related apoptosis inducing ligand (TRAIL) 
receptor 2, TRAIL receptor 3, TRAIL receptor 4 and CD27 (a TNFR superfamily 
receptor.) Hence GSK1995057 is highly selective for human TNFR1.  When bound to 
TNFR1, GSK19959057 (0.001 to 1000nM) prevented TNF (10ng/mL) from binding to 
TNFR1 with a mean half maximal inhibitory concentration (IC50) of 0.07nM. Thus 
GSK19959057 can be considered as a competitive antagonist. 
57 
 
 
Table 1.2 Binding Characteristics of GSK1995057 to Human TNFR1 
Assay GSK1995057 (nM) 
Binding to human TNFR1 (Biacore) (KD) using recombinant mammalian expressed 
cynomolgus Fc-TNFR1 
0.017 
Binding to human TNFR1 (Biacore) (KD) using recombinant mammalian expressed 
human Fc-TNFR1 
0.015 
Binding to human TNFR1 (Biacore) (KD) using E. coli expressed biotinylated human 
TNFR1 
0.47 
Binding to human TNFR1 (ELISA) (EC50) 0.113 
 
 To improve its efficacy in distal lung tissue, GSK1995057 was developed to be 
protease resistant via selection in the presence of bovine trypsin. Although susceptible to 
proteolytic degradation, it demonstrated >50% residual binding activity to TNFR1 after 
incubation with trypsin, elastase or leucozyme. These data compare favourably with other 
domain antibodies (personal communication GSK). 
 Inhibition of TNFR1 induced downstream signalling by GSK1995057 was 
evidenced in a range of human cell types using a variety of signalling events. 
Accordingly, in the human lung epithelial cell-line, A549, TNF (3ng/mL) induced 
activation of NF-κB transactivation was inhibited in the presence of GSK1995057.  
Similarly, in human lung fibroblasts, lung epithelial cells, monocytes and in human whole 
blood, IL-8 release was completely abrogated by GSK1995057 whilst TNF induced 
apoptosis was inhibited in human lung fibroblasts. Finally, TNF-induced activation of 
human umbilical vein endothelial cells (HUVEC), measured by VCAM-1 up-regulation 
was abrogated by pre-treatment with GSK1995057 (personal communication with GSK).   
 Having confirmed in vitro efficacy, single doses of nebulised GSK1995057 were 
evaluated in a well-characterised Cynomologus monkey model of acute lung 
inflammation, elicited by aerosol challenge with bacterial LPS.  This model simulates a 
number of features of direct ALI, including recruitment of inflammatory cell types into 
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the lung lumen and up-regulation cytokines, chemokines, acute phase proteins and other 
inflammatory mediators.  Nebulised GSK1995057 was well tolerated and inhibited both 
neutrophil infiltration and the expression of a broad range of inflammatory mediators in 
the BALF (interleukin-1 receptor alpha, IL-6, macrophage inflammatory protein -1 beta, 
myeloperoxidase, TNFR2 and von Willebrand factor) of animals in a dose-dependent 
manner.  Serum mediators were largely unaffected with the exception of transient 
elevations in IL-6, sTNFR1 and inhibition of IL-1 receptor alpha. Thus GSK1995057 
effectively engages and selectively inhibits TNFR1 function in the lungs of non-human 
primates leading to protection from the pro-inflammatory effects of LPS challenge 
(personal communication with GSK).  
 Most recently, data demonstrating the effects of GSK1995057 in a murine model 
of ‘pure’ VALI and an LPS plus VALI model were published (Bertok et al., 2012).  
Treatment of mice with a specific TNFR1 antagonist attenuated deteriorations in 
respiratory physiology compared to a dummy version of the dAb and a dual TNFR 
antagonist in the ‘pure’ VALI model. This was associated with attenuation of alveolar 
capillary permeability. In the LPS plus VALI model, GSK1995057 decreased levels of 
pro-inflammatory cytokines in the BALF (IL-6 and MCP-1) with a trend towards 
reductions in leukocyte chemokines. Moreover, surface alveolar macrophage expression 
of ICAM-1 was attenuated. Both the dAb and the monoclonal antibody were administered 
intra-tracheally. Of note, the beneficial effect of TNFR antagonism in the VALI model 
was not observed with a monoclonal anti-TNF antibody lending support to the concept of 
a potentially protective effect of TNFR2 signalling and improved efficacy owing to the 
small size of the dAb compared to the monoclonal antibody (both were delivered intra-
tracheally).  
59 
 
 
 Cumulatively, these data suggest that GSK1995057 potently inhibits multiple 
signalling pathways downstream of human TNFR1. Allied with its small size and 
proteolytic stability, this dAb may offer selective disruption of TNFR1 signalling, whilst 
preserving TNFR2 signalling, in a compound capable of penetrating and retaining 
stability in distal lung tissue.  
1.3.7 TNF agonism using TNFR specific muteins 
 Whilst analysis of receptor specific effects in vivo is facilitated by receptor 
knockout mice, the investigation of comparative signalling between 2 different receptors 
in vitro is more challenging. Muteins describe a general term for mutated recombinant 
proteins, which carry single or multiple amino acid substitutions. These proteins are 
derived frequently from cloned genes that have been subjected to site-directed or random 
mutagenesis, or from completely synthetic genes.  
 Hence, when arginine at position 32 was replaced by tryptophan in recombinant 
TNF, the TNFR1 selective mutein R32W was generated (Van Ostade et al., 1993). This 
demonstrated a 3300 fold decreased affinity for TNFR2 with nominal (1.4 fold) reduction 
in binding to TNFR1. Despite mutation, R32W maintains full cytotoxic potential in vitro 
and in vivo (Van Ostade et al., 1993). Similarly D143N (aspartic acid at position 143 
replaced by phenyl-alanine) (Van Ostade et al., 1994) is a TNFR2 selective mutant (Van 
Ostade et al., 1994), which has no demonstrable binding to TNFR1 but also exhibits a 30-
fold decrease in binding to TNFR2. These muteins therefore represent unique tools to 
define the roles of differential TNFR signalling in human cells and potentially corroborate 
findings using the selective TNFR1 antagonist GSK1995057. 
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1.4 The role of neutrophil endothelial interactions in acute lung injury 
1.4.1 Neutrophils – a key regulator of inflammation 
 Neutrophils are the most abundant circulating leukocyte (50-70% of total 
leukocytes) in man and play a fundamental role in the innate immune response. The 
importance of neutrophils in preserving health is exemplified by patients suffering from 
neutropenia, who are prone to life-threatening bacterial and fungal infections. Neutrophils 
are required to be highly motile, respond to the finest of chemotactic trails and have the 
ability to kill bacteria even under the most adverse (e.g. hypoxic) conditions.  
 Neutrophils are multi-lobar cells that contain a plethora of granules formed 
sequentially during myeloid differentiation. Granule formation commences in early 
promyelocytes, when immature transport vesicles bud off from the Golgi, fuse and form 
azurophilic (primary) granules, which contain large amounts of myeloperoxidase (MPO). 
Production of MPO halts at the promyelocyte-myelocyte transition therefore granules 
formed in the later stages of myelopoiesis are peroxidase negative, and can be divided into 
specific (secondary) containing lactoferrin and gelatinase (tertiary) granules containing 
matrix metalloproteinase 9 (MMP9). Neutrophils also contain secretory vesicles that can 
rapidly transport their contents, for example β2 integrins required for cell adhesion, to the 
cell surface upon activation. Tertiary granules then deliver proteases that can digest 
basement membrane and extracellular matrix, perhaps allowing for neutrophil 
transmigration (Hager et al., 2010).  
 Neutrophils are continuously generated in the bone marrow from myeloid 
precursors. Their daily production can reach up to 2 × 1011 cells, a process controlled by 
G-­‐‑CSF (Lieschke et al., 1994), which is produced in response to IL-­‐‑17A synthesized by 
regulatory T cells (Ley et al., 2006). Release of IL-­‐‑17A is in turn under the control of IL-­‐‑
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23 originating from tissue-­‐‑resident macrophages and dendritic cells. In response to 
inflammation, neutrophil numbers increase, and they are recruited rapidly to inflamed 
sites, where their primary role is to kill invading bacteria and certain fungal species 
through phagocytosis, release of preformed granular enzymes and proteins, and by the 
production of a range of oxygen species through nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase (Borregaard, 2010; Galli et al., 2011; Hager et al., 2010).  
1.4.2 Neutrophil priming, activation and degranulation  
 Circulating neutrophils may be viewed as quiescent cells that require effective 
processes to remain functionally dormant thus preventing inappropriate accumulation and 
activation with release of potentially damaging reactive oxygen intermediates and 
granular contents. The key mechanism for this is ‘priming’.  The ability of neutrophils to 
produce superoxide anions in response to a particular secretagogue agonist is significantly 
enriched when cells are exposed to mediators including TNF, GM-CSF or PAF; this has 
been described as the gold standard priming response (Condliffe et al., 1998). Priming 
agents themselves do not generate effector functions, unless applied at very high 
concentrations (Condliffe et al., 1998) and neutrophil degranulation and activation of the 
NADPH oxidase occur only in cells that have been primed prior to activation (Guthrie et 
al. 1984b). Critically, priming has been shown to be important for the induction of 
endothelial injury both in vitro (Smedly et al., 1986) and in vivo (Worthen et al., 1987) 
and affects neutrophil cytoskeletal organisation to induce a highly irregular polarized cell 
contour and reduced deformability (Worthen et al. 1987). Furthermore, priming agents, 
including TNF, modulate neutrophil adhesion molecule expression and function, inducing 
β2-integrin expression (Lauterbach et al., 2008) and L-selectin shedding thus regulating 
the adhesive and migratory capacity (Montecucco et al., 2008). 
62 
 
 
1.4.3  Neutrophil dependency of acute lung injury 
 Neutrophils are central to the initiation and propagation of inflammation and 
injury in ALI (Abraham, 2003). Neutrophil accumulation within the pulmonary 
vasculature occurs early in the evolution of clinical ALI (Bachofen and Weibel, 1977; 
Bachofen and Weibel, 1982), and neutrophilic alveolitis is a histological hallmark (Lee 
and Downey, 2001).  Neutrophilia is common in the BALF of patients with ALI (Parsons 
et al., 1985) and the extent of this correlates with clinical outcome (Steinberg et al., 1994).  
Whilst ALI has been described in neutropenic patients (Ognibene et al., 1986), recovery 
from neutropenia in patients with ALI was associated with a deterioration in pulmonary 
function (Azoulay et al., 2002). Animal models further support the importance of 
neutrophils in ALI; depletion of neutrophils, or their products, attenuated ALI (Abraham 
et al., 2000; Folkesson et al., 1995; Folz et al., 1999; Kawabata et al., 2000; Looney et al., 
2006; Shimizu et al., 2009), and delayed neutrophil apoptosis or failure of apoptotic cell 
clearance, was associated with worsened inflammation and increased mortality (Matute-
Bello and Martin, 2003). Moreover, activated neutrophils directly induced vascular leak 
by free radical production (Gao et al., 2007).  
However, the presence of neutrophils per se is not necessarily damaging, and the 
priming/activation status of these cells is a major determinant of their subsequent injury 
limiting/inducing behavior (Chollet-Martin et al., 1992; Zimmerman et al., 1983). Hence, 
whilst neutrophil products are abundant in the BALF of patients with ARDS (Cochrane et 
al., 1983; Ricou et al., 1996; Weiland et al., 1986), when neutrophils were recruited into 
the normal human lung by instillation of the chemoattractant leukotriene-B4, neutrophils 
migrated into the airspace without causing injury to the endothelial or epithelial barriers of 
the lung (Martin et al., 1989). 
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1.4.4 Mediators of neutrophil migration 
1.4.4.1 Chemokines 
 Chemokines are a family of small (6 to 15 kD), structurally related cytokines with 
chemotactic properties for leukocytes. Chemokines provide directional cues for the 
movement of leukocytes in development, homeostasis and inflammation. Hence, in 
response to inflammation, the local secretion of chemokines, results in the recruitment of 
leukocytes into activated or injured tissues. Chemokine production was originally thought 
to be limited to activated macrophages and monocytes. However, under appropriate 
conditions, their production and release has been elicited from neutrophils, endothelial 
and epithelial cells, platelets, and a variety of parenchymal cells in vitro (Crippen et al., 
1995; Furie and Randolph, 1995; Huang et al., 1992).   
 Over 50 chemokines have been identified with between 20 and 70% homology in 
amino acid sequences (Luster, 1998; D'Ambrosio et al., 2003), and they have been 
subdivided into families on the basis of the relative position of cysteine residues. 
Structurally, the majority of chemokines possess four cysteine residues in their amino-
terminal end that form disulfide bridges and are divided into the CXC (α) and CC (β) 
families dependent upon whether the two most NH2-proximal cysteines are separated by 
one amino acid (CXC) or lie adjacent to each other (CC). CXC chemokines are further 
subdivided based on the presence or absence of a Glu-Leu-Arg (ELR) motif preceding the 
first cysteine residue. In general, ELR-positive chemokines regulate neutrophil migration 
via an interaction with the CXCR2 chemokine receptor, and the ELR-negative 
chemokines modulate mononuclear leukocyte migration (Strieter et al., 1999). Whilst over 
50 human chemokines exist only 20 G-protein coupled chemokine receptors have been 
identified (Zlotnik and Yoshie, 2000). This disparity is balanced by the promiscuity of 
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ligand-receptor interactions, with multiple chemokines binding to the same receptor and 
several chemokines binding to more than one receptor.  
 The most well studied neutrophil chemokine is IL-8, which is the primary stimulus 
for neutrophil migration in humans (and rabbits). In addition to IL-8, at least six other 
CXC chemokines mediate neutrophil responses in humans: neutrophil-activating peptide-
2, three isoforms (α, β and γ) of growth-related oncogenes (GRO), and epithelial cell-
derived neutrophil-activating peptide-78 (ENA-78). There is no evidence that different 
chemokines are used to attract neutrophils to various organs; it was empirically shown 
that the differences in specific chemoattractants and the order of their action might be 
more stimulus-specific rather than tissue-specific (reviewed in (Sadik et al., 2011).  
 As a result of the increasing number of chemokines described, a standardised 
nomenclature was adopted in 2002; chemokines were named according to their family 
(CXC, CC, CX3C or XC) then L to denote ligand prior to a number. Thus IL-8, and 
MCP-1 are named CXCL8 and CCL2 respectively; the traditional nomenclature is still 
used in this thesis. 
In ALI, endothelial cells, alveolar epithelial cells and macrophages release 
chemokines in response to bacterial products and early response inflammatory mediators. 
These chemokines are retained by matrix heparin sulphate glycoproteins at the site of 
inflammation, thus establishing a chemokine gradient toward the inflammatory focus 
(Puneet et al., 2005). In the lung microvasculature, neutrophils, are first attracted via a 
gradient of ELR-positive chemokines, and subsequently retained via chemokine (and 
other mediator) induced alterations in neutrophil cytoskeletal arrangements and activation 
of neutrophil integrins (see 1.4.4.3.2). For example, IL-8, ENA-78, and GRO-α were 
present in biologically significant concentrations in BALF from patients with ALI 
(Goodman et al., 2003; Villard et al., 1995) and their concentrations correlated with 
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neutrophil numbers (Goodman et al., 1996; Miller et al., 1996; Villard et al., 1995) and 
patient outcome (Michel et al., 1997). IL-8 and ENA-78 mediated neutrophil adhesion to 
HUVEC in vitro (Zimmerman et al., 1999) as well as directing neutrophil trafficking 
during LPS-induced lung inflammation (Jeyaseelan et al., 2004). Moreover, in animal 
models, neutralisation of chemokines (Colletti et al., 1995; Folkesson et al., 1995; Miller 
et al., 1992) or their receptors (Sue et al., 2004) attenuated lung injury.  
66 
 
 
Figure 1.7 Chemokines and their receptors 
Taken from Luster (Luster, 1998) MCP- monocyte chemoattractant protein; MIP- macrophage 
inflammatory protein; RANTES- regulated upon activation normal T-cell expressed and secreted; 
MDC- macrophage derived chemokine; HCC-1- hemofiltrate CC chemokine; TECK- thymus-
expressed chemokine; SDF-1- stromal- cell derived factor-1; TARC- thymus and activation-
regulated chemokine; ELC EBL-1- (Epstein Barr virus- induced gene-1)-ligand chemokine; 
PARC- pulmonary and activation regulated chemokine; SLC- secondary lymphoid-tissue 
chemokine; 6Ckine- 6-cysteine chemokine; IP-10- interferon-inducible protein- 10; MIG- 
monokine induced by interferon γ; I-TAC- interferon inducible T-cell alpha chemoattractant; DC- 
CK1- dendritic-cell chemokine 1; LARC- liver and activation regulated chemokine; GCP- 
granulocyte chemotactic protein; GRO- growth regulated oncogene; ENA-78- epithelial cell 
derived neutrophil activating peptide 78; NAP-2- neutrophil activating peptide 2, LIX- 
lipopolysaccharide induced CXC chemokine 
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1.4.4.2 Cytokines 
 Whilst many of the inflammatory processes in ALI, including neutrophil 
migration, are accomplished through direct cell-to-cell adhesive interaction via adhesion 
molecule expression, cells also transmit signals between neighbouring cells through low 
molecular weight (mostly <40kDa) protein mediators called cytokines.  Cytokines are 
involved in almost all biological processes, from cell proliferation to inflammation, 
immunity, migration, fibrosis, repair, and angiogenesis (Vilcek and Feldmann, 2004), 
displaying concentration dependent effects. Individual subpopulations of immune cells in 
the lung, in particular alveolar macrophages, possess different capacities to elaborate and 
secrete different cytokines in response to particular stimuli. In addition to immune cells, 
endothelial cells, fibroblasts and epithelial cells also release cytokines in response to 
specific stimuli.  
 Evidence from several clinical studies indicates that pro-inflammatory cytokine 
networks (as well as chemokines) mediate, amplify, and perpetuate lung injury. Whilst the 
precise roles of individual cytokines in ALI remains elusive, several cytokines including 
IL-1β, IL-6 and TNF have been identified as key mediators of ALI (Nathan, 1987) 
stimulating local cells to release chemokines, and activating leukocytes and endothelial 
cells in preparation for neutrophil-endothelial interactions (Springer, 1994). For example, 
neutrophil activation directly correlates with severity of ALI and with levels of TNF and 
IL-6 (Chollet-Martin et al., 1996). Intra-tracheal instillation of IL-1β and TNF induced an 
intra-alveolar inflammatory response composed of predominantly neutrophils (Ulich et 
al., 1991). Moreover, TNF and IL-­‐‑1 stimulated expression of adhesion molecules on 
activated vascular endothelial cells (Springer, 1994) thus mediating firm adhesion of 
neutrophils to the endothelium. TNF and IL-1 also amplified neutrophil infiltration in an 
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autocrine and paracrine manner by activating macrophages to secrete chemokines 
including IL-8 (Fong et al., 1989).  
1.4.4.3 Adhesion Molecules 
 Neutrophil emigration from the vascular compartment is dependent upon the 
coordinated and regulated expression and function of a number of cell surface molecules, 
including the selectins CD62L (L selectin) and CD62E (E selectin), neutrophil integrins 
including CD11b and lung microvascular endothelial neutrophil ligands including ICAM-
1 and VCAM-1. Stimulation of endothelial cells or neutrophils with a range of agonists 
(including TNF) leads to altered expression of these molecules (Condliffe et al., 1996; 
Yang et al., 2005; Zhou et al., 2007) promoting neutrophil transendothelial migration. 
1.4.4.3.1 CD62L 
 CD62L is a member of the selectin family of molecules with a molecular weight 
of 95kDa. CD62L is constitutively expressed on tips of micro-processes of neutrophils 
(Picker et al., 1991) as well as monocytes and lymphocytes.  It is rapidly shed from the 
cell surface following cellular activation by chemoattractants and activating factors, 
including CD18 cross-linking (Walzog et al., 1994), via endoproteolytic cleavage from 
the cell surface at the membrane proximal extracellular site. In addition to a role in 
cellular adhesion, CD62L may signal cell responses directly; CD62L cross-linking 
stimulated intracellular release of Ca2+, O2- release and induction of mRNA for cytokine 
production in neutrophils (Crockett-Torabi et al., 1995; Laudanna et al., 1994; Simon et 
al., 1995; Waddell et al., 1994). 
 Studies to further elucidate the role CD62L in knockout mice have produced 
varying results. CD62L may play a role in the margination and sequestration of 
neutrophils within the pulmonary circulation in certain circumstances, for example 
following formyl-methionyl-leucyl-phenylalanine (fMLP) and LPS installation (Olson et 
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al., 2002; Wong et al., 2000) but not in others, such as on stimulation with complement 5a 
(Doyle et al., 1997). In patients at-risk for ALI, plasma soluble CD62L (thought to be 
shed from leukocytes) was significantly lower in those who subsequently progressed to 
ALI than in those who did not or in normal controls (Donnelly et al., 1994). Significant 
correlations were also found between CD62L levels and the requirement for ventilation, 
the degree of respiratory failure, and patient mortality. 
1.4.4.3.2 Integrins 
 Integrins are transmembrane glycoproteins expressed on neutrophils comprised of 
α and β-chains (Rose et al., 2007). The β2 integrins are composed of a common β chain 
(CD18) that is non-covalently associated with any of four types of α subunits: CD11a 
(lymphocyte function-associated antigen-1 (LFA-1)), CD11b (Mac-1), CD11c or 
CD11d80 (Carlos and Harlan, 1994). Detection of molecules such as IL-8, fMLP and 
TNF by neutrophils results in activation by conformational change in β2 integrin receptors 
on their cell surface, which interact with endothelial ligands to mediate adhesion.  
 Integrins play a crucial role in many neutrophil functions, particularly cell 
adhesion, migration and complement-mediated phagocytosis as evidenced by defects in 
these processes in patients with inherited deficiencies of the CD18 common β2 integrin 
subunit (Arnaout, 1990). CD11a/CD18 and CD11b/CD18 are the predominant receptors 
mediating neutrophil adhesion to the endothelium, interacting with the Ig gene 
superfamily (IgSF) counter-ligands on the endothelial surface, including ICAM-1 and 
ICAM-2 (Etzioni et al., 1999). ICAM-1, the major ligand for CD11b, is present 
constitutively on endothelial cells but its expression is increased by pro-inflammatory 
cytokines. For example, pre-treatment of human umbilical vein endothelial cells 
(HUVEC) with TNF increased transcellular neutrophil emigration attributable to an 
increase in ICAM-1 expression (Yang et al., 2005). Elevated neutrophil CD11b levels and 
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activation status positively correlated with indicators of disease severity in septic shock 
and adverse outcomes following cardio-pulmonary bypass (Rinder et al., 2003), both of 
which are common precipitants of ALI.    
 Of note, shape change, CD62L, and CD11b expression are affected during 
neutrophil isolation, with primed cells having less CD62L expression, greater CD11b 
expression, and a blunted response to neutrophil agonists (Haslett et al., 1985). These 
markers are therefore useful in vitro indices of neutrophil priming, either through isolation 
alone or following exposure to a stimulus. 
1.4.4.3.3 Endothelial neutrophil adhesion molecules 
 P-selectin, the largest selectin, is stored in α-granules of platelets and in Weibel–
Palade bodies of endothelial cells, and is translocated to the endothelial cell surface by 
stimuli including bacterial components and hypoxia. E-selectin is not expressed (or 
expressed at extremely low levels) under baseline conditions, except in skin microvessels, 
but is rapidly induced by inflammatory cytokines, including TNF. Whilst both E- and P-
selectin are critical for initiating neutrophil rolling and tethering neutrophils to inflamed 
endothelium in the systemic circulation (Patel et al., 2002), their role in mediating 
neutrophil sequestration in the pulmonary circulation is presumed to be less important and 
possibly even redundant owing to spatial constraints (discussed in 1.4.5) and data 
suggesting that, at least in animals P-selectin is not expressed on pulmonary capillary 
endothelium (Mulligan et al., 1992).  Moreover, any role of selectins in experimental 
models appears to be stimulus dependent. Hence, neutrophil migration associated with 
Streptococcal pneumonia was unaffected in mice deficient in E- and P-selectins (Mizgerd 
et al., 1996) and blocking of E-, P- and L-selectin did not attenuate LPS-induced alveolar 
migration of neutrophils (Burns et al., 2001). In contrast, all 3 selectins were involved in 
the progression of complement induced ALI (Mulligan et al., 1996).  
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 The role of other adhesion molecules in mediating neutrophil-endothelial 
interactions in ALI remains similarly elusive. Nonetheless, in post-mortem lung biopsy 
specimens of patients with ALI, ICAM-1, VCAM-1 (and E-selectin) were strongly up-
regulated; only ICAM-1 was up-regulated in lung capillaries, suggesting that these 
adhesion molecules may have a role in human ALI (Muller et al., 2002). Additionally, 
lung microvascular endothelial cells purified from ALI patients post-mortem revealed a 
significantly higher constitutive expression of ICAM-1 than control cells (Grau et al., 
1996). When treated with TNF, both ALI-patient derived and control patient derived cells 
showed a dose-dependent increase in ICAM-1 expression that was significantly higher in 
the ALI-derived endothelial cells.  
 
1.4.4.4 Selected other mediators 
 Platelets may promote the extravasation of neutrophils from the vasculature 
through a range of mechanisms; first, platelet adherence to activated vascular endothelium 
may further propagate endothelial activation (Gawaz et al., 2005) and second, activated 
platelets release growth factors, cytokines and chemokines to activate leukocytes (von 
Hundelshausen and Weber, 2007). Platelets, aggregating with neutrophils via P-selectin, 
facilitate neutrophil recruitment during sterile ALI (Grommes and Soehnlein, 2011; 
Zarbock et al., 2006) and LPS-induced lung inflammation (Kornerup et al., 2010). 
Moreover, platelet-derived neutrophil-attracting chemokine heterodimers of RANTES 
(regulated on activation, normal T cell expressed and secreted) and platelet factor 4 are 
important for neutrophil recruitment during ALI (Grommes et al., 2012) and endothelial 
presentation of RANTES is platelet-dependent (Drechsler et al., 2010). 
 Experimental models of LPS induced lung injury suggest that peripheral blood 
monocytes (PBMs), along with resident alveolar macrophages and recruited alveolar 
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monocytes, play a pivotal role in the neutrophilic alveolitis pathognomoic of ALI 
(Auffray et al., 2007; Henderson et al., 2003; Li et al., 1998). Indeed, depletion of 
monocytes in mice significantly reduced LPS-induced blood neutrophilia, alveolar 
neutrophilia, and markers of lung injury (Dhaliwal et al., 2012; Maus et al., 2002). 
Furthermore, a study employing two-photon imaging demonstrated that monocyte 
depletion by liposomal clodronate reduced pulmonary neutrophil transendothelial 
migration (Kreisel et al., 2010). A recent trial of sham versus actual leukapheresis to 
deplete PBMs (although lymphocytes and platelets were also reduced) in human model of 
subclinical LPS-induced lung inflammation (n=30) detected no clinical or biological 
effect (Barr et al., 2013). Whilst the lack of treatment effect may (in part) relate to 
methodological nuances of the study (for example monocyte depletion was incomplete 
despite four blood volume leukapheresis), the role of monocytes in the recruitment of 
neutrophils in human ALI remains to be fully established. 
 
1.4.5 Neutrophil migration from the pulmonary vasculature to the alveolus 
 The mechanisms by which neutrophils are sequestered at a site of inflammation 
within the alveolar space appear to be quite different in the pulmonary microcirculation 
compared to the systemic microcirculation. In the systemic microcirculation, 
extravasation of neutrophils takes place in post-capillary venules in a cascade-like 
sequence of capture, rolling, slow rolling, arrest and transmigration. Rolling is mediated 
by selectins, a family of calcium-dependent lectins that includes L-selectin expressed on 
neutrophils, P-selectin expressed on platelets and endothelial cells, and E-selectin 
expressed on endothelial cells (Kansas, 1996). Rolling is followed by chemokine receptor-
mediated signalling via G-protein-coupled receptors which, trigger activation of 
neutrophil β2 integrins. Activated integrins (LFA-1 and Mac-1) subsequently interact with 
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their endothelium-expressed ligands, including ICAM-1 and VCAM-1, leading to slow 
rolling and eventually to firm adhesion and leukocyte arrest on the endothelium. 
Subsequently, neutrophils transmigrate into tissues using a paracellular or transcellular 
route (Ley et al., 2007). 
 
 
Figure 1.8 Neutrophil migration in the systemic circulation compared to the pulmonary 
circulation 
Adapted from (Aird, 2007) 
 By contrast, the major site of neutrophil sequestration in the lung appears to be the 
alveolar capillary bed, where rolling does not occur (Doerschuk, 2000; Burns et al., 2003) 
as a consequence of the unique pulmonary capillary microanatomy; the diameters of 
spherical neutrophils (6-8 μm) are larger than the diameters of many capillary segments 
(2-15 μm). Approximately half of the capillary segments require neutrophils to change 
their shape to pass through (Doerschuk et al., 1993; Gebb et al., 1995). In addition to 
spatial limitations, the binding of neutrophil G-protein coupled receptors by chemokines 
or bacterial products induces an f-actin rim to form beneath the cell membrane rendering 
neutrophils stiff (Downey et al., 1991; Inano et al., 1992), further promoting neutrophil The predilection for postcapillary venules as a site forinducible permeability may be explained by the relative
abundance of VVOs, the relative paucity of tight junctions
(hence weak intercellular contacts), and the preferential
expression of histamine H2, serotonin, and bradykinin recep-
tors. Whether or not all postcapillary venules in the body
share these attributes is unknown. Moreover, inflammation,
when severe, may cause barrier dysfunction in other segments
of the vascular tree, including large veins, arterioles, and
capillaries. For example, tumor necrosis factor (TNF)-!
treatment resulted in increased permeability of mouse inferior
vena cava, but not the aorta, as measured by accumulation of
fluorescein isothiocyanate–dextran in the blood vessel wall.70
In EM studies, TNF-! was shown to promote intercellular
gap formation in the inferior vena cava.70 In a rat model of
diabetes, paracellular permeability was increased first in
arterioles and venules, and then in capillaries.71 VEGF has
been shown to induce intercellular gaps and fenestra in both
postcapillary venules and capillaries.54
Leukocyte Trafficking
Passage of leukocytes from blood to underlying tissue in-
volves a multistep adhesion cascade that includes initial
attachment, rolling, arrest and transmigration (Figure 2A).
These steps take place almost exclusively in postcapillary
venules. Rolling is mediated primarily by interactions be-
tween leukocyte carbohydrate-based ligands and endothelial
E- and P-selectin, and firm adhesion by interactions between
leukocyte integrins and endothelial intercellular adhesion
molecule (ICAM)-1 and vascular cell adhesion molecule
(VCAM)-1 (reviewed elsewhere72–74). The molecular basis of
transmigration is less well understood but is believed to
involve CD99, PECAM-1/CD31, and junctional adhesion
molecule-1 (reviewed elsewhere72–74).
E-selectin, among the very few genes that is highly
restricted to ECs, is expressed in activated, but not “resting”
(ie, nonactivated), endothelium (a possible exception is in the
bronchial circulation75). In activated endothelium, E-selectin
expression is largely confined to postcapillary venules.76,77 In
contrast to the usual situation in adult endothelium, E-selectin
is not inducible in early embryonic endothelium (before
E12.5).78 P-selectin is expressed in megakaryocytes and ECs.
In “resting” endothelium, P-selectin is stored intracellularly
in preexisting Weibel–Palade bodies and is expressed prefer-
entially in postcapillary venules.79 In mice, constitutive ex-
pression of cell surface P-selectin is highest in lung and
mesentery, compared with heart, brain, stomach, pancreas,
intestine, and muscle.80 Systemic administration of histamine
Figure 2. Endothelium and leukocyte
trafficking. A, According to the classical
multistep paradigm for leukocyte recruit-
ment (based on studies of skin, skeletal
muscle, and mesentery), leukocytes
(neutrophils are shown) undergo initial
attachment, followed by rolling, firm
adhesion, and transmigration through
activated endothelium in postcapillary
venules (labeled as venule). Rolling and
adhesion are mediated by interactions
between EC receptors (P- and E-selectin
and ICAM-1) and leukocyte counter-re-
ceptors/ligands (not shown). Leukocytes
may transmigrate between or through
ECs. The molecular details of transendo-
thelial cell migration (also known as dia-
pedesis or extravasation) are less well
understood but appear to involve
PECAM-1/CD31, junctional adhesion
molecule-1 (JAM-1), and CD99. Acti-
vated ECs present chemokines that
induce integrin activation on the surface
rolling leukocytes (not shown). B, In the
lung, the majority of leukocyte trafficking
takes place in pulmonary capillaries.
Leukocyte trafficking at this site is
dependent on ICAM-1 but not E- or
P-selectin. Other contributing mecha-
nisms include reduced deformability of
activated neutrophils and activation state
of the endothelium. Note that leukocytes
must cross 2 barriers (endothelium and
epithelium) to reach the airspace. C, In
the liver, leukocyte trafficking occurs pri-
marily in sinusoids by an ICAM-1–de-
pendent mechanism. Cytoplasmic proj-
ections of the neutrophil may reach through fenestrations and gaps into the space of Disse and thus sense and respond to signals
from hepatocytes and Ito cells. D, In HEVs of mesenteric lymph nodes, lymphocytes constitutively roll on, adhere to and transmigrate
across specialized cuboidal endothelium via distinct mechanisms that involve binding of lymphocyte L-selectin to EC PNAd and muco-
sal addressin cell adhesion molecule (MadCAM-1), and leukocyte integrins to ICAM-1, ICAM-2, and MadCAM-1. Not shown in the fig-
ure (but of importance in health and disease) is the transmigration of monocytes or lymphocytes in peripheral tissues, as well as leuko-
cyte trafficking in large veins and arteries.
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retention in pulmonary capillaries. Indeed, during bacterial pneumonia in rodents, 
neutrophils with f-actin rims were preferentially retained in the lungs over those without f-
actin rims at a time when sequestration was actively ongoing (Yoshida et al., 2006). 
Hence, in the pulmonary capillaries, spatial limitations allied with mediator-induced 
changes in the biomechanical properties of neutrophils promote neutrophil sequestration 
in the pulmonary capillaries. This is highlighted by animal studies demonstrating that the 
neutrophil adhesion molecules L-selectin and CD11/CD18 were not required for 
neutrophil sequestration in the pulmonary capillaries (Doerschuk, 1992; Doyle et al., 
1997; Kubo et al., 1999). However, once sequestered, both were critical for prolonged (>5 
minutes) pulmonary neutrophil retention (Doerschuk, 1992; Kubo et al., 1999).  
 As the inflammatory response progresses, cytokines including TNF, are produced 
which activate neutrophils and lung parenchymal cells including the lung microvascular 
endothelium; up-regulation of adhesion molecules on neutrophils and their cognate 
endothelial receptors thus ensues.  In addition, chemokines are induced, which activate 
integrins on neutrophils to further promote pulmonary neutrophil sequestration. 
Neutrophils then spread and crawl on the endothelial surface until they reach the site for 
transmigration (Figure 1.9).  
 Intravascular crawling is mediated by CD11b/CD18 on neutrophils and ICAM-1 
on endothelial cells. This spreading and crawling implies that the adhesive bonds between 
integrins and their ligands must be displaced while new bonds are formed. This requires 
coordinated signalling from chemokines, integrins, ICAM-1 and possibly VCAM-1 
(Burns et al., 2003; Carlos and Harlan, 1994). Besides regulating neutrophil adhesion and 
locomotion on endothelial cells, signalling during adhesion also modulates endothelial 
cell junctions, inducing expression of inflammatory genes. These responses probably play 
important roles in the progression of an inflammatory response by modulating endothelial 
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cell permeability, neutrophil transmigration and production of inflammatory mediators. 
Neutrophil transmigration through the endothelium can occur at endothelial cell borders 
(paracellular route) or through endothelial cells (transcellular route) in vitro and in vivo. 
During paracellular migration another set of adhesion molecules are engaged that include 
platelet endothelial cell adhesion molecule (PECAM)-1, VE-cadherin, junctional adhesion 
molecules (JAMs) and CD99 (Muller, 2009; Woodfin et al., 2010). 
 In other organs and in vitro, neutrophil endothelial transmigration via the 
paracellular or transcellular route is contingent upon the nature of the inflammatory 
stimulus, the tissue microenvironment, the level of ICAM-1 expression, and the 
localization of ICAM-1 (Millan et al., 2006; Woodfin et al., 2010; Yang et al., 2005). 
However, in the pulmonary microvasculature, the majority of neutrophils (and perhaps 
nearly all) appear to take the paracellular route between endothelial cells (Burns et al., 
2003; Walker et al., 1995; Behzad et al., 1996).  
Migration of neutrophils across the pulmonary interstitium is thought to be 
mediated by fibroblasts, which establish defined conduits assisting neutrophils to gain 
access to the basal surface of the epithelium (Walker et al., 1995), whilst maintaining 
alveolar-capillary integrity (Sirianni et al., 2003). Owing to the discontinuous nature of 
tight junctions at these sites, neutrophils then migrate into the alveolar space through 
tricellular corners at the junctions of type I and type II epithelial cells (Burns et al., 2003; 
Walker et al., 1995). Roles for both CD11/CD18 and the β1 integrin CD29 in neutrophil 
migration through the pulmonary interstitium toward the alveolar space have been 
established (Ong et al., 2003; Ridger et al., 2001). Once in the alveolar space, neutrophils 
adhere to the apical surface of epithelial cells, possibly through ICAM-1 interactions.  
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Figure 1.9 Neutrophil transendothelial migration 
CD62L – neutrophil L –selectin; GPCR – G protein coupled receptor; ICAM-1 – intracellular 
adhesion molecule 1; JAMs – junctional adhesion molecules; PECAM - Platelet endothelial cell 
adhesion molecule; TNF – tumour necrosis factor; VCAM-1 - vascular cell adhesion molecule 1; 
VE-cadherin – vascular endothelial cadherin (CD144).  
 
1.4.6 Resolution of neutrophilic inflammation  
1.4.6.1 Neutrophil Apoptosis 
 Once neutrophils have migrated to the alveolar space, their lifespan can be 
modified by the local inflammatory environment (Geering and Simon, 2011). For 
example, macrophages secrete death receptor ligands, such as Fas-ligand and TNF, to 
promote neutrophil survival at low concentrations and neutrophil death at higher 
concentrations (Murray et al., 1997; Salamone et al., 2001; van den Berg et al., 2001). In 
this regulatory pathway, phosphoinositide 3-kinase (PI3K)-mediated reactive oxygen 
species (ROS) production represents a key event in limiting cell survival and triggering 
apoptosis (Geering et al., 2011), whilst Btk, a negative regulator of NADPH activation, is 
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associated with neutrophil survival (Honda et al., 2012). Hence, Btk-deficient neutrophils 
demonstrate high levels of ROS production, driven by excessive NADPH and PI3K 
activation (Honda et al., 2012). Other environmental signals such as hypoxia prolong 
neutrophil lifespan via hypoxia-inducible factor-1a (HIF1a) induced mechanisms 
(Walmsley et al., 2011). Finally, GM-CSF, a survival factor for neutrophils, triggers 
extracellular signal-regulated kinases (ERK) activation; interference with ERK or other 
lifespan prolonging signalling pathways may promote neutrophil apoptosis. 
 Neutrophil apoptosis is thought to be central to the restoration phase of ALI; it 
leads to functional down-regulation, including shape change, degranulation and 
respiratory burst (Whyte et al., 1993) and to recognition and clearance of the apoptotic 
neutrophils by resident macrophages (Savill et al., 1989). Dysregulated neutrophil 
apoptosis has been proposed as an important mechanism contributing to the propagation 
of lung injury (Cox et al., 1995). Indeed, several human studies have demonstrated 
decreased neutrophil apoptosis in ALI and modulation of neutrophil apoptosis when 
treated with BALF from patients in the early phase of ALI (Lesur et al., 2000; Matute-
Bello et al., 2000; Matute-Bello et al., 1997). This inhibitory effect of BALF on neutrophil 
apoptosis is thought to mediated by the pro-inflammatory cytokines granulocyte colony-
stimulating factor (G-CSF), and GM-CSF (Matute-Bello et al., 1997; Matute-Bello and 
Martin, 2003) possibly acting through PI3K. Concentrations of G-CSF and GM-CSF in 
BALF from ARDS patients correlated with the anti-apoptotic effect of ARDS BAL fluid 
on neutrophils (Matute-Bello et al., 2000). Additionally, pre-B cell colony-enhancing 
factor has been identified as a novel cytokine that plays a requisite role in delayed 
neutrophil apoptosis in clinical and experimental sepsis (Jia et al., 2004).  
78 
 
 
1.4.6.2 Neutrophil de-priming 
 Neutrophil priming, including shape change, has been shown to be reversible in 
vitro (Kitchen et al., 1996).  Two hours after challenge with PAF, cells demonstrated 
baseline values of superoxide anion generation, cell polarisation and CD11b activity. 
Interestingly, once recovered, these cells were capable of subsequent re-priming following 
stimulation with PAF or TNF. Recently the concept that the pulmonary vasculature 
provides a protective mechanism in the role of neutrophil priming has been proposed 
(Summers et al., 2014). Hence, the healthy lung microvasculature retains primed cells and 
facilitates their de-priming and release (into the systemic circulation) in an un-primed 
quiescent state. Failure of these mechanisms, for example in endothelial injury in ALI, 
results in high circulating levels of primed neutrophils, which correlates with the severity 
of lung injury (Chollet-Martin et al., 1992).  
 
1.5 Experimental Strategy 
 Numerous clinical and experimental studies have implicated TNF as a central 
mediator of ALI.  Previous clinical trials of anti-TNF therapy have, however, failed to 
demonstrate clinical benefit; this, in part, may relate to the complex biology of differential 
TNF signalling through its two cell surface receptors, TNFR1 and TNFR2, which initiate 
distinct signalling pathways and cellular responses. Using a novel, highly selective 
TNFR1 domain antibody GSK1995057 allied with TNFR specific muteins, we sought to 
investigate the roles of differential TNFR signalling in a range of human in vitro models 
of ALI. In particular, we focused on the role of differential TNFR signalling in 
components of the cascade of events, which lead to neutrophil migration into the alveolar 
space during ALI including; chemokine and cytokine release; lung microvascular 
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permeability, neutrophil priming and activation, neutrophil chemotaxis and adhesion 
molecule expression on both neutrophils and lung microvascular endothelial cells. 
 Experiments were performed using human neutrophils, human lung microvascular 
cells and human alveolar type II epithelial cells to represent the major cell types involved 
in modulating neutrophil migration in human lung. 
 Finally, we aimed to establish a robust and reproducible human ex vivo model of 
LPS induced ALI. The purpose of this work was to overcome the failings of current 
animal models of ALI to translate promising preclinical data into clinically beneficial 
therapies and to confirm our in vitro data in a highly relevant and tractable whole human 
lung model. 
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2 Chapter 2: Materials & methods 
2.1 Materials 
2.1.1 Cells and cell culture reagents and materials 
Human alveolar type 2AT2 cells and human alveolar macrophages 
40µm cell strainer BD Biosciences (352340) 
Collagen I Coated Bioflex plates DunnLab (BF30010/40) 
DCCM-1 Medium React Scientific (05-010-1A) 
DNase I Sigma-Aldrich (DN-25) 
Hanks balanced salt solution (HBSS) Invitrogen (14025-050) 
Newborn calf Serum (NCS) Invitrogen (26010-074) 
Purecol, type I collagen Advanced BioMatrix (5005-B) 
Penicillin/Streptomycin/Glutamine  Invitrogen (10378-016) 
Trypsin (from bovine pancreas) Sigma-Aldrich (T8003) 
 
HUVEC  
Endothelial Growth Media-2 Bullet Lonza (CC3162) 
Human Umbilical Vein Endothelial Cells (Pooled) Lonza (C2519A) 
Reagent Pack - subculture kit Lonza  (CC5034) 
 
HMVEC-L 
3µm polycarbonate membrane inserts 12mm membrane VWR (734-1570) 
Cryo SFM Promocell (C29910) 
Detach Kit 30 Promocell (C41200) 
ENDOHM for 6mm culture cup World Precision Instruments 
(ENDOHM-6) 
Endothelial Growth Media MV2 Kit Promocell (22121) 
Human Pulmonary Microvascular Endothelial Cells 
(Proliferating) 
Growth factor reduced matrigel 
µ-slide angiogenesis slide 
 
Promocell (C12282) 
 
BD Biosciences (734-0269) 
IBIDI (81506) 
Neutrophils 
Citrate Concentrated Solution 4% Sigma-Aldrich (S5770) 
Dextran 500 from Leuconostoc sp 
Dulbecco’s phosphate buffered saline (with CaCl2 & MgCl2) 
Dulbecco’s phosphate buffered saline (without CaCl2 & 
MgCl2) 
Sigma-Aldrich (31392-10G) 
Sigma-Aldrich (D8662) 
 
Sigma-Aldrich (D8537)) 
Iscove’s Modified Dulbecco’s medium (IMDM) IMDM media Invitrogen (12440-046) 
Iscove’s Modified Dulbecco’s medium IMDM media (no 
without phenol red) 
Life technologies (21056-023) 
Percoll VWR (17-0891-0L)  
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2.1.2 Cytokines, inhibitors and other drugs 
Evans Blue Sigma Aldrich (E2129) 
Human Interleukin-8 (IL-8) R&D Systems (208-IL-100) 
Human GM-CSF R&D Systems (285-IF-100) 
Human Tumour Necrosis Factor R&D Systems (210-TA-10) 
Human Vascular Endothelial Growth factor R&D Systems (293-VE-10) 
Lipopolysaccharide from Escherichia coli 011:B4 Sigma Aldrich (L2630) 
Luminol Sigma-Aldrich (123072) 
N-formyl-Met-Leu-Phe Sigma-Aldrich (F3506) 
TNFR1-Fc R&D Systems (372-R1) 
TNFR2-Fc R&D Systems (726-R2) 
U0126 Calbiochem (662005) 
 
2.1.3 Flow Cytometry and Immunofluorescence antibodies and reagents 
Alexa Fluor 594 Donkey anti-goat IgG Antibody Life Technologies (A-11058) 
CellFIX BD Biosciences (340181) 
Cell dissociation solution Non-enzymatic x1 Sigma Aldrich (C5789) 
Compensation beads BD Biosciences (552843) 
Goat Polyclonal IgG VE-Cadherin Antibody Santa Cruz Biotech (sc-6458) 
Mouse IgG1 κ Isotype APC Isotype Control Antibody Cambridge Biosciences (400120) 
Mouse IgG1 κ Isotype APC Isotype Control Antibody Biolegend (400119) 
Mouse IgG1 κ Brilliant Violet 421 Isotype Control Antibody Cambridge Biosciences (400158) 
Mouse IgG1 Phycoerythrin Isotype Control Antibody R&D Systems (10002P) 
Mouse IgG1 Pacific Blue Isotype Control Antibody Biolegend (400131) 
Mouse IgG1 Fluorescein Isotype Control Antibody R&D Systems (10002F) 
Mouse IgG2a FITC κ Isotype Control Antibody Biolegend (400209) 
Mouse IgG2 Phycoerythrin Isotype Control Antibody Biolegend (400213) 
Cell dissociation solution Non-enzymatic x1 Sigma Aldrich (C5789) 
ProLong Antifade Reagent with DAPI Life Technologies (P-36931) 
2.1.4 Western blotting antibodies and reagents 
5x Loading buffer Invitrogen  
10% Tris-HCl ready gel Bio-Rad (161-1155) 
10X Cell Lysis Buffer New England Biolabs (9803) 
10x Tris/Glycine/SDS (TGS) buffer Bio-Rad  (161-0732) 
Amersham Rainbow Markers (full range) GE Healthcare (RPN 800E) 
Anti BMX (phosphor 456) Antibody Abcam (ab59409) 
Bmx Antibody (C-17) Insight Biotech (sc-8874) 
Hyperfilm ECL (X ray film) Amersham Biosciences 
 (RPN203D) 
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Laemmli Sample Buffer Bio-Rad (161-0737) 
LumiGLOTM Reagent and Peroxide New England Biolabs (7003) 
Milk powder Waitrose 
Phototope®-HRP Western Blot Detection New England Biolabs  
Phospho-p44/42 MAPK Antibody Cell Signalling Tech (9101) 
Phospho-Etk (Tyr40) Antibody Cell Signalling Tech (3211) 
Phospho-STAT-1 Antibody Cell Signalling Tech (9167) 
Phospho-STAT-3 Antibody Cell Signalling Tech (9131) 
p44/42 MAPK Antibody Cell Signalling Tech (9102) 
STAT-1 Antibody Cell Signalling Tech (9172) 
STAT-3 Antibody Cell Signalling Tech (9132) 
 
2.1.5 Molecular Biology Reagents 
dNTP (set) Sigma-Aldrich (DNTP100A) 
GAPDH primer Qiagen (QT01192646) 
Moloney murine leukaemia virus reverse transcriptase  Invitrogen (28025-13) 
Oligo (dT) 12-18 primer Invitrogen (18418-012) 
PCR oligonucleotide primers Invitrogen Life Sciences 
PCR tubes and caps Qiagen 
QuantiTect primer pairs Qiagen 
RNase Sigma-Aldrich (R4875) 
RNeasy Mini Kit Qiagen (74104) 
RNase free DNase set Qiagen (79254) 
Surfactant Protein C Primer Qiagen (QT00000714) 
Trizol Sigma-Aldrich (1559-026) 
 
2.1.5.1 Primers 
  
Both were purchased from Qiagen and selected with the aid of Primer3 software. 
Primer     Sequence 
Surfactant Protein C   Forward GCAGGGAGAGACAGGTGAAG 
     Reverse  GGTGGCCTGGATTCTAACAA 
GAPDH    Forward GAAGGTGAAGGTCGGAGT 
     Reverse GAAGATGGTGATGGGATTTC 
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2.1.6 Kits 
Annexin V FITC Apoptosis Detection Kit BD Biosciences (556547) 
Cytoselect Leukocyte Transmigration Assay Cambridge Bioscience (CBA 212) 
Human CXCL8/IL-8 DuoSet ELISA Kit R&D Systems (DY208) 
Human sTNFR-1 duoset R&D Systems (DY225) 
Human sTNFR-2 duoset R&D Systems (DY726) 
Mini Trans-Blot Electrophoretic Transfer Cell Bio-Rad (170-3930) 
MPO Human ELISA kit Hycult biotech (HK324-02) 
pP38 MAPK alpha (pT180/Y182) PhosphoTracer ELISA kit Abcam (ab119638) 
QuantiTect Reverse Transcription kit Qiagen (205310) 
QuantiTect SYBR Green PCR kit Qiagen (74104) 
 
2.1.7 MSD plates 
Custom V-plex Meso Scale Discovery (K15047D) 
Prototype duplex Meso Scale Discovery (N45ZA) 
Human cytokine 9-plex Meso Scale Discovery (K15007B) 
Human chemokine 7-plex Meso Scale Discovery (K15031C) 
Custom 5-plex Meso Scale Discovery (N751A) 
Vascular Injury Panel II Meso Scale Discovery (K15136C) 
 
2.1.8 Ex vivo lung perfusion hardware 
Biomedicus BPx80 Pump head Medtronic (95204) 
Bovine serum albumin (BSA) Low Endotoxin Fisher Scientific (BPE9705) 
DMEM high glucose Sigma-Aldrich (D5671) 
ECMOTHERM II Heat Exchanger Medtronic (ECMOTHERM II) 
Heater Cooler 3T Sorin Biomedical (16-02-80) 
Lung Catheter Pulmonary Artery (unwashed) Vivoline Medical (410018-01) 
Lung Research Pack Maquet (H19702) 
Organ Box Insert (unwashed) Vivoline Medical (410008-01) 
Organ Box Lid (unwashed) Vivoline Medical (410007-01) 
Organ Box Reservoir (unwashed) Vivoline Medical (410006-01) 
Perfadex XVIVO perfusion (19017) 
Red cell lysis buffer Sigma-Aldrich (R7757) 
Steen Solution XVIVO Perfusion (19004) 
XVIVO Organ Chamber XVIVO Perfusion (19020) 
XVIVO Lung cannula set XVIVO Perfusion (19022) 
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2.1.9 General reagents 
2-mercaptoethanol Sigma-Aldrich (M-7522) 
Agarose, low gelling temperature Sigma-Aldrich (A9414) 
Albumin FITC-conjugated Sigma-Aldrich (A9771) 
Benzamide Sigma-Aldrich (125828) 
Bovine serum albumin (BSA) Sigma-Aldrich (A7030) 
Bradford protein assay dye reagent concentrate Bio-Rad (500-0203) 
Dextran Blue (from Leuconostoc sp) Sigma-Aldrich (31393) 
Dimethyl sulphoxide (5×5mlmL DMSO) Sigma-Aldrich (D2650) 
Dimethyl sulphoxide (DMSO) Sigma-Aldrich (D5879) 
Dithiothreitol (DTT) Sigma-Aldrich (D5545) 
Reastain DiffQuick solution Gentaur Molecular Products (102035) 
ELISA substrate reagents A+B BD Biosciences (555214) 
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich (E6511) 
Evans Blue Sigma Aldrich (E21299) 
Ethanol BDH (L227007) 
Formalin solution, neutral buffered, 10% Sigma-Aldrich (HT501128) 
HEPES Sigma-Aldrich (H7006) 
Hank’s Balanced Salt Solution (HBSS) Sigma-Aldrich (55021C) 
Human albumin solution (20%) Bioproducts Laboratory 
Hydrogen Peroxide (H2O2) Sigma-Aldrich (H6520) 
Glutamine Invitrogen (25030-024) 
Growth factor reduced Matrigel BD Biosciences (734-0269) 
Methanol BDH (10158BD) 
Methylthiazolitetrazolium (MTT) Sigma-Aldrich (M2128) 
Penicillin / Streptomycin Invitrogen (15140-122) 
Phenylmethanesulphonyl fluoride (PMSF) Sigma-Aldrich (D7626) 
Phosphate buffered saline tablets Sigma-Aldrich (P4417) 
Propidium Iodide Sigma-Aldrich (P4864) 
Protein standard Sigma-Aldrich (P5619) 
Red Blood Cell Lysing Buffer Hybri-Max Sigma-Aldrich (R7757) 
Sodium Azide (NaN3) Sigma-Aldrich (S2002) 
Sodium chloride 0.9% Baxter (TRF7124) 
Sodium fluoride Sigma-Aldrich (S7920) 
Sodium pyrophosphate Sigma-Aldrich (P8135) 
Streptavidin Peroxidase (for ELISA) Sigma-Aldrich (S5512) 
Sucrose BDH  (102745C) 
Triton X-100 BDH (30632) 
Trypsin (0.25%) + EDTA (1mM) Invitrogen (15400-054) 
TRIZMA base Sigma-Aldrich (T6791) 
TRIZMA hydrochloride Sigma-Aldrich (T3253) 
Vectashield mounting medium Vector Labs (H1000)  
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2.1.10 Company Locations 
Abcam Cambridge, UK 
Advanced BioMatrix Inc San Diego, CA, USA 
Amersham Biosciences Little Chalfont, UK 
Baxter Deerfield, IL, USA 
BD Bioscience Palo Alto, CA, USA 
BDH Poole, UK 
Biolegend San Diego, CA, USA 
Bio-Rad Laboratories Hercules, CA, USA 
Calbiochem San Diego, CA, USA 
Cambridge Bioscience Cambridge, UK 
Cell Signaling Technologies Beverley, MA, USA 
DunnLab Asbach, Germany 
Fisher Scientific Loughborough, UK 
GE Healthcare Little Chalfont, UK 
Gentaur Kampenhout, Belgium 
Hycult biotech Uden, The Netherlands 
Invitrogen Carlsbad, CA, USA 
Insight Biotech Wembley, UK 
Life Technologies Carlsbad, CA, USA 
Lonza Basel, Switzerland 
Maquet Rastatt, Germany 
Meso Scale Discovery Rockville, MD, USA 
Medtronic Minneapolis, MN, USA 
New England Biolabs Hitchin, UK 
Promega Madison, WI, USA 
Promocell Heidelberg, Germany 
Qiagen Venlo, Netherlands 
R&D Systems Abingdon, UK 
React scientific Troon, UK 
Santa Cruz Biotechnology Santa Cruz, CA, USA 
Sigma-Aldrich Poole, UK 
Vector Labs Burlingame, CA, USA 
XVIVO Perfusion Gothenburg, Sewden 
Vivoline Medical Lund, Sweden 
VWR Radnor, PA, USA 
World Precision Instruments Sarasota, FL, USA 
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2.2 General Methods 
2.2.1 Centrifugation 
 Centrifugations were carried out for volumes less than 2mL in one of two fixed 
angle machines Hawk 15/05 (Sanyo GallenKemp, Etten Leur, Netherlands) or Boeco M- 
240 R (Hettich, Germany). For larger volumes a Hettich Rotina 46R swing bucket 
centrifuge was used (Hettich AG). Centrifugation speeds are quoted as the relative 
centrifugal force (rcf) or centrifuge rotor speed (revolutions per minute: rpm) followed by 
time, and temperature. For neutrophil isolation, the acceleration and brake parameters are 
also quoted. 
2.2.2 Cell counting 
 Cells were counted by using a haemocytometer (improved Neubauer model) under 
a phase contrast microscope (CK40, Olympus UK, Southend, UK). The total cell number 
in the four corner squares was counted including cells that overlapped the bottom and 
right border of squares but not those overlapped top and left border. Appropriate dilutions 
were made such that the total number of cells counted was between 100 and 400. The 
volume of each square’s area was 10-4mL, and the number of cells per mL was calculated 
using the following formula: 
 
2.2.3 MTT determination of cell viability and proliferation 
 Yellow tetrazolium MTT (3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium 
bromide) is cleaved into purple formazan by metabolically active cells, to generate 
reducing equivalents such as NADH and NADPH. The resulting intracellular purple 
formazan can be solubilised and quantified spectrophotometrically. In a homogeneous cell 
 Cells/mL  =      
Total cell number of four corner squares x 10000 
    4 
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population, the amount of formazan generated is directly proportional to the number of 
viable cells over a wide range. After cell treatments, cell supernatants were removed, the 
cells washed with buffer and incubated at 37°C with MTT (1mg/mL) in medium for a 
period of time dependent on the cell type. Following incubation, MTT solution was 
removed completely and the plates dried. Formazan dye was dissolved in DMSO for 15 
minutes and excitation measured at 550nm. 
2.2.4 Trypan blue determination of cell viability 
 Non-viable cells with compromised membranes absorb and fail to exclude trypan 
blue, whilst healthy cells are refractile (unstained). An equal volume of cell suspension 
and Trypan Blue (0.4% w/v) were mixed and observed after 2-3 minutes. Viability was 
expressed as the percentage of unstained cells relative to the total number of cells and 
determined according to the following equation: 
 
2.2.5 Cell culture Protocols 
2.2.5.1 Isolation of human alveolar type 2 cells 
 Human alveolar type 2 (hAT2) cells were isolated, purified and cultured from 
disease-free lung parenchyma removed as part of a tumour resection (Pinhu et al., 2008; 
Witherden and Tetley, 2001). This practice was approved by the Local Ethics Committee 
(REC reference 10/H0504/9). Lung sections were perfused by injection of 0.9% sterile 
0.9% sodium chloride (saline) until the draining lavage ran clear and the cell count was 
less than 1x104 cells/mL. The tissue was then perfused and inflated with trypsin (0.25% in 
HBSS; Sigma, Poole, UK) and incubated at 37oC for 45 min; trypsin was replaced twice 
during this time. The tissue was finely chopped in the presence of newborn calf serum 
Viability (%) =   
Viable cell number x 100% 
  Total cell number 
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(NCS; Invitrogen). The chopped tissue was then incubated with DNase (250 μg/mL; 
Sigma) and the mixture shaken by hand for 5 minutes before being passed through a 
300μm filter, followed by a 40μm filter to remove large tissue debris. The cell suspension 
was then centrifuged at 1300 rpm for 10 min and the cell pellet re-suspended in DCCM-1 
media (React Scientific) containing DNase (50μg/mL). These cells were incubated in 
tissue culture flasks for 2 hours at 37oC, 5% CO2 to allow differential adherence of 
mononuclear cells. 
 After 2 h the non-adherent ATII cells were removed and the cell suspension 
centrifuged at 1300 rpm for 10 min. The cell pellet was then re-suspended in DCCM-1 
containing 10% NCS and 1% PSG at a concentration of 1x106 cells/mL. Following 
isolation, cells were counted by using a haemocytometer under a phase contrast 
microscope and seeded onto type 1 collagen-coated well (1% Purecol 3mg/mL) at the 
optimum density (Table 2.1). hAT2 cells were stained with alkaline phosphatase, which 
has been used to characterise isolated cells (Edelson et al., 1988). The intensity of pink 
stain reflects the amount of alkaline phosphatase present (Figure 2.1). The cells used for 
experimentation were over 95% “alkaline phosphatase-positive” representing hAT2 
purity, and expressed surfactant protein C (figure 2.1). After 48h the confluent monolayer 
was washed 3 times with DCCM-1 medium containing 10% NCS to remove debris and 
blood. New medium was added and cells were ready for experimentation 72 hours after 
seeding. 
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Table 2.1 Optimum seeding density of hAT2 cells in various well sizes 
 Growth Surface (cm2) Culture medium (mL) Recommend density 
6 well plate 9.6 2.0 2.5-5.0×106 per well 
12 well plate 3.8 1.0 1.0-2.0×106 per well 
24 well plate 2.0 0.5 0.5-1.0×106 per well 
48 well plate 0.75 0.3 2.0-3.75×105 per well 
96 well plate 0.32 0.1 1.0-1.5x105 per well 
 
 
Figure 2.1 Characterisation of human alveolar type 2 cells 
Human alveolar type II (hAT2) cells were stained with alkaline phosphatase. Image A shows cells 
at x10 power, 72h hours following seeding while Image B shows cells at x5 power 96 hours after 
seeding. The cells are virtually 100% alkaline phosphatase-positive, representing the hAT2 cell 
purity. To further confirm purity, RNA was extracted from monolayers of hAT2. Polymerase 
chain reaction of RNA demonstrated surfactant protein C cDNA (arrowed lines, Image C) with 
co-expression of reference genes GAPDH and HMBS. These are representative images of n=4. 
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2.2.5.2 Isolation of human alveolar macrophages 
The draining lavage from perfused lung sections outlined above was collected into 50mL 
Falcon tubes. The first two Falcons, which contained large numbers of red blood cells 
were discarded and the remaining falcons centrifuged at 300rcf for 10 minutes. The cell 
pellets was re-suspended in pre-warmed serum-free DCCM-1 containing 1% 
penicillin/streptomycin/ glutamine and plated in 24-well tissue culture plates (0.5x106 
macrophages/well). After 3 hours, macrophages had adhered and the medium was 
removed and the wells were washed with pre-warmed DCCM-1 four times, to remove 
non-adherent cells and ensure minimal red cell contamination. The macrophages were 
maintained in serum-free DCCM-1 and treated within 15 hours of plating. 
2.2.5.3 Human lung microvascular endothelial cell line 
 Primary human lung microvascular endothelial cells (HMVEC-L) were purchased 
from Promocell (Germany). These cells are isolated from post mortem normal human 
tissue and stain positive for CD31 and von Willebrand factor, and negative for smooth 
muscle alpha-actin. They are shipped as proliferating cells at passage 2. The cells were 
maintained in microvascular endothelial cell growth medium-2 (EGM-MV2, Promocell) 
supplemented with 2% FBS and growth factors, antibiotics and other additions according 
to the manufacturer’s guidelines. They were incubated at 37oC in a humidified atmosphere 
of 5% CO2 in air. Cells were passaged when 70-90% confluent (figure 2.2) using 
Trypsin/EDTA for between 2 and 3 minutes, until 90% of cells were detached from the 
growth flask. Trypsin activity was stopped using trypsin neutralising solution (TNS, 
Promocell). The cells were centrifuged at 220rcf for 3 min at room temperature and re-
suspended in culture medium. The morphology of confluent HLMVEC under phase 
contrast microscopy is shown in figure 2.2. After a variable number of passages, cell 
growth pattern or morphology altered, at which point cells were abandoned and a new vial 
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purchased. For all experiments cells were used at passage 3-6. Cells were routinely seeded 
at a density of 1x104 cells/cm2 unless otherwise stated. 
 
Figure 2.2 Morphology of confluent HMVEC-L 
 
2.2.5.4 Human umbilical vein endothelial cells cell line 
 Pooled human umbilical vein endothelial cells (HUVEC) were purchased from 
Lonza (UK). These cells are isolated from up to 4 different umbilical cords and stain 
positive for CD31 and von Willebrand factor and negative for smooth muscle alpha-actin. 
They are shipped as cryopreserved cells at passage 2. The cells were maintained in 
microvascular endothelial basal medium-2 (EGM-2) supplemented with 5% FBS and 
growth factors, antibiotics, and additives according to the manufacturer’s guidance. 
HUVEC were incubated at 37oC in a humidified atmosphere of 5% CO2 in air and 
passaged when 80% confluent (figure 2.3) using Trypsin/EDTA for between 2 and 3 
minutes, until 90% of cells were detached from the growth flask. Trypsin activity was 
stopped using trypsin neutralising solution (TNS). The cells were centrifuged at 220rcf for 
3 min at room temperature and re-suspended in culture medium. The morphology of 
confluent HUVEC under phase contrast microscopy is shown in figure 2.3. For all 
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experiments cells were used at passage 3-7. Cells were routinely seeded at a density of 
5x103 cells/cm2 unless otherwise stated. 
 
Figure 2.3 Morphology of confluent HUVEC 
 
2.2.5.5 Purification of human neutrophils for in vitro studies 
 Ethical permission was granted by the local ethics committee (REC reference 
11/LO/1092), for obtaining peripheral venous blood from healthy non-medicated 
volunteers. Neutrophil isolation was undertaken at room temperature, using endotoxin-
free reagents and plastic-ware, under sterile conditions in a laminar flow cell culture hood 
(Microflow Class II cabinet) as previously described by Haslett (Haslett et al., 1985). 
 Venupuncture was undertaken using a sterile 19 gauge Butterfly needle (Hospira 
Venisystems) and 50mL Plastipak disposable syringes. The blood was immediately 
transferred into 50mL Falcon tubes (BD) containing 4mL (3.8%) sodium citrate to make a 
total volume of 40mL. Cells were centrifuged at 320 rcf for 20 min at room temperature. 
The platelet-rich plasma (PRP) supernatant layer was removed and used to make platelet 
poor plasma (PPP) and autologous serum. To prepare PPP, the PRP was centrifuged at 
1400 rcf for 20 min and the pellet discarded. Simultaneously, the pelleted cells from the 
initial blood centrifugation were subjected to dextran sedimentation using 6% dextran 500 
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(2.5mL/10mL of cell pellet). The volume was made up to 50mL with 0.9% pre-warmed 
(37oC) sterile 0.9% saline and the tubes then mixed gently and allowed to stand for 30 min 
to allow the erythrocytes to sediment. 
 The leukocyte-rich plasma was aspirated and centrifuged at 320 g for 6 minutes. 
The pellet was gently re-suspended in 2mL PPP and transferred to a 15mL Falcon tube, 
where it was under-layered with 2mL freshly prepared 42% Percoll in PPP, which was in 
turn under layered with 2mL of freshly prepared 51% Percoll in PPP. Under-layering was 
performed using a Pasteur pipette (2mL, Sigma-Aldrich). The gradients were centrifuged 
for 14 min at 150 rcf, with the brake and acceleration speed set to zero. Mononuclear cells 
and some platelets remained at the top interface between the plasma and 42% Percoll 
layer, with neutrophils in a wider band at the interface of the 42% and 51% layer Percoll 
layers and extending into the 51% Percoll layer to a few millimeters above the erythrocyte 
pellet (figure 2.4). Each band was aspirated with a Pasteur pipette. The neutrophils were 
sequentially washed in PPP, phosphate buffered saline without Ca2+/Mg2+ (PBS-/-) and 
phosphate buffered saline with Ca2+/Mg2 (PBS+/+) (centrifuged at 256 rcf, 5 min) prior to 
re-suspension at 5 x 106 cells/mL in PBS+/+ or Iscove’s Modified Dulbecco’s medium 
(IMDM) containing 1% autologous serum.  
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Figure 2.4 Plasma-Percoll gradation of freshly isolated leukocytes 
   
 Cell purity was confirmed by examination of cytocentrifuged neutrophils. 
Labelled Polycine microscope slides were placed in funnel clips in a cytospin (Cytospin 2, 
Thermo Scientific). The cell suspension (100µL of 2x106 cells /mL) was placed into the 
funnel and centrifuged at 300 rpm for 3 minutes, at high acceleration. Slides were 
removed and allowed to air dry before being placed in methanol for 4 minutes. Slides 
were then sequentially placed in DiffQuick stain; orange/red for 1 minute, then blue for 2 
minutes, with excess stain being rinsed off in between with distilled water. Stained slides 
were allowed to air dry for 30 minutes before being coverslip mounted using DPX (Sigma 
Aldrich). Cells were examined by light microscopy, magnification x20, 300 cells/ per 
slide in triplicate. Analysis of freshly isolated neutrophils confirmed that neutrophil 
preparations were routinely >99% viable (trypan blue negative) and analysis of cytospun 
neutrophils were 95 ± 1.8% pure (eosinophils being the dominant non-neutrophil 
contaminant), with less than 0.1% monocytes. In addition, basal median forward scatter 
(shape change) (Qu et al., 1995) did not significantly differ between donors (p=0.0443, 
figure 2.5). 
Mononuclear*cells*
Neutrophils*
Erythrocyte*pellet*
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Figure 2.5 Mean forward scatter in freshly isolated human neutrophils 
Freshly isolated human granulocytes (5x106/mL) were analysed by flow cytometry. Shape change 
was assessed by mean forward scatter (FSC, n=11).  
 
2.2.6 In vitro ALI modelling 
2.2.6.1 Applying cyclic mechanical strain to hAT2 
 The FX-4000TM system was used to apply cyclic mechanical strain (CMS, stretch) 
to cell monolayers according to computer-controlled protocols. Amplitudes of 0, 5, 20 and 
30% elongation were used at a frequency of 20 cycles per minute. The system consists of 
a FlexCentral® computer, BioFlex® Baseplate & Gaskets, BioFlex® Loading stations 
and BioFlex® plates (figure 2.6). The system applies strain using a vacuum to deform the 
flexible membrane on which cells are cultured (Gilbert et al., 1994; Schaffer et al., 1994). 
 The BioFlex culture plate has 6-wells, which can be deformed by up to 30% 
elongation. The BioFlex loading stations are designed to provide uniform radial and 
circumferential strain across the membrane surface up to 20% elongation. The membrane 
is pulled over the post by the vacuum; each radius is stretched by same amount at any 
point in the circle, providing uniform “equibiaxial” strain for all cells on the membrane 
when applied elongation to the cell is ranged between 0 to 20%. Loading posts are 
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removed when greater than 20% elongation is used. The inability to achieve 30% strain 
whilst using the loading posts is a limitation of the FlexercellTM system. Without loading 
posts a radially non-uniform strain field is produced, such that only a fraction of cells in 
the well's periphery are exposed to the desired amplitude of strain (i.e. 30%) (Gilbert et al. 
1994; Schaffer et al. 1994). Furthermore, mechanical strain is not confined to the 
basolateral cell surface. The radial acceleration of cells relative to the stationary medium 
produces shear forces over the apical cell surface that are of uncertain significance. 
 
Figure 2.6 Flexcell FX-4000 system 
Image A – shows the Flexcell® FX-4000™ computational system. Image B - diagram to illustrate 
the application of the vacuum to the flexible membrane with (B1) and without (B2) loading posts. 
 
2.2.6.2 Endothelial monolayer permeability assay 
 Electrical resistance of endothelial cell monolayers was measured using an 
electrical cell impedance sensor (ECIS) technique (Applied Biophysics, Inc., NY, USA). 
HMVEC-L (2.5 x 105 cells/mL, 400µL) were cultured in proprietary chamber slides with 
8 wells per slide. Each well contains ten circular 250µm diameter active electrodes 
connected in parallel on a common gold pad, measuring approximately 500 to 1000 cells. 
The chamber slide was connected to the 16 well array station and placed in an incubator at 
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37oC, 5% CO2. Following growth to confluence (normally over 72 hours), the endothelial 
monolayer acts as insulating particles and the total resistance across the monolayer is 
composed of the resistance between the ventral cell surface and the electrode and the 
resistance between cells. A 4,000-Hz AC signal with 1-volt amplitude through a 1mΩ 
resistor created an approximate constant current source (1µA). The lock-in amplifier 
attached to the electrodes detects changes in both magnitude and phase of the voltage 
appearing across the endothelial cell and was controlled by an IBM-compatible personal 
computer, which was used both for data accumulation and processing. Transendothelial 
resistance (TER, generated by a proprietary alogorithm) increased immediately after cell 
attachment and achieved a steady state when endothelial cells became confluent. Thus, 
experiments were conducted after the electrical resistance achieved a steady state of 3000 
ohms. Resistance data were normalised to the initial voltage and plotted as a normalised 
TER over 20 hours.  
2.2.6.3 Neutrophil Apoptosis Assay 
 Neutrophil apoptosis was assessed using a commercial kit purchased from Becton 
Dickenson (Annexin V FITC Apoptosis Detection Kit). Double labelling of neutrophils 
with Annexin-V-7AAD (AnV), which binds to phosphatidylserine on the surface of 
apoptotic cells, and the nuclear stain propidium iodide (PI), which allows assessment of 
membrane integrity, enables differentiation between viable non-apoptotic cells (AnV-, PI-
), viable early apoptotic cells (AnV+, PI-), and late apoptotic/necrotic cells (AnV+, PI+). 
 Purified neutrophils were re-suspended at 5x106 (200µL) in IMDM supplemented 
with autologous serum (10%) and streptomysin and penicillin (50U/mL) and cultured in 
Falcon flexiwell 96-well plate inserts. Following treatment for 6 or 20 hours, neutrophils 
were pulse-centrifuged, then re-suspended in binding buffer (100µL: 0.1M HEPES pH 
7.4, 1.4M NaCl, 25mM CaCl2), containing annexin-V-fluorescein isothiocyanate (FITC: 
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2.5µL) and propidium iodide (PI: 5µL). Samples were incubated for 20 minutes at 4°C in 
the dark, and the volume increased to 500µL with buffer immediately before analysis 
using a fluorescence-activated cell sorter with FACS Diva software. Ten thousand events 
were collected for each sample, and data analysed using FlowJo software (v10.0, Treestar, 
USA). Viable, non-apoptotic neutrophils were defined as being negative for both annexin 
V-FITC and PI, and apoptotic neutrophils were defined being as positive for annexin V-
FITC. Apoptosis was expressed as a percentage in relation to the total number of counted 
neutrophils.  
 These data were confirmed by assessing microscope slides (×100 objective) of 
cytocentrifuged neutrophils fixed in methanol and stained with DiffQuick™. Apoptotic 
neutrophils were identified by cell shrinkage, blebbing of the cell membrane and the 
presence of darkly stained, condensed and fragmented nuclei. For each condition, 
duplicate slides were prepared and 300 neutrophils counted per slide in a blinded fashion.  
2.2.6.4 Oxidative burst in human neutrophils 
 The kinetics of TNFR dependency on oxidative burst in TNF primed, fMLP 
stimulated neutrophils was obtained assessed using luminol-dependent 
chemiluminescence. Human neutrophils (5x106/mL, 400µL) were harvested as outlined 
previously. Neutrophils were exposed to treatments and controls for 45 minutes at 37oC at 
300rpm in a thermomixer (Thermomixer Comfort, EppendorfEppendorf, USA). Luminol 
(1µM) and horseradish peroxidase (HRP: 62.5U/mL) in PBS were added to the treated 
cells. After 3 minutes, 150µL of this the cell suspension was transferred to a pre-warmed 
96-well luminometer plate. Neutrophils were stimulated with fMLP (100nM); fMLP was 
added through the injection port and light emission was recorded by a Berthold 
MicroLumat Plus luminometer (Berthold Technologies, UK). Data output was measured 
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in relative light units per second and data analysed as fold change in peak height of 
luminescence intensity over a period of 10 minutes.  
2.2.6.5 Leukocyte transendothelial migration assay 
2.2.6.5.1 Confirmation of HMVEC-L monolayer integrity on Transwell filters 
Prior to assessing neutrophil migration, monolayer integrity in HMVEC-L grown 
on Transwell inserts was confirmed. At a seeding density of 4x104 cells/well, by 72 hours 
fluorescent confocal microscopy of Transwell filters stained strongly positive for VE-
cadherin suggesting intact adherens junctions in monolayers (Figure 2.7A & B). 
Transendothelial resistance increased over 72 hours, suggestive of monolayer integrity 
(Figure 2.7C); this effect was associated with impermeability to FITC-labelled albumin 
(Figure 2.7D).  
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Figure 2.7 Confirmation of HMVEC-L monolayer integrity on Transwell filters 
 HMVEC-L (5x104) on Transwell filters were stained with antibody to VE-cadherin (anti-goat 
Alexafluor 594) for imaging using fluorescent confocal microscopy. The red stain was indicative 
of intact VE cadherin staining across the field of view (Image A, 10x, Image B, 40x 
magnification). Transendothelial resistance was measured at days 1-3 (Image C) (n=3). 
Permeability of FITC labelled albumin (1mg/mL, 200µL) across monolayers was measured on 
days 2 and 3 of HMVEC-L culture. After 3 hours, 100µL was removed and measured in triplicate 
on a fluorescent plate reader at 480nm (n=3). Data are presented as mean ± SEM and analysed by 
Mann Whitney U test **p<0.01, *** p<0.001 
 
 The possibility that fluorescent staining with Leukotracker™ solution adversely 
affected baseline neutrophil priming status, was also excluded prior to migration studies. 
Ideally, thorough interrogation of the combination of shape change, CD11b and CD62L 
expression would have been undertaken. However, the green fluorescence of 
Leukotracker™ excluded analysis of CD11b or CD62L expression by flow cytometry. 
Nonetheless, fluorescently labelled neutrophils did not show any evidence of shape 
change suggestive of neutrophil priming (Figure 2.8) 
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Figure 2.8 Leukotracker™ labelled neutrophils did not undergo shape-change 
Neutrophils were exposed to Leukotracker™ or PBS. Following washing according to the 
manufacturer’s guidelines, cells were analysed for shape change. Data are presented as mean ± 
SEM (n=3)  
 
 IL-8 was chosen as the most relevant neutrophil chemokine in migration 
experiments. The dose response curve of neutrophil migration through HMVEC-L 
monolayers is shown in figure 2.9. Based on these data a dose of 100ng/mL was used for 
further experiments. 
 
Figure 2.9 Dose response curve of neutrophil migration through HMVEC-L to IL-8  
 Leukotracker™ labelled neutrophils (1x106/mL, 200µL) were added to the upper chamber of a 
Transwell covered with confluent HMVEC-L. Migration was triggered by the addition of 
interleukin (IL)-8 1, 10, 100 or 1000 ng/mL in the lower chamber. Neutrophil migration was 
assessed by measurement of fluorescence accumulated in the lower chamber after 3 hours, read at 
480nm on a fluorescent plate reader. Each condition was measured in triplicate and data presented 
as mean ± SEM (n=3)  
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2.2.6.6 Neutrophil migration through HMVEC-L monolayers 
 To assess the functional consequences of selective TNFR antagonism on 
neutrophil migration through TNF stimulated HMVEC-L, a static proprietary migration 
assay (CytoSelect™ Leukocyte Transmigration assay, Cambridge Biosciences, UK) was 
used. The principal of this assay is outlined in figure 2.10. HMVEC-L (1.6 x105/mL, 
200µL) were seeded onto the upper chamber of Transwell filters (24-well size, 3µm pore 
size) and left for 72 hours. Medium (700µL) was placed in the lower chamber.  Growth to 
confluence was confirmed by 3 distinct methods outlined above; light microscopy, TER 
measurement and confocal microscopy to assess adherens junction formation. Cells were 
then washed twice with PBS and exposed to treatments for 4 hours at 37oC, 5% CO2. All 
conditions were performed in triplicate. Following a further 2 washes in PBS (to remove 
basal chemokine release from stimulated HMVEC-L), the media in the lower chambers 
was changed to IMDM containing IL-8 (50ng/mL, 700uL).  
 During HMVEC-L monolayer stimulation, healthy volunteer neutrophils were 
harvested as outlined previously. Neutrophils were suspended at 1x106 cell/mL in serum 
free IMDM and Leukotracker™ was added at the manufacturer’s recommended dilution. 
Cells were incubated at 37oC, 5% CO2 for 1 hour then washed twice and re-suspended at 
1x106 cells/mL in serum free media. 200µL of this solution was added to the upper 
chamber and neutrophils left to migrate over 3 hours. After 3 hours, the medium in the 
upper chamber was discarded and non-migratory cells were removed with a cotton swab. 
The Transwell filter was then placed in a well containing proprietary lysis buffer (150µL) 
and 400µL of media from the lower chamber containing migrated neutrophils. The plate 
was gently shaken for 5 minutes at room temperature then 150µL of the mixture was 
transferred to black 96 well plates suitable for fluorescence measurement. Fluorescence 
was read in triplicate at 480mm/520nm. 
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Figure 2.10 Principle of the leukocyte transmigration assay 
 
2.2.6.7 Scratch assay in human alveolar type 2 cells 
 The bottoms of collagen coated, 48 well plates were marked with a scalpel or fine 
pen across the centre of the well, and hAT2 seeded at 3x105 cells per well. Following 
growth to confluence, the medium was changed to serum free DCCM-1 overnight prior to 
scratch assay. The cell monolayer was then disrupted in a straight line to create a 
‘‘scratch’’ with a p200 pipette tip; this was performed through the marker on the well base 
outlined below (figure 2.11). Cell debris was removed washing the cells twice with 
DCCM-1 media and then replaced with medium (500µL) containing relevant inhibitors 
and controls. It is important to create scratches of approximately similar size to minimize 
any possible variation in healing rates caused by the difference in the width of the 
scratches. The wounded monolayer was then imaged by phase-contrast microscopy with 
reference mark outside the capture image field but within the eyepiece field of view. 
Wounded cells are then incubated for 20 hours at 37oC and cells re-imaged aligning the 
reference point with the baseline image. The images acquired for each sample were 
 
3 
Assay Principle 
 
Related Products 
1. CBA-070: CytoSelect™ 48-Well Cell Adhesion Assay (ECM Array, Colorimetric) 
2. CBA-071: CytoSelect™ 48-Well Cell Adhesion Assay (ECM Array, Fluorometric) 
3. CBA-100: CytoSelect™ 24-:HOO&HOO0LJUDWLRQ$VVD\ȝP&RORULPHWULF 
4. CBA-101: CytoSelect™ 24-:HOO&HOO0LJUDWLRQ$VVD\ȝP)OXRURPHtric) 
5. CBA-120: CytoSelect™ 24-Well Wound Healing Assay 
6. CBA-125: Radius™ 24-Well Cell Migration Assay 
7. CBA-126: Radius™ 96-Well Cell Migration Assay 
8. CBA-210: CytoSelect™ Leukocyte-Endothelium Adhesion Assay 
9. CBA-211: CytoSelect™ Leukocyte-Epithelium Adhesion Assay 
10. CBA-215: CytoSelect™ Tumor-Endothelium Adhesion Assay 
11. CBA-216: CytoSelect™ Tumor Transendothelial Migration Assay 
 
Kit Components 
1. 24-well Migration Plate (Part No. 121201): One 24-well plate containing 24 cell culture inserts (3 
µm pore size) 
2. 500X LeukoTracker™ Solution (Part No. 12101): One 100 µL tube  
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analysed quantitatively using Image J software (v1.45, National institutes of Health, 
USA). Repair was expressed as the percentage of the original wound area covered by 
cells. 
 
Figure 2.11 Mechanical wounding of hAT2 cells 
Following scratch with a pipette tip a homogenous wound is created (Image A). Depending on 
ambient conditions and treatment, the wound heals over 18-24 hours (Image B) 
 
2.2.6.8 In vitro angiogenesis assay 
 The in vitro formation of capillary-like tubes by endothelial cells on a basement 
membrane matrix is a powerful in vitro method to screen for various factors that promote 
or inhibit angiogenesis. The basement membrane extract used for this assay, sold 
commercially as Matrigel (BD Biosciences), is obtained from a murine tumour that 
produces an abundant extracellular matrix of basement membrane (Kleinman and Martin, 
2005). The extract is a liquid at 4°C and it forms a gel at 16–37°C.  
 The angiogenesis assay was based on published methodology (Arnaoutova and 
Kleinman, 2010). 10µL Matrigel was added to wells in a pre-warmed ibiTreat 
Angiogenesis µ-slide (Ibidi, Germany) and incubated at 37°C for ≥60 minutes. HUVEC 
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and HMVEC were then admixed with the relevant treatments and controls. Cells at 
passages 4 and below were seeded in triplicate wells at a density of 1×104  HUVEC and 
6x103 HMVEC-L per well. EGM-2 and EGM-MV2 media containing 2% FCS and 
without VEGF (for HUVEC and HMVEC-L respectively) were used for cell seeding and 
the additions of treatments. A total volume of 50µL (cells plus treatment) was added to 
each well. 
 Cells were incubated for 4 hours at 37°C, 5% CO2; preliminary experiments (data 
not shown) determined that this was the optimal time-course for tube formation in both 
cell types. After 4 hours, the medium was aspirated from the wells and replaced with 75µl 
of warmed PBS. Wells were imaged using a digital camera attached to an inverted phase 
contrast microscope (CK40, Olympus, UK) UK with x4 objective (figure 2.12). Total tube 
length per well was measured using Image J software. The observer was blinded to the 
treatment conditions to avoid measurement bias and the mean total tube length of 
triplicate wells analysed.  
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Figure 2.12 A representative image of tube formation in HMVEC-L after 4 hours 
 
2.2.7 Antibody based assays 
2.2.7.1 Protein Assay 
 The Bradford assay is a colorimetric assay based on the principle of binding 
brilliant blue to protein (Bradford, 1976). Protein standards (BSA at 400µg/mL) were 
prepared between 5 and 400µg/mL in distilled water. Standard or diluted samples (100µL) 
were added to 96-well micro-titre plate in triplicate. Bio-Rad Bradford Reagent (200µL) 
diluted reagent was added to each well. Absorbance was measured at 620nm using an  
Anthos Ht2plate reader (Anthos, Italy). The absorbance of cell lysis buffer alone was 
measured to exclude the possibility of interference with the assay. Unknown protein 
concentrations were calculated using a standard curve. 
2.2.7.2 Enzyme Linked Immunosorbent Assay (ELISA) 
2.2.7.2.1 Basic Principles  
 Enzyme linked immunosorbent assay (ELISA) is an immunologic assay that uses 
specific antibodies to detect and quantify solid phase bound proteins on a membrane, and 
proteins in solution. There are two common types of ELISA (figure 2.13). Sandwich 
ELISAs detect proteins in solution using an immobilized capture antibody. A washing 
step removes non-specifically bound material and an enzyme-marked secondary antibody 
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with a second epitope to target protein is added. An enzyme-substrate reaction is used to 
amplify the signal (2.13A). Alternatively, the target protein is immobilized and captured 
by the antibody in solution (2.13B). The basic methodology of a sandwich ELISA is 
described in Figure 2.14. 
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Figure 2.13 Two common types of Enzyme Linked Immunosorbent Assay (ELISA) 
A: Sandwich ELISA, capture antibody is immobilized on a solid support and captures target 
antigen in solution. B: Target protein is immobilized (such as expressed on the cell surface) and 
captures antibody in solution.  
 
Figure 2.14 Basic principle of a sandwich ELISA 
2.2.7.2.2 Duoset ELISA 
Sandwich ELISAs for detection of a variety of proteins were performed using a generic 
ELISA protocol according to the guidelines provided by the supplier of the paired 
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antibodies. Supernatants were examined immediately after experiments or frozen at -80oC 
and used when necessary. The constituents of the reagents for the ELISA and ELISA 
protocol are shown in table 2.2 and figure 2.15. The Duoset ELISAs were used to analyse 
for IL-8, human sTNFR1, human sTNFR2 (R&D Systems, UK).  
Table 2.2 Duoset ELISA reagents 
 Wash buffer Blocking buffer Assay Diluent Substrate solution Stop solution 
IL-8 0.05% Tween 
20 in PBS 
1% BSA in PBS 
(pH 7.2-7.4) 
Tris buffered 
saline (20mM 
Trizma base, 
150mM NaCl), 
0.1% BSA, 0.05% 
Tween-20 
Reagents A & B 2N H2SO4 
sTNFR1 0.05% Tween 
20 in PBS 
 1% BSA in PBS 
(pH 7.2-7.4) 
Reagents A & B 2N H2SO4 
sTNFR2 0.05% Tween 
20 in PBS 
1% BSA in PBS 
(pH 7.2-7.4) 
1% BSA in PBS 
(pH 7.2-7.4) 
Reagents A & B 2N H2SO4 
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Figure 2.15 Duoset ELISA protocol and reagents 
 
2.2.7.2.3 Human MPO ELISA 
 Myeloperoxidase (MPO) is a glycoprotein present in azurophilic granules of 
neutrophils, which is rapidly released upon neutrophil activation. MPO activity can 
therefore be used as a surrogate marker of neutrophil influx and activation into tissues. 
Classical MPO assays are often hampered by the presence of tissue inhibitors of MPO 
(Ormrod et al., 1987). The human MPO ELISA (Hycult biotech, The Netherlands) is not 
influenced by these inhibitors and was therefore chosen for this assay. 
 Protein was harvested from ex vivo lung tissue according to the protocol outlined 
in 2.2.15.3 and stored at -80oC until analysis. Proprietary wash buffer, dilution buffers A 
and B, standard, biotinylated tracer, streptavidin-peroxidase, TMB substrate and stop 
solutions were reconstituted and used at the manufacturer’s recommended concentration. 
Control/sample/standard (100µl) was added in duplicate to microtitre wells pre-coated 
with antibodies recognizing human MPO and stored at room temperature for 60 minutes. 
Day 1: Coat wells with 100µL of 4µg/mL capture Ab diluted in PBS 
Seal & incubate at room temperature overnight 
ê 
Day 2: Aspirate well and wash (x3) with wash buffer. 
Dry plate well on paper towel. Block plate with 300µL of blocking buffer per well 
Seal & incubate at room temperature for 2 hours 
ê 
Aspirate and wash (x3) 
Pipette 100µL of control/standard/sample into appropriate wells 
Seal & incubate at room temperature for 2 hours 
ê 
Aspirate and wash (x3) 
Add 100µL of 20ng/mL biotinylated detection antibody 
Seal & incubate at room temperature for 2 hours 
ê 
Add 100µL Streptavidin HRP per well 
Seal & incubate at room temperature for 20 minutes 
ê 
Aspirate and wash (x3) 
Add 100µL substrate solution. Incubate for 20-30 minutes in dark at room temperature 
ê 
Add 50µL stop solution, tap to mix 
ê 
Read absorbance at 450nm (λ correction of 570nm) within 30 mins 
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Following washing (x4), 100µL of biotinylated tracer antibody was added to each well 
and left for 60 minutes at room temperature. Wells were washed (x4) and 100µL of 
streptavidin-peroxidase conjugate added and left for 60 minutes at room temperature. 
After a final wash (x4) 100µL of TMB solution was added, incubated for 30 minutes at 
room temperature before 100µL of stop solution was added. Plates were immediately read 
at 450 nm using a spectrophotometer. MPO activity was corrected for the total protein 
content of the samples as measured by Bradford assay and calculated from the standard 
curve. 
2.2.7.2.4 pP38 MAPK alpha PhosphoTracer ELISA 
 PhosphoTracer assays use a traditional immuno-sandwich format, but with a major 
difference; both the analyte and the assay reagents are added to the PhosphoTracer assay 
microplate (optimised to form an active surface for the capture of immunocomplexes 
formed as part of the assay procedure) at the same time. After a short incubation period, 
unbound assay reagents and analytes are washed away, and immuno-complexes 
containing both antibodies are detected. Protein extracts from control and LPS injured ex 
vivo human lung tissue were analysed according to the protocol outlined in figure 2.16 
and read on a fluorescent plate reader with excitation band width of 530nm and an 
emission filter of 590nm. Assay control lysates are provided for use as an assay positive 
controls, and the Hardie lysis buffer (chapter 2.2.15.3) was used as the negative control. 
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Figure 2.16 p38 MAPK alpha PhosphoTracer ELISA protocol 
The antibody mix is comprised of a 1:1 mixture of proprietary Capture Antibody Reagent and the Detection 
Antibody Reagent and contains all the antibodies required for the assay. The substrate mix is a combination 
of 10-acetyl-3,7-dihydroxyphenoxazine (ADHP) and a stabilised H2O2 solution.  
 
2.2.7.3 Electrochemiluminescence (MSD) 
2.2.7.3.1 General principles of MSD multiplex plates 
 Meso-Scale Discovery (MSD) multiplex plates allows the detection of multiple 
proteins from a single biological sample, across a wide range of concentrations. Each well 
of a microplate features several micro-spots, each corresponding to a specific analyte 
(figure 2.17); plates are available in 3 geometries with 4, 7 or 10 spots. The samples are 
added to the wells and processed similarly to a standard ELISA. The detection antibody is 
conjugated to a Sulpho-Tag™ group. When the protocol has been completed the plate is 
placed within a plate-reader (MSD SECTOR® imager) and a small electric current run 
across each micro-spot within each well. By electrochemiluminescence, a luminous 
intensity is generated in proportion to the extent the Sulpho-tagged antibody present and 
this varies in proportion to the quantity of analyte present within each well (figure 2.15). 
A series of dilutions of known concentrations of analytes provided a reference and the on-
computer software (MSD Discovery workbench) calculates the levels of each analyte in 
each well and exports the data to a spreadsheet. 
Add protein extracts to PhospoTracer assay microplate 
ê 
Add Antibody Mix to microplate 
ê 
Incubate at room temperature for 1 hour 
ê 
Wash microplate (x3) 
ê 
Add Substrate mix to microplate 
ê 
Cover with foil and Incubate at room temperature for 10 minutes 
ê 
Read microplate 
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 In addition to measuring multiple analytes simultaneously, the advantage of the 
MSD system is that wide range of concentrations that can be measured without sample 
dilution – a traditional ELISA can measure over 2 to 3 log ranges, the MSD system can 
measure over 4 to 5. The main disadvantage of the system is expense. 
 
Figure 2.17 Cytokine capture antibody is pre-coated on specific spots of a 4-Spot MSD 
MULTI-SPOT plate.   
Calibrator solutions or samples are incubated in the MULTI-SPOT plate, and each cytokine binds 
to its corresponding capture antibody spot.  Cytokine levels are quantitated using a cytokine-
specific detection antibody labelled with MSD SULFO-TAG reagent. 
 
2.2.7.3.2 MSD protocol 
 Samples were collected and reagents prepared as per the manufacturers’ 
instructions. Undiluted supernatants were used for analysis. Calibrators were dilated in 
Calibrator Diluent generating a standard curve from 10,000 to 2.4pg/mL with minor 
adjustments to ensure that analytes for all samples were within the standard curve.  
Diluent 2 (25µL) was pipetted into each well, ensuring coverage of the entire bottom of 
the well; a slight tap may be necessary to allow the fluid to settle to the bottom. The plate 
was then sealed with an adhesive plate seal and incubated for 30 minutes with vigorous 
shaking (700 rpm) at room temperature. 25µL of each calibrator or sample solution was 
were then added into a separate wells of the MSD plate. Calibrators were measured in 
duplicate, whilst samples were measured in triplicate. The plate was sealed and incubated 
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for 2 hours with vigorous shaking (700 rpm) at room temperature.  Following washing 
(x3) with PBS + 0.05% Tween-20, 25 µL of the 1X Detection Antibody Solution was 
added to each well of the MSD plate.  The plate was again sealed and incubated for 2 
hours with vigorous shaking (700 rpm) at room temperature.  Following a final wash (x3) 
with PBS + 0.05% Tween-20, 150µL of 2x Read Buffer T was added to each well. The 
plate was read immediately on the SECTOR® reader. Standard curves were fitted using 
MSD Workbench software (version 4.0) and the samples back-calculated to the curve.  
The mean and standard deviation for sample replicates were calculated in MSD 
Workbench software and exported into Microsoft Excel for plotting.  
2.2.7.4 Confocal laser scanning microscopy 
2.2.7.4.1 Basic principle  
 The principle of immunocytochemistry is the same as that of ELISA and 
immunoblotting but this technique uses antibodies to visualize target antigens in cultured 
cells. The following protocol uses fluorescent antibodies and confocal microscopy. The 
cultured cells are incubated with antibody to identify specific antigens. After washing, the 
cells are incubated with secondary antibody labelled with fluorescence. The fluorescent 
antibody can be visualized directly observed by a laser or UV microscope.  
2.2.7.4.2 Immunocytochemistry and image acquisition  
 HMVEC-L were seeded on Transwell filters (3µm pore size, 12mm polycarbonate 
filter) and grown to confluence over 72 hours in an incubator at 37oC in a humidified 
atmosphere of 5% CO2 in air. Growth to confluence was confirmed by light microscopy. 
The medium was removed from both upper and lower wells of the Transwell filter and 
replaced with 3.5% formaldehyde (700µL bottom well, 200µL top well) and left for 5 
minutes at 37oC. Cells were then permeabilised by treatment with 0.5% Triton X-100 for 
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10 minutes at room temperature before incubation with 0.5% bovine serum albumin in 
PBS for 30 minutes at room temperature.  
 The filter with the confluent monolayer on the apical surface was then cut out 
using a scalpel and placed onto a labelled polycine slide with the apical surface of the 
filter to air. The filter was then incubated with 125µL goat polyclonal IgG VE-cadherin 
antibody (1:250 dilution in PBS/0.1% BSA) for 60 minutes at room temperature. 
Following incubation, the filter was gently washed three times with PBS. 125µL Alexa 
Fluor 594 donkey anti-goat IgG antibody (1:250 dilution in PBS/0.1% BSA) was then 
added and filters left at room temperature for 60 minutes in the dark. A negative control, 
with the primary antibody omitted, was used to quantify non-specific background 
fluorescence. Filters were washed 3 times before mounting with ProLong Gold anti-fade 
reagent containing 4',6-diamidino-2-phenylindole (DAPI) to stain endothelial cell nuclei. 
Confocal imaging was carried out using a Leica SP5 inverted confocal microscope (Leica, 
Switzerland), with a ×40 1.25 oil objective and 405 diode, argon, and HeNe 543 lasers. 
Leica Application Systems AF software (v2.7, Leica Microsystems, Switzerland) was 
used for quantification. 
2.2.7.5 Western Blotting 
2.2.7.5.1 Basic Principle 
 Western analysis or immunoblotting is a direct method for identifying and 
quantifying specific proteins in complex mixtures such as cell lysates. The complex 
protein mixture is fractionated according to molecular weight by gel electrophoresis. 
Separated proteins are transferred and blotted onto a membrane made of nitrocellulose, 
most commonly polyvinylidene fluoride (PVDF) or nylon. The membrane is incubated 
with a blocking reagent to shield non-specific binding sites. The primary antibody 
captures the target protein on the membrane. After washing steps to remove the unbound 
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primary antibody, horseradish peroxidase conjugated secondary antibody binds to the 
primary antibody immobilized on the membrane with the specific protein. Horseradish 
peroxidase secondary antibodies are utilized in conjunction with specific 
chemiluminescent substrates to generate a light signal. The amount of peroxidase activity 
present is related to the amount of the target protein fixed to the membrane. The general 
principle for western blotting is summarised in Figure 2.18. 
 
Figure 2.18 The general principle of western blotting  
Image courtesy of L Pinhu 
 
2.2.7.5.2 Preparation of whole cell protein extracts 
 Whole cell extracts were prepared by harvesting cells in 1× cell lysis buffer (CLB) 
including 20mM Tris-HCl (pH 7.5), 150mM NaCl, 1mM Na2EDTA, 1mM ethylene 
glycol tetraacetic acid (EGTA), 1% Triton, 2.5mM sodium pyrophosphate, 1mM β- 
glycerophosphate, 1mM Na3VO4, 1µg/mL leupeptin and 1mM phenylmethylsulfonyl 
+
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fluoride (PMSF). The whole cell extract was kept at -20oC until required. Samples were 
then centrifuged and supernatants collected as described in figure 2.19. 
 
Figure 2.19 Protocol for intracellular whole cell protein harvest 
  
2.2.7.5.3 Gel electrophoresis, blotting and immunodetection of proteins 
 The preparation of cell lysates is described in figure 2.19. The protocol for 
electrophoresis and immunodetection of proteins is shown in Tables 2.3 and 2.4 and 
figure 2.20. Samples were boiled with dithiothreitol (DTT) to reduce oxidised disulphide 
bonds and loaded onto sodium dodecyl sulphate (SDS) gels for electrophoresis. Molecular 
weight markers were also added to one well on each gel to monitor the progress of the 
electrophoresis. The membrane was incubated with LumiGLO (0.5mL 20x LumiGLO, 
0.5mL 20x peroxide and 9mL Milli-Q water) with gentle agitation for 1-5 minutes at 
room temperature following incubation of secondary antibody. Duration of exposure to x-
ray film varied between antibodies and the amount of protein in the sample loaded. 
 
 
 
 
Stimulate cells. Harvest supernatants and aspirate well to dryness 
ê 
Add 150µL of CLB to well (for 6 well plate) 
ê 
Scrape well with cell scraper and transfer the CLB mix into a pre-chilled eppendorf 
ê 
Store Eppendorf on ice for 5 minutes and then vortex 
ê 
Centrifuge sample to precipitate cell debris (4oC at 14000rpm for 5 minutes) 
ê 
Aliquot sample into 2x50µL aliquots and a third with the remainder of the supernatant (for Bradford 
assay) 
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Table 2.3 Western blot buffer and solutions 
Solution                Preparation of working solution        Use 
1x SDS sample buffer 62.5Mm 5mM Tris-HCl (pH 6.8 at 25oC), 2% w/v 
SDS, 10% glycerol, 50mM DTT, 0.01% w/v 
bromophenol blue or phenol red 
Sample loading 
Running buffer For 2L – Trizma base 21.11g, SDS 2g, Glycine 
57.65g, H20 2L 
 
Transfer buffer 25mM Tris base, 0.2M Glycine, 20% methanol (pH 
8.5). For 1.5L – Trizma base 4.5g, Glycine 21.525, 
dH2O 1200mL, methanol 300mL 
Transfer 
Blocking buffer 1xTBS, 0.1% Tween-20, 5% w/v non-fat dry milk 
(100mL TBS and 5g milk powder 
Blocking 
Wash buffer TBS 20mM Tris base, 137mM NaC, 0.1% Tween Washing solutions 
 
 
Table 2.4 Gels for western blotting (for 2x 10% gels) 
               Separation gel           Stacking gel 
Protogel 8.3mL           1.3mL 
Protogel buffer 6.5mL 2.5mL (stacking buffer) 
dH2O 10.2mL           6.1mL 
Aluminummmonium 
persulphate 
(10% 0.1g in 1mL H2O) 
300µL           150µL 
TEMED (add last) 30µL           30µL 
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Figure 2.20 Protocol for western blotting  
 
2.2.7.6 Flow Cytometry 
2.2.7.6.1 Basic principles of Flow Cytometry 
 Flow cytometry is a technique that can be used for counting, characterising, and 
sorting cells suspended in a stream of fluid, either by their physical characteristics, or by 
the extent of presence of bound, labelled antibodies or dyes. Individual cells are scanned 
as they flow past an excitation light source and the scattered light is picked up by 
detectors. Cells are processed to allow binding of fluorescently-labelled monoclonal 
antibodies to the cells. Following removal of excess antibodies by washing, cell fluid 
dynamics are used to generate a stream of single cells from a cell suspension which pass 
through a series of lasers and paired detectors. Light scattered in the forward direction of a 
laser beam is focused by a confocal lens and detected by a light detector which converts it 
into an electrical signal that is digitalised to generate a parameter known as Forward 
Mix 950µL of Laemmli sample buffer with 50µL of β-mercaptoethanol for 2x SDS sample buffer 
ê 
Mix 20-50 µg of protein sample with 1-2 volume of 2x SDS sample buffer 
ê 
Boil for 5 min at 100oC, then centrifuge at 100rpm for 5 minutes to retrieve and condensation 
ê 
Load samples (30µL)  and biotinylated protein marker (10µL) onto gels 
ê 
Electrophorese the gels for 15 minutes at 100V, then 40-60 minutes at 150V according to the molecular 
weight of the protein 
ê 
Electro-transfer the separated protein at 150V for 1h onto nitrocellulose membranes 
ê 
Incubate the nitrocellulose membrane in blocking buffer for 1h at room temperature 
ê 
Incubate the membrane with primary antibody overnight at 4oC 
ê 
Wash three times in TBS (10 minutes per wash) 
ê 
Incubate the membrane with appropriate secondary antibody for 1hour at room temperature 
ê 
Wash three times in TBS (10 minutes per wash) 
ê 
Develop the membrane with LumiGLO by gentle agitation for 1-3 minutes 
ê 
An initial 1 minute exposure to x-ray film, then adjust to appropriate exposure time 
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Scatter (FSC). The FSC signal will give information about the size and shape of the cell, 
and information can also be gathered by a side confocal lens and detected by a detector 
reading side scattered light. The Side Scatter (SSC) signal gives information about the 
granularity of the cell and surface topography. As FSC and SSC are unique for each type 
of particle, the combination of the two can help identify distinguish different types of cell 
types. 
 Several optical detectors called photomultiplier tubes (PMT) are used in a flow 
cytometer to read measure fluorescence. These read detect the light emitted from the 
particle crossing the laser beams that excite the attached fluorochromes at one range of 
wavelengths. Different fluorochromes will emit light at a second range of wavelengths 
and these are split into specific colours by optical filters and sent to PMT’s (figure 2.21). 
PMT’s convert light into an electrical pulse that is digitalised by other converters into 
signals readable by a computer as events, which are then used to generate histograms and 
dot plots. 
 Identification of specific populations of cells is possible through comparison of the 
fluorescence in several channels and the use of ‘gating’ strategies. Extent of fluorescence 
data is usually represented as a histogram with number of events on the y- axis and the 
fluorescence along the x-axis as a logarithmic scale. The distribution of events may be 
presented as the median fluorescence intensity (MFI) to represent the degree of 
fluorescence emitted by certain populations (assuming non-parametric distribution). 
121 
 
 
Figure 2.21 Schematic of FACS CantoII flow cytometer 
 
Table 2.5 Antibodies used for flow cytometric analyses 
Antibody Flourochrome conjugate 
Host 
species Clone  Supplier Code 
CD11b Brilliant Violet Mouse ICRF44 Cambridge Bioscience 301324 
CD54 Pacific Blue Mouse HA58 Biolegend 353109 
CD62E Phycoerytherin Mouse HCD62E Biolegend 322605 
CD62L APC Mouse DREG-56 Cambridge Bioscience 304810 
CD62P FITC Mouse AK4 Biolegend 304903 
CD102 APC Mouse CBR-IC2/2 Biolegend 328507 
CD106 APC Mouse STA Biolegend 305809 
CD321 Phycoerytherin Mouse M.Ab.F11 BD Bioscience 552556  
TNFR1 Phycoerytherin Mouse 16803 R&D Systems FAB225P 
TNFR2 Fluorescein Mouse 22235 R&D Systems FAB226F 
 
2.2.7.6.2 Flow cytometer set-up and sample acquisition 
 Compensation beads (BD Biosciences) were used to set up single colour 
compensation. Compensation was calculated automatically using FACSDiva™ software 
(v6.0, BD Biosciences, USA). Unstimulated, stained controls were used to detect the level 
of basal receptor expression and singlet discrimination was performed for each 
experiment. Titration experiments were performed to determine the optimum volume of 
antibody per test, to optimise signal-to-noise ratio and to minimise background.  
Sample 
Laser 
Flow cell 
Scatter detectors 
Laser 
Band pass filters 
Dichroic 
filters 
Photomultipliers 
PMT4 
PMT3 
PMT1 
PMT2 
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 Cells stained with isotype control antibodies were used as the negative control 
population; a gated marker was placed around the negative peak of the isotype control 
(≥98% events) stained cells (figure 2.22). Expression of the ligand of interest was 
determined by gating of fluorescence outside the negative control population and was 
expressed as either median fluorescence, or percentage of cells positively expressing the 
ligand compared to control cells. A minimum of 10,000 cells were analysed, in triplicate, 
per condition and the mean value of triplicate experiments used for analysis. A FACS 
Canto II Flow cytometer was used for all experiments. Data collected using FACSDiva™ 
software (BD Biosciences, USA) and analysed using FlowJo™ software (v10.0, TreeStar 
Inc, USA) 
 
Figure 2.22 Gating of negative and positive populations by flow cytometry 
The negative isotype control population was gated to include ≥98% of events (left hand image). 
The positive population was defined the median fluorescence outside this gate or percentage of 
cells outside this gate (right hand image). 
 
2.2.7.6.3 Cell surface staining of neutrophils 
 Healthy volunteer peripheral blood neutrophils (5x106/mL) were harvested from 
healthy volunteers by dextran/percoll gradation from whole blood, as outlined in chapter 
2.2.5.4 and re-suspended in PBS. Cell solution (200µL) was left to stand at room 
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temperature for 5 minutes then treated and placed on a thermomixer (300rpm 21oC). After 
45 minutes the cells were placed on ice then centrifuged at 12000rpm for 7 seconds. 
Supernatants were removed and stored at -80oC for ELISA analysis and the cell pellet was 
re-suspended in PBS containing both anti-human CD11b Pacific Blue conjugate, anti-
human CD62L APC conjugate, anti-human TNFR1 Phycoerytherin conjugate, anti-human 
TNFR2 Fluorescein conjugate, or the relevant isotype control antibody. Samples were 
incubated at 4oC in the dark then washed twice in PBS before being re-suspended in 
250µL of optimised CellFIX solution (1mL CellFIX, 9mL distilled water, 30mL PBS) in 
FACS tubes. Samples were kept at 4oC in the dark until analysis using a FACSCanto™ II 
flow cytometer (BD Biosciences). Neutrophils granulocytes were gated based on their 
characteristic side scatter and forward scatter criteria pattern (Dorward et al., 2013). 
2.2.7.6.4 Cell surface staining of HMVEC-L 
 HMVEC-L cells were seeded into 6-well plates at a density of 1.2 x 105 cells/well 
and grown to confluence over 3 days in an incubator at 37°C in a humidified atmosphere 
of 5% CO2 in air. Owing to limited cell numbers, treatments were performed in single 
wells only. After 4 hours treatment, cells were first washed 3 times using HBSS (400µL), 
then harvested using non-enzymatic cell dissociation buffer (400µL). The cell suspension 
was then placed in an eppendorf on ice and centrifuged at 400rcf for 5 minutes at 4oC. 
The supernatant was removed and the cell pellet re-suspended in 50µL of blocking buffer 
(5% FBS in 0.5% BSA) for 10 minutes at 4oC; 5µL was taken from each eppendorf and 
added to a labelled tube for unstained cells and a further 20µL was taken from each 
eppendorf and combined to generate the isotype control samples; 20µL of this mixed 
sample was then removed to generate compensation and isotype controls. The blocked 
cells were then incubated with the relevant antibodies (CD54, CD62E, CD62P, CD102, 
CD106 and CD321) and isotype controls for 30 minutes at 4oC in the dark. Cells were 
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washed twice with the addition of 800µL of PBS and centrifugated at 400g for 5 minutes 
at 4oC. The washed, stained cell pellet was re-suspended in 200µL of stain buffer (PBS 
+1% FBS + 0.09% sodium azide) and transferred to a FACS tube containing 200µL of 
stain buffer. Cells were stored for a maximum of 1 hour at 4oC in the dark prior to 
analysis on a FACSCanto™ II flow cytometer (BD Biosciences). 
2.2.7.6.5 Cell surface staining of TNFR expression in hAT2 
 hAT2 cells were seeded into 24-well plates at a density of 1 x 106  cells/well and 
grown to confluence over 4 days in an incubator at 37°C in a humidified atmosphere of 
5% CO2. Cells were first washed 3 times using HBSS (100µL) then harvested using non-
enzymatic cell dissociation buffer (100µL). The cell suspensions were then placed in an 
Eppendorf on ice and centrifuged at 400rcf for 5 minutes at 4oC. The supernatant was 
removed and the cell pellet re-suspended in 50µL of blocking buffer (5% FBS in 0.5% 
BSA) for 10 minutes at 4oC. 5µL was taken from each Eppendorf and added to a labelled 
tube for unstained cells and a further 20µL was taken from each Eppendorf and combined 
to generate the isotype control samples; 20µL of this mixed sample was then removed to 
generate compensation and isotype controls. The blocked cells were then incubated with 
the relevant antibodies (TNFR1 and TNFR2) and isotype controls for 30 minutes at 4oC in 
the dark. Cells were washed twice with the addition of 400µL PBS-/- and centrifugation at 
400g for 5 minutes at 4oC. The washed, stained cell pellet was re-suspended in 200µL of 
stain buffer (PBS-/- +1% FBS + 0.09% sodium azide) and transferred to a FACS tube 
containing 200µL of stain buffer. Cells were stored for a maximum of 1 hour at 4oC in the 
dark prior to analysis on a FACSCanto™ II flow cytometer (BD Biosciences). Cells were 
analysed in triplicate. 
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2.2.8 Generation of surfactant protein C cDNA 
2.2.8.1 Ribose nucleic acid extraction from hAT2 
 Total ribose nucleic acid (RNA) was extracted from cultured cells using RNeasy 
mini Kit (Qiagen, The Netherlands) according to the manufacturer’s protocol. Cells were 
scraped from the surface of the well in buffer supplied (RLT buffer) and dissolved in 
equal volumes of 70% ethanol. The mixture was then added to an RNeasy mini spin 
column and centrifuged to fix total RNA to the column. The RNA in the column was then 
washed with further buffers and eluted into an Eppendorf using RNase free water and 
used or stored at -20oC (figure 2.23). 
 
Figure 2.23 Protocol for RNA extraction using RNeasy spin columns 
 
2.2.8.2 Determining the concentration of RNA 
 The RNA concentration was determined using the nano-drop ND1000 
spectrophotometer (supplied by Lab Tech International, East Sussex). RNA can be 
RLT buffer mixed with β-Mercaptoethanol (β-ME; 10µL β-ME per 1mL buffer RLT) 
Cells harvested once confluent in 350µL buffer RLT 
ê 
Buffer RLT/cell sample mixed with equal volume (350µL per well) 70% ethanol 
700µL of sample transferred to RNeasy spin column and centrifuged for 15s at >8000rcf and discard 
flow-through 
ê 
Add 350µL buffer RW1 to the RN easy spin column 
Centrifuge 15 seconds at >8000rcf to wash the spin column membrane and discard flow-through 
ê 
Add 70µL RDD buffer to 10µL DNase 1 
Add directly to membrane and leave to stand at room temperature for 15 minutes 
ê 
Add 350µL buffer RW1 to the RNeasy spin column 
Centrifuge 15 seconds at  >8000rcf to wash the spin column membrane and discard flow-through 
ê 
Add 500µL buffer RPE to the RNeasy spin column 
Centrifuge 15 seconds at  >8000rcf to wash the spin column membrane and discard flow-through 
ê 
Add 500µL buffer RPE to the RNeasy spin column 
Centrifuge 2 minutes at  >8000rcf to wash the spin column membrane and discard flow-through 
ê 
Place the RNeasy spin column in a new 1.5mL Eppendorf. Add 30-50µL RNase free water to the spin 
column membrane and centrifuge for 1 minute at >8000rcf to elute the RNA 
Store at -20oC 
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quantified using the absorption of light at 260 and 280nm. For high quality nucleic acid 
the ratio of Abs 260/280 should be close to 2. However ratios above 1.6 still result in 
useful real -time PCR results. 
2.2.8.3 Reverse Transcription Polymerase Chain Reaction (RT-PCR) 
 mRNA was reverse transcribed into complementary DNA (cDNA) using the 
QuantiTect Reverse Transcription kit (Qiagen). The kit components and samples were 
thawed on ice. Total mRNA (0.6µg) diluted in RNase free water (7µL) was used for 
reverse transcription and incubated with oligo(dT)12-18 primer (1µL) at 65°C for 10min. 
The reverse transcriptase mixture containing first strand buffer (5×, 2.8µL), DTT (0.1M, 
2µL), deoxyribonucleotide triphosphate (dNTP, 10mM, 2µl), RNase free H2O (1.7µL), 
RNasine (0.5U/µL, 0.5µL) and Moloney Murine Leukemia Virus Reverse Transcriptase 
(MLV-RT, 200U/µL, 1µL) was added (10µL for each sample) and incubated for 1 hour at 
37°C, then at 65°C for 5min. The synthesized cDNA could be used immediately or stored 
at -20°C for several months until required. 
2.2.8.4 Real Time Polymerase Chain Reaction  
 Surfactant protein C gene expression in hAT2 was assessed by real time 
polymerase chain reaction (RT-PCR) using the Rotor-Gene® SYBR® Green PCR Kit 
(Qiagen) and Rotor-Gene 6000 thermal cycler (Corbett, Australia) according to the 
manufacturer’s instructions. The RT-PCR reaction was performed in a total volume of 
20µl reaction solution containing QuantiTect SYBR Green PCR Master Mix (2×, 10µL), 
forward primer (10µM, 1µL), reverse primer (10µM, 1µL), template cDNA (1µM, 1µL) 
and RNase-free water (7µL). SYBR Green fluoresces when it binds to the minor groove 
of the double stranded DNA. SYBR Green emits a low signal when in solution, but a 
much higher signal when bound to DNA. Thus, as the reaction proceeds there is a 
corresponding increase in signal intensity (Figure 2.24). Target gene amplification was 
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performed under the following cycling conditions: initial denaturing at 95°C for 15 
minutes and then 65 cycles of sample denaturation at 95°C for 10 seconds and annealing 
at 55°C for 20 seconds, extension at 72°C for 20 seconds and a final extension at 72°C for 
1 minute. This was followed by a final hold at 25°C for 1 minute. The house- keeping 
gene GAPDH (Qiagen) was used as the reference molecule for PCR amplifications. The 
surfactant protein C primer (Qiagen) was selected with the aid of Primer3 software. 
 
Figure 2.24 The basic principle of real-time PCR using SYBR green 
 
2.2.9 Generation of TNFR specific muteins 
 The TNFR1 and TNFR2 specific muteins, R32W and D143N respectively, were 
gifts from GSK. Muteins were generated using site-directed mutagenesis using the pUC19 
cloning vector as a template. The primer sequences for each mutein are outlined in table 
2.6. The gene product was confirmed as low endotoxin (<0.16EU/mL) and the predicted 
molecular weight of each product was confirmed by mass spectrometry.  
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Table 2.6 Primer sequences for TNFR specific muteins  
(forward strand below/reverse is complementary) 
R32W 5’-CAG CTG CAG TGG CTG AAC CGT TGG GCT AAC GCC CTG CTG GCA AAC-
3’ 
D143N 5’- CGT CCT GAC TAT CTA AAT TTC CGT GAA TCT GGC CAG GTG-3’ 
 
  
 To confirm receptor specificity, Surface Plasmon Resonance (SPR) measurements 
were carried out on a Biacore T100 instrument (GE Healthcare Life Sciences) under 
standard conditions (25°C and 1 atmosphere). Anti-human IgG specifically directed 
towards the Fc-gamma fragment was immobilized covalently on all channels of a CM4 
chip by amine derivatisation. TNF (50µg/mL, R&D Systems) diluted in HBS-EP buffer  
(GE Healthcare Life Sciences) was passed over the sensor in three flow channels in a 
range of concentrations. A 0nM TNF curve was used for double referencing. The 
association (ka) and dissociation (kd) rate constants for binding of R32W (11mg/mL) and 
D143N (4.7mg/mL) were measured during each set of SPR runs.  
 As expected, TNF bound to both receptors. The TNFR1 mutein and TNFR2 
mutein bound specifically to TNFR1 and TNFR2 respectively, with no evidence of non-
specific binding. The biphasic curves for both TNF and the TNFR2 mutein suggested that 
both TNF and D143N have a low affinity for TNFR2, with D143N being a weaker binder 
than TNF (figure 2.25).   
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Figure 2.25 TNF muteins display receptor specificity  
Anti-human IgG specifically directed towards the Fc-gamma fragment was immobilized 
covalently on all channels of a CM4 chip by amine derivatisation. TNF (50µg/mL) diluted in 
HBS-EP buffer was passed over the sensor in three flow channels in a range of concentrations. A 
0nM TNF curve was used for double referencing. The association (ka) and dissociation (kd) rate 
constants for binding of R32W (11mg/mL) and D143N (4.7mg/mL) were measured during each 
set of SPR runs.  
 
2.2.10 Preparation of precision cut human lung slices 
 Precision cut human lung slices (PCLS) were generated from disease-free lung 
parenchyma removed as part of a tumour resection (∼6g). The tissue was washed twice 
with ice-cold HBSS containing penicillin (100µg/mL), streptomycin (100µg/mL). Tissue 
was immersed in ice-cold HBSS containing penicillin and streptomycin and inflated by 
injecting 3% (w/v) low melt agarose (Sigma-Aldrich, UK) using a total volume of ∼3–
5mL/g wet weight of tissue. The tissue was cooled and cut using a microtome blade, into 
slices approximately 0.5cm thick. Using an 8mm coring tool, cylindrical cores of the 
inflated tissue were prepared and cut into ∼400µm thick slices by a Krumdieck Tissue 
Slicer (TSE Systems, Germany). Lung slices were transferred to a 12-well tissue culture 
plate containing 1mL of RPMI medium (Life Technologies, UK) supplemented with 1% 
TNFR1 
binding 
TNFR2 
binding 
wt TNF R1 mutein R2 mutein 
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penicillin, streptomycin, L-glutamine and gentamicin and incubated at 37 °C in 5% CO2. 
Slices were washed six times in RPMI media with a 30min incubation period between 
each wash to remove endogenous factors released from the slices. Slices were then 
incubated overnight and medium removed and replaced with 1mL of fresh medium 
approximately 30 min prior to treatment protocols. 
 
2.2.11 Ex vivo lung perfusion 
2.2.11.1 Harvesting of porcine lungs for model development experiments 
Heart-lung blocks from domestic pigs were obtained from a local abattoir where 
pigs are treated according to European Union legislation governing such facilities. The 
trachea was cannulated with an endotracheal tube and the lungs were gently inflated 
several times with room air. The trachea was then clamped in inflation. The main 
pulmonary artery (PA) was cannulated and flushed with preservation solution (Perfadex; 
Vitrolife, Sweden: 2000mL at 4°C) supplemented with heparin (20,000iu; LEO 
Laboratories, Denmark: 20,000iu), THAM (3mL; Northwick Park Hospital, UK), 
Calcium Chloride (10%, 0.6mL, Martindale Pharmaceuticals, UK) and Glyceryltrinitrate 
(8mL, Hameln pharma, Germany; 8mL). The lungs were transported soaked in 
preservation solution (1000mL) surrounded by crushed ice.  
2.2.11.2 Establishment of a contract for shipment of whole human lungs 
 While current UK legislation permits organ donation for primary research 
purposes, available numbers are small as the vast the majority of potential donors consent 
for organ donation for the purposes of transplantation. Thus, study in of whole human 
lungs from the UK donor pool is logistically problematic. Moreover, with the 
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development of clinical EVLP, increasing numbers of borderline donor lungs should be 
used for clinical EVLP assessment to increase the donor pool in the UK.  
 The International Institution for the Advancement of Medicine (IIAM) in the USA 
is a non-profit organisation that works with almost all of the 58 organ procurement 
organizations (OPOs) in the United States to provide non-transplantable, human 
biomaterials for medical research. Consent for donation for research purposes is obtained 
in accordance with hospital, state and federal regulations in the USA. In conjunction with 
the Tissue Governance Manager at our institution, we established a contract with IIAM 
ensuring compliance with The Human Tissue Act (HTA 2004) code of practice relating to 
the import and export of human bodies, body parts and tissue. Information is anonymised 
but demographic data, organ procurement times, donor medical history and pre-explant 
biochemical and physiological parameters are provided with the tissue for baseline data 
collection. To improve the quality of donor lungs we stipulated a cold ischaemic time of 
less than 36 hours. Approval by the National Research Ethics Service was not deemed 
necessary as our proposed study does not involve NHS patients or use tissue from NHS 
patients (assuming an HTA license was in place). 
2.2.11.3 Selection criteria for donor human lungs 
All cases were discussed with a coordinator at IIAM. A copy of the lung 
harvesting protocol and shipping contract are contained in Appendix B. Lungs were 
cooled in situ with preservation solution (University of Wisconsin solution, 50mL/kg) and 
transferred in 1L of preservation solution on ice. Donor criteria are outlined in table 2.7. 
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Table 2.7 Donor criteria for ex vivo human lungs 
Clinical variable Criteria 
Age 16 - 65 years 
Smoking history Smokers or non-smokers 
Cold Ischaemic Time <36 hours 
Warm Ischaemic Time (if donation after cardiac 
death) 
< 1 hour from cross-clamp time 
Serology HIV, HBsAb, EBV, CMV negative 
Bacteriology Sputum culture –ve, MRSA -ve 
Time on ventilator <10 days 
Radiology Absence of dense consolidation Diffuse 
shadowing consistent with pulmonary oedema or 
ALI 
Oxygenation PaO2:FiO2 ratio >200mmHg 
Anatomical Adequate PA cuff or trachea 
Absence of lung contusions or haemorrhage or 
persistent pneumothorax 
HBsAb: Hepatitis B surface antibody, EBV: Epstein Barr virus, CMV: cytomegalovirus, PA: 
pulmonary artery 
2.2.11.4 EVLP circuit  
Following receipt of the lungs at our institution, they were inspected for 
contusions and anatomical suitability for connection to the ex vivo circuit, namely; at least 
2cm of main PA, a left atrial cuff (closed system) or intact pulmonary venous drainage 
and at least 5cm of trachea. As soon as the lungs were deemed anatomically acceptable, 
the main pulmonary artery (PA) was cannulated with a pre-fashioned cannula (Vivoline, 
Sweden) and the left atrium (LA) was cannulated with a conical cannula (Vitrolife, 
Sweden: closed system), or the pulmonary veins were left open to air (open system). The 
trachea was cannulated with an endotracheal tube and secured with 2.0 silk. The lungs 
were then transferred to the perfusion container (Vivoline, Sweden) and connected to the 
perfusion circuit and ventilator. The perfusion circuit (Maquet, Germany), outlined in 
appendix 7.2, was connected to an ECMOtherm II heat exchanger (Medtronic, USA). A 
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paediatric nasogastric tube was inserted via a side-port into the pulmonary artery (PA) 
cannula and connected to a pressure transducer to allow continuous PA pressure 
monitoring.  
The circuit was de-aired with perfusion solution (high glucose DMEM containing 
5% human albumin solution, 1350mL). Perfusion was started at the highest flow rate that 
maintained PA pressure at less than 15mmHg, to avoid hydrostatic damage. Following re-
warming to 37°C, ventilation was commenced (Evita XL, Drager, Germany) with settings 
as follows: tidal volume 300mL, respiratory rate 10/min, positive end-expiratory pressure 
8cm water and fraction of inspired oxygen 0.21. Perfusate flow rate was increased 
incrementally to a target of 0.8L/minute without exceeding a target PA pressure of 
15mmHg. In experiments using a closed system, the left atrial pressure was maintained at 
less than 5mmHg by adjusting the height of the reservoir. In experiments, using an open 
system, the pulmonary veins were left open to air and assumed to have a pressure of 
0mmHg.  
2.2.11.5 ALI modelling in ex vivo human lung 
Following rewarming, 150mL of group matched healthy volunteer whole blood 
was added to the perfusate. Baseline tissue and BALF sampling was undertaken and the 
lungs were maintained with a protective ventilator strategy perfusate flow as outlined in 
figure 2.25. When logistically possible (a clinical scanning facility was used), baseline 
computed tomography was undertaken to exclude significant radiological infiltrates or 
consolidation. Where infiltrates or consolidation were present, the respective lobe(s) were 
excluded from experimental intervention. 
Immediately after baseline sampling, E.coli endotoxin (LPS, 0.6mg/mL, 10mL) 
and vehicle control (10mL, 5% human albumin solution) were instilled via a 
bronchoscope or blindly placed catheter (7 French size, coronary guide catheter, 
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Medtronic, USA). The periphery of the lung was viewed to identify ‘blebbing’ from the 
injectate, firstly to confirm that the LPS or vehicle control reached distal lung, and 
secondly to allow demarcation of the injured area for subsequent tissue sampling (figure 
2.29D). The right lower lobe was used preferentially for LPS injury and the left lower 
lobe for vehicle control.  Following injury, BALF and tissue were harvested at 4 and 8 
hours post-LPS injury (figure 2.26). In experiments investigating soluble TNF receptor 
release in the alveolar space, an additional BALF was performed 2 hours after LPS injury. 
 
Figure 2.26 Protocol for LPS induced human ex vivo ALI model 
BAL: broncho-alveolar lavage, DMEM: Dulbecco’s modified eagle medium, HAS: human 
albumin solution, LPS: lipopolysaccharide, PA: pulmonary artery, PAP: pulmonary artery 
pressure, PEEP: positive end expiratory pressure, Vt: tidal volume 
 
2.2.11.6 Development of a robust and reproducible model of human ex vivo ALI 
 Having established a technique that maintained human lungs for up to 8 hours ex 
vivo, it was necessary to produce a robust method to deliver LPS / vehicle control and 
subsequently sample the respective lobes of ex vivo human lung.  
 A fibre-optic bronchoscope with a catheter in the working channel was used to 
firstly allow passage to distal lung and secondly to avoid contamination of injured and 
control BALF samples. Preliminary data did not demonstrate robust and reproducible 
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injury as measured by BALF cytokine IL-8 (figure 2.27A) release and neutrophil 
infiltration. We therefore moved to a model where the LPS (2.4mg/mL, 2.5mL), was 
injected locally to discrete segments of the right middle lobe and vehicle control in similar 
fashion to the left lower lobe (figure 2.28A). Tissue samples from the relevant infiltrated 
area were then collected and analysed. Whilst this provided a mechanism to sample tissue 
that we knew had been infiltrated with LPS or vehicle control, the corresponding BALF 
IL-8 data again were not suggestive of localised injury (figure 2.27B).  This was probably 
due to an inability to direct the bronchoscope to the extreme periphery of the lung where 
LPS was at its highest concentration. Indeed, LPS concentrations in the BALF were 
markedly lower in these samples compared to samples derived from bronchoscopy–
delivered LPS (figure 2.28). 
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Figure 2.27 BALF IL-8 concentrations in endobronchially delivered vs locally delivered LPS 
in human ex vivo lung 
LPS (0.1mg/kg, 10mL) or vehicle control (10mL) were instilled blindly via a bronchoscope into 
the right middle lobe or left lower lobe respectively of human lungs on the EVLP circuit (panel 
A). In separate experiments LPS (0.4mg/kg, 2.5mL) or vehicle control (2.5mL) were injected via 
an orange needle into discrete areas of peripheral lung tissue. After 4 hours, the injury and control 
lobes were lavaged with 5% human albumin solution (50mL). Interleukin-8 was measured by 
sandwich enzyme linked immunsorbent assay (ELISA). Each number represents a separate 
experiment.  
 
Figure 2.28 Comparison of LPS concentrations in human lung tissue using 2 different 
methods of LPS administration 
LPS (0.1mg/kg, 10mL) or vehicle control (10mL) were instilled via a catheter into the right middle lobe or 
left lower lobe respectively of human lungs on the EVLP circuit (Catheter, n=3). In separate experiments 
LPS (0.4mg/kg, 2.5mL) or vehicle control (2.5mL) were injected via an orange needle into discrete areas of 
peripheral lung tissue (injectate, n=2). After 4 hours, the injury and control lobes were lavaged with 5% 
human albumin solution (50mLmL). LPS concentration in the corresponding BALF was measured by 
Limulus Amebocyte Lysate (LAL) assay using the PTS Endosafe®PTS™ system (0.05 EU/mL 
sensitivity),  
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 Finally, we developed a model whereby angiography catheters (Medtronic, USA) 
were fed either directly into the trachea, or via a port in the endotracheal tube mount. The 
catheters were gently passed into distal lung until resistance was felt, ensuring that the 
pleural surface was not compromised. Three catheters were placed in discrete areas of the 
right lower lobe and 3 catheters were placed in the left lower lobe (figures 2.29 panels B 
& C). LPS (0.6mg/mL, 10mL) or vehicle control (10mL) was instilled via each catheter 
into distal lung and then flushed with air (10mL). The area of infiltrated lung, evidenced 
by ‘blebbing’ of the peripheral tissue was delineated with a marker pen to guide 
subsequent tissue harvesting (figure 2.29D). After 4 and 8 hours perfusion, BALF (0.9% 
saline with 5% HAS, 50mL) was undertaken in duplicate catheters for both LPS and 
vehicle control, and tissue was harvested in the demarcated area. The 3rd catheter was 
used to guide tissue harvesting for wet:dry ratio. This method provided robust, 
reproducible data, at least for BALF cytokine release and neutrophil infiltration into the 
alveolar space. 
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Figure 2.29 Administration of localised injury to the distal lung ex vivo perfused lung 
LPS (0.6mg/mL, 2mL) or vehicle control was instilled via an orange (22G) needle into discrete 
areas of peripheral lung (panel A). Localised tissue was then resected after 4 hours perfusion and 
analysed. Alternatively, endotoxin (0.6mg/mL, 10mL) or vehicle control (10mL) was 
administered via cardiac catheters inserted endobronchially to distal lung (panels B, C). During 
infusion of endotoxin, the area perfused was marked externally with a marker pen to guide biopsy 
samples at 4 hours following injury (panel D). 
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2.2.11.7 Methods of drug delivery to ex vivo lung 
Having established a human ex vivo model of LPS induced ALI with robust and 
reproducible data output, we next investigated means of administering therapeutic 
intervention in ex vivo models to harness their translational potential. These experiments 
were undertaken to establish the optimum method of administration of GSK1995057 in 
our human ALI model. Given the paucity of available human lung tissue, this component 
of model development was undertaken in porcine lung.  
 Nebulisation of Evans blue dye via the endotracheal tube demonstrated 
homogeneous distribution of dye throughout the lower lobe of porcine ex vivo lung (figure 
2.30). Significant deposition also occurred in the upper airways, however.  
 
Figure 2.30 Distribution of nebulised Evans blue dye in porcine ex vivo lung 
Evans blue (1mg/mL, 5mL) was nebulised endotracheally into porcine tissue lungs ventilated 
and& perfused ex vivo. After 2 hours, the lung demonstrated homogenous distribution of 
nebulised Evans blue in coronal section (panel A) and peripheral distribution of the dye (panel B) 
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2.2.12 Statistical analysis 
2.2.12.1 Data processing 
 Data were entered in Excel spreadsheets prior to statistical analysis using PRISM 
v5.0 (GraphPad software, CA, USA). 
2.2.12.2 Data presentation and analysis 
  All data (unless where stated) were analysed using non-parametric methods 
(Kruskal Wallis, Mann Whitney), as the sample sizes were not sufficient to ensure that the 
data were normally distributed. All p values were adjusted for multiple comparisons and a 
value of <0.05 was considered significant. Post hoc testing of groups to determine the 
underlying source of statistical significance was only undertaken if there was an overall 
statistically significant difference. 
Table 2.8 Statistical tests used according to dataset distribution and number of groups 
Distribution Groups Paired Test 
Non-parametric 2 N Mann Whitney U 
Parametric >2 N Dunnet’s 
 
Non-parametric >2 N Kruskal-Wallis test with Dunn’s multiple comparisons test 
correction 
 
 Data in this thesis are almost exclusively presented as bar charts with errors bars 
delineating standard error of the mean.  This allows any treatment effect to be 
readily observed, and is in keeping with the method employed by the majority of scientific 
journals. Boxplots may be more informative about the spread of the data for large datasets 
and facilitate the identification of outliers. However, the majority of in vitro experiments 
undertaken in this thesis have sample sizes of 5 or less, with a small intrinsic spread 
despite the use of primary cells. Therefore boxplots were only employed for ex 
vivo experimental data where the spread of values was more apparent.  
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3 Chapter 3: Effect of selective TNFR1 inhibition on in -vitro models of 
ALI 
3.1 Introduction 
The cells lining both the pulmonary capillaries and alveolar compartments are the 
primary barrier to inflammatory cell migration into the alveolar space and as such, are 
ideally situated to regulate the activation and recruitment of inflammatory cells into the 
alveolar space. Although alveolar macrophages are a major source of chemokines in the 
air spaces (Goodman et al., 1998), the pulmonary epithelium and endothelium release a 
complex network of cytokines and chemokines, which, in unison with alterations in the 
expression of cell adhesion molecules (chapter 1.1.2), direct leukocyte trafficking and 
orchestrate the inflammatory response in ALI. For example, hAT2 release a range of 
neutrophil chemokines after stimulation with LPS, including IL-8, monocyte chemotactic 
protein-1 (MCP-1) and growth related oncogene-alpha (GRO-α) (Witherden et al., 2004). 
Although neutrophils provide a first line of defence against invading pathogens, excessive 
recruitment and activation of neutrophils (and other inflammatory cells including 
monocytes) can initiate the loss of alveolar capillary membrane function and permeability 
pathognomonic of ALI (chapter 1.4.3). Therefore, the release of neutrophil chemotactic 
factors is thought to contribute significantly to the progression of ALI. 
Chemokine release from lung epithelium and endothelium occurs predominantly in 
response to early phase cytokines, including TNF, released from alveolar macrophages 
and circulating monocytes triggered by pathogen recognition. Levels of TNF and its 
soluble receptors are consistently elevated in bronchoalveolar lavage (BAL) and blood of 
patients with ALI (Hyers et al., 1991), and levels of downstream TNFR1 signalling 
products (e.g. interleukin- 6, soluble TNFR1, soluble TNFR2 and IL-8) in blood have 
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been associated with a poor outcome (Parsons et al., 2005) and sequential organ failure in 
ALI patients (Liu et al., 2007). 
Alveolar capillary membrane inflammation is further propagated by ventilator 
associated lung injury (VALI) whereby mechanical forces induce signal transduction in 
epithelial (and endothelial) cells, further promoting local chemokine release, amplifying 
local cellular injury and neutrophil influx into the alveolar space. TNF has similarly been 
implicated in the pathogenesis of both experimental and clinical VALI. Indeed, in a 
clinical study, BALF and plasma levels of TNF and its soluble receptors fell after 36 to 40 
hours in patients with ALI subjected protective ventilation compared to those ventilated 
using a conventional strategy (Ranieri et al., 1999). Early experimental studies yielded 
conflicting results (Imai et al., 1999; Murphy et al., 2000; Ricard et al., 2001; Tremblay et 
al., 2002), however recent work has demonstrated that the complexities of differential 
TNF signalling may underlie some of the confusion. Hence TNFR2-/- mice exposed to 
high tidal volume ventilation developed pulmonary oedema whereas TNFR1-/- mice were 
protected (Wilson et al., 2007).  
Disruption of the alveolar capillary membrane and the associated influx of protein-
rich and highly cellular oedema fluid into the interstitium and alveoli is pathognomic of 
ALI. Recent results have indicated a dichotomous role for TNF in this process, perhaps 
suggestive of differential TNFR signalling effects. TNF has been proposed to mediate the 
induction of apoptosis of lung microvascular endothelial cells, thus contributing to the 
disruption of the endothelial barrier (Hamacher et al., 2002; Lucas et al., 1998) while also 
indirectly promoting oedema formation by decreasing the expression of ENaC and the 
Na+/K+ ATPase (Dada and Sznajder, 2007). TNF directly induced barrier dysfunction via 
disruption of adherens junctions in endothelial cells (Angelini et al., 2006; Petrache et al., 
2001). In rat alveolar epithelial cells, TNF inhibited sodium uptake, which is crucial for 
143 
 
 
alveolar fluid clearance, by reducing the expression of at least 3 subunits (alpha, beta, 
gamma) of the epithelial sodium channel ENaC (Dagenais et al., 2004). By contrast, TNF 
opposed oedema formation by enhancing alveolar fluid reabsorption in a rat pneumonia 
model (Rezaiguia et al., 1997) and in a rat intestinal ischemia reperfusion model 
(Borjesson et al., 2000). 
 Experimental studies have suggested a beneficial role of TNFR2 signalling in 
tissue repair, regeneration, and the resolution phase of tissue injury following trauma, 
ischaemia/reperfusion (IR) injury, or acute inflammatory insults. For example, in mice 
TNFR2 was protective in the pathogenesis of heart failure (Hamid et al., 2009; Higuchi et 
al., 2004), renal allograft failure due IR injury (Al-Lamki et al., 2005), neuronal injury 
(Fontaine et al., 2002), and ischaemic neovascularisation (Goukassian et al., 2007; Zhang 
et al., 2013). Moreover, TNF or TNFR2 agonism was associated with pancreatic 
regeneration (Kodama et al., 2003; Ban et al., 2008), remyelination (McCoy and Tansey, 
2008; Arnett et al., 2001) and stem cell proliferation (Al-Lamki et al., 2013; Bocker et al., 
2008).  
Resolution of ALI requires reabsorption of alveolar oedema, repair of the epithelial 
and endothelial barriers, and removal of inflammatory cells from the distal airspaces. 
Hence, early epithelial repair with re-epithelialisation of the denuded basement membrane 
and regeneration of the lung endothelial barrier is important for the restoration of the 
normal architecture and alveolar fluid clearance of the lung. Indeed, repair of the lung 
epithelium correlated with prognosis in ALI (Ware and Matthay, 2001). hAT2 are thought 
to act as progenitor cells for both daughter type II cells and type I cells (Gonzalez et al., 
2005; Sannes, 1991), differentiating into type I cells in response to specific developmental 
cues; these de-differentiated hAT2 cells in vivo may have a similar phenotype to hAT2 in 
vitro as both are attempting to re-epithelialise a denuded membrane.  
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Owing to the ethical and logistical difficulties of procuring lung tissue for hAT2 cell 
harvest, most research in the role of epithelial cell activation and injury in ALI has used 
the human A549 adenocarcinoma cell line. However, the A549 cell line has little in 
common with hAT2 cells as they do not from tight junctions, contain no surfactant 
apoproteins (including surfactant protein C) and possess no contact inhibition of growth. 
In addition chemokine release, including IL-8, was higher in hAT2 cells (Masubuchi et 
al., 1998; Witherden et al., 2004). Human alveolar type I cells are extremely fragile and to 
date their culture in vitro has proved challenging; some researchers rely upon hAT2 cell 
differentiation into type I cells in vitro over several days, however, these terminally 
differentiated cells cannot be passaged. Highly sophisticated three-dimensional models 
may arguably be more representative of in vivo pathobiology, but these require the use of 
immortalised cell lines (Carterson et al., 2005; Lehmann et al., 2011). We have developed 
the facility and experience in our laboratory to isolate hAT2 and consider these cells most 
representative of the in vivo alveolar epithelium.  
The experiments in this chapter were designed to establish clinically relevant human 
in vitro models of alveolar-capillary cell activation and injury to allow characterization of 
the role of differential TNFR signalling in these processes. In view of data suggesting 
beneficial effects of differential TNFR signalling in the resolution phase of tissue injury, 
we also investigated the role of TNF and TNFR signalling in lung microvascular 
endothelial regeneration and alveolar epithelial repair.  
 
3.2 Specific methods 
hAT2 were seeded on BioFlex™ 6 well plates (Dunn Laboratories, Germany) at a 
density of 2.5x106 cells/well and exposed to 2 hours of 30% CMS (0.33Hz). This regimen 
was chosen because it demonstrated robust production of IL-8 from hAT2 cells in 
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previous experiments by our group (Pinhu et al., 2008). Following overnight serum 
starvation, cells were exposed to CMS for 2 hours at 0.33Hz and then incubated for 24 
hours prior to the removal of supernatants for the assessment of cytokine levels by Meso 
Scale Discovery (MSD®) analysis. These experiments were repeated following 1-hour 
pre-treatment of the cells with GSK1995057 (10nM), Adalimumab (1nM) or dummy 
domain antibody (10nM) followed by 2 hours of 30% CMS. 
3.2.1 Treatment of hAT2 with BALF from ALI patients 
Following consent, BALF was harvested from patients with moderate to severe 
ARDS (table 1.1). Lavage fluid was filtered through gauze to remove debris then 
irradiated with ultraviolet light (458nm) for 1 hour to kill contaminating bacteria. 
Following overnight serum starvation, cells were treated with BALF diluted 5-fold with 
serum free DCCM-1 media. Supernatants were harvested over 24 hours and IL-8 
concentrations determined by ELISA. 
3.2.2 Wound healing assay 
hAT2 were grown to confluence in 24 well plates. Following overnight serum 
starvation cells were exposed to GSK1995057 (10nM), Adalimumab (1nM) and a dummy 
domain antibody (10nM) or vehicle control for 1-hour, scratched with a p200 pipette tip, 
washed prior to the addition of new 2% medium containing TNF (10ng/mL). In 
experiments using selective TNFR muteins, cells were serum starved, scratched then 
washed, followed by the addition of serum free DCCM-1 media, R32W (10,100ng/mL), 
D143N (10,100ng/mL) or 10% serum. A time course of 24 hours was chosen as 
preliminary experiments suggested sub-maximal (75-80%) wound closure in positive 
control (10% serum) treated cells. Wound closure was measured by subtracting the 24-
hour wound area from the initial wound area (measured in pixels) and calculating this as a 
percentage of initial wound area using Image J software. 
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In experiments using supernatants from treated alveolar macrophages, isolated 
from disease free lung resection specimens (chapter 2.2.5.2) macrophages were exposed 
to GSK1995057 (10nM), Adalimumab (1nM) and a dummy domain antibody (10nM) or 
vehicle control for 1-hour, then TNF (10ng/mL) added overnight (16 hours). Harvested 
supernatants were then added to scratched cells and imaged as above. 
3.2.3 Tube formation assay 
HUVEC and HMVEC-L were treated in suspension with vehicle control (media 
alone), TNF (10ng/mL), R32W (10-100ng/mL), D143N (10-100ng/mL) and VEGF 
(100ng/mL). Cells were added to an ibiTreat angiogenesis µ-slide (Ibidi, Germany) pre-
coated with reduced growth factor Matrigel™ matrix (chapter 2.2.6.8). Tube formation 
was analysed after 4 hours and recorded as total tube length analysed by image analysis 
software (Image J, USA). 
3.2.4  Assessment of permeability in HMVEC-L monolayers  
HMVEC-L (1x106/mL, 400µL) were grown in complete EGM-MV2 media (chapter 
2.2.5.3) on proprietary 8 well Electrical Cell-substrate Impedence Sending (ECIS®) 
cultureware slides (Applied Biophysics, USA) containing gold film electrodes to allow 
time-course measurement of electrical resistance, capacitance and impedance (chapter 
2.2.6.2). Growth to confluence was confirmed by light microscopy and steady state 
resistance of >3000Ω. Cells were pre-treated with GSK1995057 (10nM), Adalimumab 
(1nM) and a dummy domain antibody (10nM) for 1 hour then TNF (10ng/mL) or vehicle 
control was added. Transendothelial resistance was measured at 4000 Hz over 20 hours 
using the ECIS® ZTheta array station (Applied Biophysics, USA) and time-course 
resistance data normalised to the initial voltage. 
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3.2.5 Analysis of cytokine release from stimulated hAT2 and HMVEC-L 
hAT2 and HMVEC-L were grown to confluence (chapter 2.2.5) then pre-exposed to 
GSK1995057 (10nM), dummy domain antibody (10nM), Adalimumab (1nM) or vehicle 
control (media alone) for 1 hour prior to the addition of TNF (10ng/mL)  or vehicle 
control. Cells were incubated at 37oC, 5% CO2 for 24 hours then supernatants were 
collected and immediately frozen at -80oC. MTT assay (chapter 2.2.3) was performed on 
cells immediately after supernatant harvesting. Analysis of cytokine release was 
undertaken by MSD analysis according to the manufacturer’s instructions (chapter 
2.2.7.3.2). The cytokine panel was partially bespoke; specific analytes of interest were 
added to a proprietary standard human 9 plex kit that contained the majority of clinically 
relevant cytokines and chemokines.   
3.3 Results 
3.3.1 In vitro models of acute lung injury induced a dose dependent increase 
in IL-8 release from human alveolar type 2 cells 
Initial experiments were designed to develop in vitro models of ALI, which could 
be used to analyse the effects of differential TNFR signalling. The in vitro injury models 
consisted of TNF a clinically relevant pro-inflammatory cytokine, hydrogen peroxide 
(H2O2) as a model of oxidative stress, cyclic mechanical strain (CMS) as a model of 
VALI, and finally BALF from ARDS patients as a model of the inflammatory milieu in 
ALI. TNF and CMS elicited a dose dependent increase in IL-8 release from stimulated 
hAT2 monolayers (figure 3.1 A & D). Bronchoalveolar lavage fluid (BALF) induced a 
time-dependent increase in IL-8 release compared to treatment with vehicle control 
(figure 3.1 C). Reassuringly, the IL-8 release could not be attributed to cell death as the 
MTT assay for each condition did not demonstrate a significant loss of cell viability, 
despite increasing doses of each respective injury (figure 3.2).  
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Figure 3.1 In vitro ALI models demonstrated a dose dependent increase in IL-8 production  
hAT2 cells were grown to confluence and treated with tumour necrosis factor (TNF 0, 1, 10, 100 
pg/ml) n=8-10 panel A or Hydrogen Peroxide (H2O2 10, 50, 100, 200nM) n=5-8 panel B for 
twenty-four hours in the absence of serum. Alternatively, they were exposed to bronchoalveolar 
lavage fluid (BALF) from ALI ARDS patients for 2, 12, 24, 48 hours (panel C, n=6) or 0,5,20, 
30% CMS for two hours (panel D, n=4). In all experiments, the medium was collected and 
concentrations of Interleukin-8 (IL-8) were measured by sandwich ELISA in supernatant. Data are 
presented as mean ± SEM and analysed by Kruskall-Wallis (Dunns) A, B & D or two way 
ANOVA, C *p<0.05 **p<0.01 ***p<0.001 
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Figure 3.2 In vitro injury ALI models had no effect on hAT2 viability  
Confluent hAT2 were subjected to TNF (Image A, 0, 1, 10, 100ng/mL), H2O2 (Image B, 0, 10, 50, 
100, 200uM), BALF diluted 5 fold (Image C) and cyclic mechanical strain (image D, 0, 5, 20, 
30%, 2 hrs,). Cell viability was measured 24 hours after injury by MTT assay. Data are presented 
as mean optical density at 550nm ± SEM from 4 independent experiments.  
 
3.3.2 hAT2 and HMVEC-L expressed both TNFR 
Prior to undertaking experiments investigating selective TNFR antagonism and 
agonism we confirmed that hAT2 (figure 3.3) and HMVEC-L (figure 3.4) expressed both 
TNF receptors. In preliminary experiments, the human alveolar epithelial cell line A549 
expressed TNFR1 only (personal communication from GSK).  
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Figure 3.3 hAT2 expressed both TNFR 
hAT2 were grown to confluence over 5 days then re-suspended using non-enzymatic dissociation 
buffer, transferred on ice and stained with anti-human TNFR1 PE and anti-human TNFR2 PE or 
isotype controls. Receptor expression was analysed by flow cytometry. Panels A and B are 
representative of 2 separate experiments and demonstrate TNFR1 expression (Panel A) and 
TNFR2 expression (Panel B). IgG isotype controls are shown with the dotted line 
 
Figure 3.4 HMVEC-L expressed both TNFR 
HMVEC-L were grown to confluence over 3 days then re-suspended and stained with anti-human 
TNFR1 PE and anti-human TNFR2 FITC or isotype controls. Receptor expression was analysed 
by flow cytometry. Panels A and B are representative of 2 separate experiments and demonstrate 
TNFR1 expression (Panel A) and TNFR2 expression (Panel B). IgG isotype controls are shown 
with the dotted line 
 
 
 
A" B"
A" B"
151 
 
 
3.3.3 Selective TNFR1 antagonism abrogated IL-8 release from human 
alveolar type 2 cells in a dose responsive manner 
 The effect of TNFR antagonism was investigated in TNF stimulated hAT2, pre-
incubated with GSK1995057, Adalimumab and a dummy domain antibody. The dose of 
TNF used (10ng/mL) was the approximate half maximal effective concentration (EC50) 
from the dose response experiments shown in figure 3.1 A. GSK1995057 (10nM) and  
Adalimumab (1nM) abrogated IL-8 release from TNF stimulated hAT2 (Figure 3.5A). 
The dummy domain antibody had no effect on IL-8 release and none of the treatments 
influenced cell viability, measured by MTT assay (figure 3.6). Based on these data, all 
future experiments investigating selective TNFR antagonism used a dose of 1nM 
Adalimumab and 10nM GSK1995057 and dummy domain antibody. 
Figure 3.5 Selective TNFR antagonism abrogated IL-8 release from TNF stimulated human 
alveolar type 2 cells  
hAT2 were exposed to GSK1995057, Adalimumab or dummy domain antibody for 1 hour. Cells 
were then treated with TNF 10ng/mL for 24 hours. The medium was collected after a further 24 
hours and concentrations of Interleukin-8 (IL-8) measured by ELISA (Panel A, n=4-5). Panel B 
shows the TNF dose response curve (n=4). Data are presented as mean ± SEM. 
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Figure 3.6 Effect of selective TNFR antagonism on hAT2 viability 
hAT2 were pre-incubated with the GSK1995057 (10nM), Adalimumab (1nM) and a dummy 
domain antibody (10nM) for 1 hour then exposed to exogenous TNF (10ng/mL) or vehicle 
control. After 24 hours cell viability was measured by MTT assay. Data are presented as median 
optical density at 550nm ± interquartile range (n=2). 
 
3.3.4 Effect of selective TNFR1 antagonism on cytokine and chemokine 
release in TNF treated hAT2 
 Exposure of hAT2 to TNF (10ng/mL) induced release of IL-8, IL-6 and GM-CSF. 
Levels of IL-1β, CXCL-1 and ENA-78 were increased at least 2 fold but failed to reach 
statistical significance owing to small sample numbers (n=3, figure 3.7). GSK1995057 
reduced release of IL-8, IL-6, GM-CSF and ENA-78 towards control levels, but again this 
failed to reach statistical significance owing to the small sample size (n=3-6). 
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Figure 3.7 Effect of selective TNFR1 antagonism on cytokine and chemokine release from 
TNF treated hAT2  
Monolayers of hAT2 were pre-incubated with GSK1995057 (10nM), Adalimumab (1nM) and a 
dummy domain antibody (10nM) for 1 hour then exposed to exogenous TNF (10ng/mL) or 
vehicle control. Supernatants were collected after 24 hours and analysed for cytokines and 
chemokines using MSD® multiplex panels (n=4). Data are presented as mean ± SEM and analysed 
using Kruskall-Wallis (Dunns) test *p<0.05, **p<0.01.  
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3.3.5 Effect of selective TNFR1 antagonism on cytokine and chemokine 
release in hAT2 exposed to cyclic mechanical strain 
30% CMS for 2 hours significantly increased IL-8, IL-6 and IL-1β protein release 
from hAT2 cells (figure 3.8). Selective TNFR1 antagonism demonstrated no effect on 
release of IL-8, IL-6 or IL-1 β. There was no effect of CMS on release of other cytokines 
or chemokines, in particular TNF, hence it was impossible to establish any effect of 
selective TNFR1 antagonism. 
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Figure 3.8 Effect of selective TNFR1 antagonism on cytokine and chemokine release from 
hAT2 exposed to 30% cyclic mechanical strain 
Monolayers of hAT2 were pre-incubated with GSK1995057 (10nM), Adalimumab (1nM) and a 
dummy domain antibody (10nM) for 1 hour then exposed to cyclic mechanical stretch (30%, 2 
hours) or no stretch. Supernatants were collected 24 hours after cessation of stretch and analysed 
for cytokines and chemokines using MSD® multiplex panels or duoset ELISA kits (sTNFR1 & 
sTNFR2) n=3-5. Data are presented as mean ± SEM and analysed using Kruskall-Wallis (Dunns) 
test *p<0.05, **p<0.01  
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3.3.6 Effect of selective TNFR1 antagonism on cytokine and chemokine 
release from TNF stimulated HMVEC-L 
 Treatment of HMVEC-L monolayers with TNF (10ng/mL) induced release of the 
cytokines IL-8, IL-6, IL-1β and IL-10 and the chemokines ENA-78, CXCL-1 and GM-
CSF (figure 3.9). Pre-treatment of cells with GSK1995057 significantly abrogated IL-8 
release whilst TNF induced release of IL-6, IL-1β, ENA-78 and GM-CSF was abrogated 
by GSK1995057 and Adalimumab as evidenced by the loss of significance compared to 
TNF (or dummy dAb) treatment. Dual TNFR blockade with Adalimumab paralleled the 
effects observed with GSK1995057. Pre-treatment with GSK1995057 had no effect on 
IL-10 release from TNF stimulated HMVEC-L whilst dual receptor blockade with 
Adalimumab returned IL-10 release towards control levels suggesting that IL-10 release 
may be regulated predominantly via TNFR2 signalling.  
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Figure 3.9 Effect of selective TNFR1 antagonism on cytokine and chemokine release from 
TNF treated HMVEC-L  
Monolayers of HMVEC-L were pre-incubated with GSK1995057 (10nM), Adalimumab (1nM) 
and a dummy domain antibody (10nM) for 1 hour then exposed to exogenous TNF (10ng/mL) or 
vehicle control. Supernatants were collected after 24 hours and analysed for cytokines and 
chemokines using MSD® multiplex panels (n=4). Data are presented as mean ± SEM and analysed 
using Kruskall-Wallis (Dunns) test *p<0.05, **p<0.01  
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Figure 3.10 Effect of selective TNFR antagonism on HMVEC-L viability  
HMVEC-L monolayers were pre-incubated with the GSK1995057 (10nM), Adalimumab (1nM) 
and a dummy domain antibody (10nM) for 1 hour then exposed to exogenous TNF (10ng/mL) or 
vehicle control. After 24 hours, cell viability was measured by MTT assay. Data are presented as 
median optical density at 550nm ± interquartile range (n=2).  
 
3.3.7 Differential TNFR signalling did not promote wound healing in hAT2  
Across a range of  TNF concentrations (1-100ng/mL respectively), wound healing 
of scratched hAT2 did not increase beyond basal levels (figure 3.11). The effect of TNF 
was further investigated using selective TNFR antagonsim and agonism. Neither selective 
TNFR1 antagonism, in principal ‘forcing’ TNFR2 signalling in the presence of TNF 
(figure 3.12), nor TNFR2 agonism with D143N (figure 3.13) promoted wound healing. 
TNF stimulation alone had no effect on wound healing, however pre-incubation with the 
dummy domain antibody stimulated wound healing similarly to experiments in figure 
3.12. Of note, treatment with media containing 10% serum did not induce a significant 
increase in wound healing compared to media without serum. 
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Figure 3.11 TNF dose response of wound closure in hAT2  
Wounded hAT2 monolayers were incubated with TNF (1, 10 or 100ng/mL), vehicle control, or 
media containing 10% serum. After 24 hours the wound was re-imaged and percentage wound 
closure calculated using image analysis software (n=12). Data are presented as mean ± SEM 
analysed using Kruskall-Wallis (Dunns) test. ** p<0.01 
Figure 3.12 Effect of differential TNFR signalling on wound healing in hAT2  
Wounded hAT2 monolayers were incubated with GSK1995057 (10nM), Adalimumab (1nM) and 
a dummy domain antibody (10nM) for 1 hour then exposed to exogenous TNF (10ng/mL), vehicle 
control, or media containing 10% serum (Figure A, n=3-5) or treated with R32W (1, 10 or 
100ng/mL), D143N (1, 10 or 100ng/mL), vehicle control or 10% serum (Figure B n=4-6).  After 
24 hours the wound was re-imaged and wound closure calculated using image analysis software. 
Data are presented as mean ± SEM and analysed using Kruskall-Wallis (Dunns) test. * p<0.05 
 
To assess the effect of cytokine release from TNF stimulated cells on wound 
healing of hAT2 monolayers and the effects of differential TNF signalling, we stimulated 
alveolar macrophages with TNF in the presence of GSK1995057 and controls. The 
harvested supernatant did not significantly promote wound healing (figure 3.14). 
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Similarly, selective TNFR antagonism had no effect. In separate experiments, IL-8 levels 
in the harvested supernatant were measured and this demonstrated nominal IL-8 release 
and no difference between treatments. 
 
Figure 3.13 Effect of supernatants from alveolar macrophages stimulated with TNF in the 
presence of GSK1995057 and controls on hAT2 wound healing  
Human alveolar macrophages were incubated with GSK1995057 (10nM), Adalimumab (1nM) or 
dummy domain antibody (10nM) then exposed to exogenous TNF (10ng/mL) or vehicle control. 
After 20 hours, the supernatants were collected and frozen at -80oC. Supernatants were later added 
to wounded hAT2 and wound closure measured over 24 hours was calculated using image 
analysis software (n=3-5). Data are presented as mean ± SEM 
 
3.3.8 Effect of selective TNFR agonism on tube formation in HUVEC and 
HMVEC-L 
In an angiogenesis or vascular wound healing assay, selective TNFR2 agonism 
significantly promoted tube formation in HUVEC compared to unstimulated cells (figure 
3.14A). The magnitude of this effect was similar to that of the positive control, vascular 
endothelial growth factor (VEGF), a known angiogenic factor in vitro. A similar trend 
was observed in HMVEC-L but this effect was non-significant (figure 3.14B). Both cell 
types expressed TNFR1 and TNFR2 although relative expression between cell types was 
not demonstrated.  
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Figure 3.14 Effect of selective TNFR agonism on tube formation in in HUVEC and 
HMVEC-L  
HUVEC and HMVEC-L were diluted in TNF (1 or 10ng/mL), R32W (10 or 100ng/mL), D143N 
(10 or 100ng/mL), VEGF (10ng/mL) or vehicle control and seeded onto angiogenesis slides 
coated with Matrigel. After 4 hours, the well was imaged and total tube length measured using 
image analysis software. Figure A represents tube formation in HUVEC (n=7) and figure B tube 
formation in HMVEC-L (n=4). Data are presented as mean ± SEM analysed using one way 
ANOVA (Dunnett’s) test *p<0.05, **p<0.01 
 
3.3.9 Selective TNFR1 antagonism abrogated TNF induced permeability in 
HMVEC-L  
Both selective TNFR1 antagonism and dual blockade of both TNFR abrogated 
TNF induced changes in endothelial permeability as measured by trans-endothelial 
resistance (figure 3.15B). The effects of TNF were maximal at around 8 hours following 
stimulation and plateaued for the duration of the experiment (figure 3.15A). Electrical 
impedance and capacitance across the cells remained unchanged suggesting that the 
observed changes in electrical resistance were not due to alterations in cell morphology or 
cell death. 
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Figure 3.15 Effect of selective TNFR antagonism on TNF induced endothelial permeability, 
as measured by transendothelial resistance 
HMVEC-L plated on an ECIS 8-well electrode array plate were incubated with GSK1995057 
(10nM), Adalimumab (1nM) or a dummy domain antibody (10nM) for 1 hour then exposed to 
exogenous TNF (10ng/mL) or vehicle control. Transendothelial resistance (TER) was measured 
continuously over 20 hours. Figure A shows a representative tracing of normalised resistance 
where the black arrow indicates timing of pre-incubation and the grey arrow TNF administration. 
Figure B shows the trough-normalised resistance over the 20 hour period for each condition (n=3-
5). Data are presented as mean ± SEM analysed by Kruskal Wallis (Dunns) *p<0.05, **p<0.01 
 
3.3.10 Effect of selective TNFR1 antagonism on release of vascular injury 
markers from TNF stimulated HMVEC-L 
 Treatment of HMVEC-L monolayers with TNF (10ng/ml) resulted in elevation of 
the vascular injury markers, soluble ICAM-1, soluble VCAM-1 and soluble E-selectin. 
There was a 3-fold increase in C-reactive protein (CRP) and serum amyloid protein A 
(SAA) release but this did not reach statistical significance (figure 3.16). Pre-treatment of 
cell monolayers with GSK1995057 resulted in a reduction of these vascular injury 
markers to basal (unstimulated) levels although again none of these data reached 
significance owing to small n numbers (n=4). MTT data confirmed that release of these 
markers was not due to cell death (figure 3.10) 
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Figure 3.16 Effect of selective TNFR1 antagonism on release of vascular injury markers 
release from TNF treated HMVEC-L  
Monolayers of HMVEC-L were incubated with GSK1995057 (10nM), Adalimumab (1nM) or a 
dummy domain antibody (10nM) for 1 hour then exposed to exogenous TNF (10ng/mL) or 
vehicle control. Supernatants were collected after 24 hours and analysed for cytokines and 
chemokines using MSD® multiplex panels (n=4). Data are presented as mean ± SEM and analysed 
using Kruskall-Wallis (Dunns) test *p<0.05 SAA; serum amyloid protein A, CRP; C-reactive 
protein 
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3.3.11 Summary of important findings in this chapter 
 TNF induced release of IL-8, IL-6 and GMCSF from hAT2. TNF stimulation of 
hAT2 increased release of IL-1β, CXCL-1 and ENA-78 at least 2- fold but these data 
failed to reach statistical significance. GSK1995057 pre-treatment reduced release of IL-
8, IL-6, GMCSF and ENA-78 towards control levels but again this failed to reach 
statistical significance. 
Similarly, chemokine and cytokine release from TNF stimulated HMVEC-L was 
markedly attenuated by GSK1995057 suggesting that pro-inflammatory signalling in 
these cells is significantly influenced by TNFR1 signalling. Pre-treatment of HMVEC-L 
with GSK1995057 had no effect on IL-10 release from TNF stimulated cells, whereas 
dual TNFR blockade reduced IL-10 release to basal levels, suggesting that IL-10 release 
may be under the dominant control of TNFR2 signalling 
hAT2 monolayers exposed to 30% CMS  released IL-8, IL-6, and IL-1β but the 
release of the majority of cytokines and chemokines assayed was unaffected. TNFR1 
anatgonism had no significant effect IL-8, IL-6, and IL-1β release. Interestingly, there was 
no effect of CMS on either sTNR1 or sTNFR2 release.  
TNF had no effect on wound healing in hAT2. In addition, neither selective TNFR 
antagonism nor TNFR agonism promoted wound healing. TNFR2 signalling appeared to 
promote tube formation in HUVEC. Owing to lower experimental numbers (n=4), whilst 
there was a trend towards a similar effect in HMVEC-L, this was not statistically 
significant.  
TNF reduced transendothelial resistance in HMVEC-L. This was mediated by 
TNFR1 signalling as GSK1995057 pre-treatment abrogated the effect. Similarly TNF 
activated HMVEC-L as evidenced by release of sICAM-1, sVCAM-1 and soluble E-
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selectin. Whilst there was a reduction to basal (untreated) levels in cells pre-exposed to 
GSK1995057, these data failed to reach statistical significance.  
3.3.12 Development of in vitro models of ALI and selective TNFR antagonism 
thereof 
Stimulation of hAT2 cells with TNF, hydrogen peroxide, CMS and 
bronchoalveolar lavage fluid (BALF) from ARDS patients demonstrated a dose-
dependent increase in IL-8 production (figure 3.1). These in vitro models were designed 
to reflect several key pathomechanisms of in vivo ALI, including direct ALI, oxidative 
stress and VALI.  IL-8 is a potent neutrophil chemokine produced by respiratory 
epithelium (Standiford et al., 1990) in response to pro-inflammatory cytokines and is the 
predominant chemokine in BALF in human ALI (Goodman et al., 1996); concentrations 
of IL-8 in BALF from patients with ALI were elevated compared to those with 
cardiogenic pulmonary oedema (Miller et al., 1996; Pugin et al., 1999). Moreover, 
increased BALF IL-8 levels predicted both the development of ALI in an at-risk 
population and mortality (Donnelly et al., 1993; Miller et al., 1996; Rodriguez et al., 
1992). As a primary read-out of epithelial injury with relevance to in vivo injury, IL-8 
therefore seemed an appropriately robust and relevant marker.  
TNF induced significant release of IL-8 from hAT2 (figure 3.1). Under 
inflammatory conditions, TNF concentrations between 1 and 10 ng/mL have been 
measured in the BALF of ARDS patients (Meduri et al., 1995).  A concentration of 10nM 
GSK1995057 and 1nM Adalimumab abrogated IL-8 release from TNF stimulated hAT2 
(Figure 3.5). These effects and concentrations paralleled preliminary experiments 
performed in fibroblasts and A549 cells (personal communication from GSK). 
Accordingly, we chose a concentration of 10ng/mL TNF and 10nM GSK1995057 (and 
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dummy domain antibody) with 1nM Adalimumab for all future experiments in all cell 
types.  
Whilst BALF from ARDS patients induced IL-8 release (figure 3.1), in subsequent 
experiments investigating the effect of selective TNFR1 antagonism on IL-8 release from 
BALF stimulated hAT2, IL-8 release failed to reach statistical significance so further 
analysis was abandoned. Similarly, hydrogen peroxide (200µM) induced IL-8 release 
from hAT2 (figure 3.1), but the treatment effect was small and further analysis was not 
pursued. 
3.3.13 The effect of differential TNFR signalling on cytokine and chemokine 
release from TNF stimulated hAT2 and HMVEC-L  
Selective TNFR antagonism in both hAT2 and HMVEC-L reduced cytokine (IL-8 
and IL-6) and neutrophil chemokine (ENA-78, CXCL-1 and GMCSF) release to basal 
(unstimulated levels) although these data were not statistically significant (figures 3.7 and 
3.9).  Although the precise role of each cytokine and chemokine in the pathogenesis of 
ALI is not fully understood, the putative benefits of blockade of pro-inflammatory 
cytokine and neutrophil chemokine release have been highlighted by a number of both 
clinical and experimental studies. Hence, passive immunisation of rabbits with 
neutralising antibodies to IL-8 abrogated neutrophil recruitment and tissue injury in a 
rabbit model of acid aspiration lung injury (Folkesson et al., 1995) and ischemia–
reperfusion injury (Strieter et al., 1999). Furthermore, antibody neutralization of ENA-78 
attenuated lung injury in a rodent model of hepatic ischemia/reperfusion injury (Colletti et 
al., 1995) whilst pretreatment of rats with a neutralising antibody to CINC, cytokine-
induced neutrophil chemoattractant (CINC), the homolog of human CXCL-1, protected 
rats against pancreatitis-associated lung injury (Bhatia et al., 2000).  
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 Moreover, human data suggest that early enhanced neutrophil migration due to 
elevated alveolar IL-8 concentrations may be critical to neutrophilic alveolitis in ALI or 
those at risk (Pallister et al., 2002) and neutrophil activation directly correlates with 
disease severity and with levels of IL-8, TNF and IL-6 (Chollet-Martin et al., 1996). 
Furthermore, whilst other chemokines are elevated in BALF from ARDS patients, only 
IL-8 consistently correlates with the number of neutrophils and disease severity 
(Goodman et al., 2003; Villard et al., 1995).   
Plasma IL-6 was associated with oxygenation index, fewer ventilator free days and 
28-day mortality in patients enrolled in the ALVEOLI (high PEEP vs low PEEP) trial 
(Brower et al., 2004). Other investigators have reported elevated plasma IL-6 in patients 
who developed ALI in comparison to those who did not (Takala et al., 2002) and high 
baseline Il-6 levels were seen in patients with ARDS who died (Parsons et al., 2005; 
Meduri et al., 1995) and a persistently elevated circulating level of IL-6 predicted 
mortality (Meduri et al., 1995).Whilst IL-1β is the major inflammatory mediator in BALF 
of ALI patients (Pugin et al., 1996), large multi-centre studies investigating the role of IL-
1β are lacking, but small studies showed persistent elevation of plasma IL-1β	  (Meduri et 
al., 1995) and elevated BALF levels of IL-1β(Pugin	   et	   al.,	   1996) were associated with 
worse outcomes 
 Despite IL-8 being considered the main neutrophil chemoattractant in ALI, 
neutralisation of IL-8 in the BALF of patients with mild ALI did not completely abolish 
its neutrophil chemotactic activity (Miller et al., 1992), suggesting that other chemotactic 
factors are present that contribute to neutrophil migration. Hence, plasma and BALF 
levels of chemokines including CXCL-1 and ENA-78 have were elevated in patients at 
risk for, and with established, ALI (Goodman et al., 1996; Villard et al., 1995; Donnelly et 
al., 1993) and levels correlated with outcome (Miller et al., 1992).  GM-CSF is recognised 
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to have effects on neutrophil recruitment, macrophage biology, surfactant homeostasis, 
and host defence in the lungs (Trapnell et al., 2009). Acute blockade of GM-CSF 
decreases pulmonary neutrophil recruitment elicited by LPS or cytokines (Bozinovski et 
al., 2004; Bozinovski et al., 2002; Laan et al., 2003) Furthermore, in 31 patients with ALI, 
whilst GM-CSF did not correlate with BALF neutrophil levels, G-CSF but not GMCSF 
negatively correlated with survival (Aggarwal et al., 2000).   
 TNFR1 inhibition of pro-inflammatory cytokine and chemokine release from both 
hAT2 and HMVEC-L is probably mediated via inhibition of NF-κB signalling. Fifty-five 
genes known to be regulated by NF-κB were analysed in TNF stimulated human 
microvascular endothelial cells (HMVEC) and HUVEC (Perrot-Applanat et al., 2011). 
The chemokines IL-8, GRO-α, MCP-1 and GMCSF cytokines IL-6 and IL-1β and 
neutrophil adhesion molecules ICAM-1 and VCAM-1 were up-regulated more than 5 fold 
in HMVEC and HUVEC. The TNFR1 dependency of this effect was investigated using 
small inhibitory RNA (siRNA) to TNFR1. The expression of IL-8, IL-6, IL1-α, IL-1β, 
GMCSF, ICAM-1 and VCAM-1 were inhibited more than 30% compared to TNF 
stimulated siRNA control-transfected cells. Interestingly, transfection of HMEC with 
TNFR2 siRNA also inhibited up-regulation of IL-1β and GMCSF suggesting that TNFR2 
signalling is additionally involved in the control of the NF-κB gene signature of TNF 
stimulated HMVEC. In agreement with these data TNF-stimulated ICAM-1 and VCAM-1 
expression in HUVEC was mediated exclusively NF-κB signalling, but not the ERK, 
p38MAPK or JNK kinase signalling; this effect was under the exclusive control of 
TNFR1 signalling (Zhou et al., 2007). Similarly, TNF-induction of inflammatory genes 
was under the dominant control of TNFR1 in airway smooth muscle (Amrani et al., 2001). 
 Interestingly, TNFR1 antagonism had no effect on IL-10 levels in TNF stimulated 
HMVEC-L whilst dual TNFR blockade reduced IL-10 release to basal levels (figure 3.9) 
169 
 
 
suggesting that TNFR2 signalling has anti-inflammatory and reparative roles in certain 
tissues (chapter 1.3.4). IL-10 therapy abrogated LPS induced ALI via its anti-
inflammatory actions including inhibition of TH1 differentiation, suppression of neutrophil 
activation, and neutrophil chemokine down regulation (Inoue, 2000). IL-10 has also been 
shown to counteract LPS and TNF induced inhibition of neutrophil apoptosis (Keel et al., 
1997) and trans-epithelial migration of neutrophils (Ajuebor et al., 1999).  Moreover, IL-
10 may be central to the resolution of inflammation; intravenous administration of 
mesenchymal stem cells in a murine sepsis model reduced mortality and organ injury, an 
effect mediated primarily by increased IL-10 levels. Analysis of plasma samples from 
ARDS patients enrolled in the 2000 ARMA study (Network, 2000), demonstrated a 
negative correlation of plasma IL-10 with a poor outcome (Parsons et al., 2005).  
 Whether IL-10 release represents a TNFR2 mediated anti-inflammatory pathway 
in HMVEC-L requires further investigation, but it was notable that TNFR1 antagonism 
reduced the putative anti-inflammatory cytokine IL-1 receptor alpha (an antagonist to the 
pro-inflammatory cytokine IL-1β) to near basal levels. 
3.3.14 TNFR1 antagonism had no effect on chemokine or cytokine release 
from mechanically stretched hAT2 or hAT2 treated with BALF from 
patients with ALI 
Numerous cytokines have been detected in BALF and plasma from ALI patients 
subjected to mechanical ventilation. Similar variation in results has been observed in 
animal models of VALI (Held et al., 2001; Imai et al., 1999; Narimanbekov and Rozycki, 
1995; Tremblay et al., 1997) and from in vitro models where mechanical strain was 
applied to tissues or cells. These results indicate that the release of a variety of pro-
inflammatory mediators and several cytokines are dependent upon species, cell line and 
ventilation or CMS conditions. Using a protocol of 30% elongation, 20 cycles per minute 
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for 2 hours, we observed significant increases in IL-8, IL-6, and IL-1β from hAT2 (figure 
3.8) whilst release of the majority of cytokines and chemokines was unaffected. Our 
regimen was chosen because data from our group has demonstrated robust production of 
IL-8 from hAT2 cells (Pinhu et al., 2008). In animal models, however, a 2-hour high 
stretch regimen up-regulated TNF in the lavage fluid but was insufficient to up-regulate 
neutrophil chemokines (Tremblay et al., 1997; Tremblay et al., 2002; Wilson et al., 2005). 
It is therefore plausible that our protocol did not allow for analysis of the kinetics of 
cytokine and chemokine release thus accounting for the observed lack of stretch response 
for the majority of analytes. MTT data (figure 3.2D) suggest that release of cytokines is 
unlikely to be due to cell death; previous unpublished data from our group has confirmed 
that, at least in A549 cells, our regimen did not induce cell death although cell membrane 
damage was evident, as previously described (Tschumperlin and Margulies, 1998; 
Vlahakis et al., 1999).  
IL-8, IL-6, and IL-1β are clinically relevant pro-inflammatory cytokines in ALI; 
BALF levels of these cytokines decreased over 36 hours in patients exposed to low tidal 
volume ventilation compared to conventional ventilation (Ranieri et al., 1999), whilst in 
the ARDS Network low tidal volume study (Network, 2000), plasma levels of IL-6 
decreased by 26% and IL-8 by 12% in the low tidal volume group. Similarly, plasma 
levels of IL6- and IL-8 increased in patients exposed to high tidal volume ventilation 
(Stuber et al., 2002); this effect was also seen in the plasma with levels returning to 
baseline with tidal volume reduction. 
Our group (unpublished data) and others (Vlahakis et al., 1999) have failed to 
detect TNF release from A549 cells exposed to 30% CMS. Similarly, we detected no 
response of hAT2 to CMS induced TNF protein release (figure 3.8). As outlined 
previously (chapter 1.3.5) experimental data regarding the role of TNF in VALI has been 
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inconsistent. One explanation for these conflicting data relates to the kinetics of TNF 
release. Despite BALF TNF levels in Ranieri’s clinical study increasing at both 24 and 36 
hours after conventional (12ml/kg) ventilation (Ranieri et al., 1999), data in a murine 
VALI model demonstrated that TNF expression was transient; animals terminated at the 
onset of VALI when physiological signs of injury were starting to become apparent 
expressed significantly higher levels of TNF than animals with advanced lung injury 
(Wilson et al., 2003). An interrogation of the time course of TNF release, as opposed to 
measurement at a single time point, may therefore have yielded more information about 
TNF release from hAT2 exposed to CMS.     
More definitive data regarding the role of TNF and in particular differential TNFR 
signalling was provided by data from the Takata group (Wilson et al., 2007). Using 
selective TNFR knockout mice, signalling through TNFR1 promoted the development of 
high stretch-induced pulmonary oedema, while signalling through TNFR2 was protective. 
These opposing effects were independent of TNF-mediated leucocyte recruitment. 
Interestingly, mice devoid of both TNF receptors showed no protection against oedema 
suggesting that TNFR1 signalling is injurious whilst TNFR2 signalling is protective, at 
least in murine VALI. These observations were further confirmed by the same group, 
using the selective TNFR1 antagonist GSK1995057 (Bertok et al., 2012). GSK1995057 
attenuated deteriorations in respiratory mechanics and oedema formation in a murine 
model of VALI whilst dual TNFR blockade had no effect. The mechanisms of TNFR1 
mediated pulmonary oedema have yet to be established although recent results from a 
murine acid induced ALI model suggested that TNFR1 mediated caspase-8 signalling 
induced lung epithelial injury and dysfunction (Patel et al., 2013). 
 In our in vitro study, we observed no effect of selective TNFR1 antagonism on 
IL-8, IL-6 or IL-1β release from hAT2 exposed to CMS (figure 3.8). The absence of 
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effect may again relate to the kinetics of TNF release in VALI models; a time course 
experiment, including early time points where TNF release may have yielded positive 
data. Alternatively, TNF production in VALI may be predominantly macrophage derived 
as opposed to released from alveolar epithelium. Indeed, alveolar macrophages (co-
stimulated with LPS) respond to mechanical stress by releasing TNF (Pugin et al., 1998) 
and depletion of alveolar macrophages in a rat VALI model decreased lung endothelial 
and epithelial permeability and lowered BALF neutrophil counts (Frank et al., 2006).  
Moreover, in an LPS plus VALI (20mL/kg tidal volume) model, up-regulation of 
cytokines and chemokines in the BALF, and accordingly neutrophil recruitment, was 
abrogated by selective TNFR1 antagonism (Bertok et al., 2012). This effect was 
associated with reduced activation of alveolar macrophages further suggesting that 
alveolar macrophages are a major source of cytokines in the alveolar compartment and 
that this process may be partly mediated by TNFR1 signalling.  
Levels of sTNFR in the plasma and BALF fell after 36 to 40 hours in patients with 
ALI subjected protective ventilation compared to those ventilated using a conventional 
strategy, whilst BALF sTNFR1 levels, but not sTNFR2, increased in patients exposed to 
injurious ventilation (12mL/kg) compared to protective ventilation (6mL/kg) (Parsons et 
al., 2005). Despite hAT2 expressing both TNFR (figure 3.3), CMS did not induce sTNFR 
release from hAT2 in our study. Our human in vitro data therefore support murine in vivo 
data suggesting that elevated levels of sTNFR in the airspace associated with high stretch 
ventilation reflects increased alveolar epithelial permeability as opposed to pulmonary 
epithelial cell sTNFR release (Dorr et al., 2011). Injurious ventilation induced alveolar 
protein influx, which strongly correlated with BALF levels of both sTNFR but this effect 
was abolished in isolated buffer-perfused lungs devoid of circulating sTNFRs.  
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3.3.15 Differential TNFR signalling did not promote wound healing in hAT2 
Neither TNF nor TNFR specific muteins promoted wound healing in hAT2 (figure 
3.11 and 3.12). TNF induced urokinase-type plasminogen activator (u-PA), a key 
component of fibrinolysis that accompanies tissue repair promoting tissue remodeling and 
cell migration in A549 cells (Marshall et al., 1992). Further studies confirmed that 
recombinant TNF stimulated bovine bronchial epithelial cell migration, an effect mediated 
by activation of PKC (Wyatt et al., 1997), whilst TNF induced airway epithelial cell 
wound healing required matrix metalloproteinase-9 release, epidermal growth factor 
(EGF) shedding and subsequent EGF receptor transactivation (Maille et al., 2011). 
Why was no effect observed in wounded hAT2? The concentration of TNF used 
was similar to other studies investigating cell proliferation and migration. In endothelial 
cells, however, wound repair was promoted at low concentrations (1ng/mL) and inhibited 
at higher concentrations (5 and 10ng/mL) (Pan et al., 2002). Both TNFR were present on 
the cell surface of hAT2 (figure 3.3) and previous data suggest that in response to injury, 
TNF responses are diminished by down-regulating TNFR1 mRNA and protein (Al-Lamki 
et al., 2003) or shedding of TNFR1 (Wang et al., 2003) whilst in tissues, TNFR2 is up-
regulated at sites of injury (Al-Lamki et al., 2009; Al-Lamki et al., 2010; Al-Lamki et al., 
2005). Indeed, in microvascular endothelial cells harvested from patients with established 
ALI, TNFR2 expression was up-regulated compared to both TNFR1 in the same cells and 
TNFR2 expression in control cells from cancer-free lobectomy specimens (Lucas et al., 
1997). Although we did not measure TNFR expression in cells at the wound edge, it 
would seem unlikely that the lack of response was therefore due to a lack or indeed 
absence of TNFR2. It remains unclear whether the selective TNFR mutein D143N has 
functional activity. Whilst a small but significant increase in tube formation in HUVEC 
was demonstrated with D143N (figure 3.14A), suggestive of functional activity, this is the 
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only positive ‘read-out’ across a range of cell types. Receptor binding studies demonstrate 
selective binding to TNFR2 with no cross-reactivity with TNFR1 (chapter 1.3.6.3) but we 
have been unable to demonstrate downstream signalling specific to TNFR2 (Appendix A). 
In organ cultures, TNFR2 promoted cell adhesion, migration, proliferation, survival and 
angiogenesis through activation of endothelial/epithelial tyrosine kinase (Etk) (Al-Lamki 
et al., 2009; Pan et al., 2002). Indeed, in epithelial cells, Etk may regulate cell junctions by 
promoting a redistribution of actin filaments (Hamm-Alvarez et al., 2001). Despite 
attempts to measure Etk phosphorylation and upstream AKT phosphorylation in both cell 
lysates and organ culture (precision cut lung slices), we have been unable to demonstrate 
any robust effect of either selective TNFR1 antagonism or TNFR2 agonism (Appendix 
A).  
Consistent with observations in other organ injury (chapter 1.3.4), we speculated 
that preferential TNFR2 signalling would promote wound healing in injured hAT2. Pre-
exposure of cells to the selective TNFR1 antagonist GSK1995057, in parallel with 
TNFR2 agonism demonstrated no effect on hAT2 wound healing (figure 3.12A). This 
regimen should, in principal ‘force’ TNFR2 signalling. One explanation for this lack of 
treatment effect could be a report suggesting TNFR2 was not efficiently activated in vitro; 
the membrane bound 26-kda from of TNF has been shown to be vastly superior to 
recombinant 17kDa soluble TNF in activating TNFR2 (Grell et al., 1995; Grell et al., 
1998).  Alternatively, TNFR2 signalling may contribute at lower concentrations of TNF 
(Slowik et al., 1993); hence the doses of the TNFR2 specific mutein D143N used in our 
studies (10 and 100ng/mL) may have been too high to observe a measurable effect. 
Nonetheless, it is difficult to draw firm conclusions from this assay as we did not observe 
a significant effect with the addition of 10% serum to cells compared to serum free 
treatment (figure 3.11), suggesting sub-optimal baseline experimental conditions. 
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As a final line of investigation, we speculated that conditioned medium from TNF 
treated macrophages in the presence of GSK1995057 and controls may promote hAT2 
wound healing. Mononuclear cell conditioned medium enhanced bovine bronchial 
epithelial cell migration in a TNF dependent manner (Ito et al., 1996), whilst in a rodent 
model, TNF released from LPS activated alveolar macrophages induced epithelial GM-
CSF expression, which in turn initiated alveolar epithelial cell proliferation, contributing 
to alveolar repair (Cakarova et al., 2009). We did not observe any differences in wound 
healing between TNF and vehicle treated macrophages, with no further effect from 
selective TNFR1 antagonism (figure 3.13). These data are consistent with those generated 
by the Matthay group in San Francisco (Geiser et al., 2001). Pulmonary oedema fluid 
from patients with ALI increased alveolar epithelial repair by 33% compared to pooled 
plasma from healthy donors. Consistent with their own animal data (Geiser et al., 2000) 
this effect appeared to be mediated by IL-1β. Of note, TNF did not promote wound 
healing in their models and inhibition of TNF in the BALF by recombinant sTNFR1 had 
no effect on wound healing in vitro.  
The in vitro scratch assay has a number of limitations. Since the scratch is 
introduced manually with a pipette tip, the wound sizes are variable and hard to 
reproduce. Moreover, the biologic relevance of scratch wounding for lung disease is 
unclear. Electron microscopic images of type I alveolar epithelial cells of severely 
stressed rat lungs show large cell breaks and fenestrations of denuded basement 
membrane (Dreyfuss et al., 1985; Tsukimoto et al., 1991; West et al., 1991), which 
resemble some of the lesions produced by in vitro scratch. Nevertheless, the mechanisms 
responsible for repair of these very large cell wounds could be very different from those 
observed in other in vitro models (e.g. CMS), and presumably in patients. Despite these 
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limitations, the in vitro scratch assay offered a simple method to screen for effects of 
differential TNFR signalling on hAT2 wound healing.  
 
3.3.16 Effect of differential TNFR signalling on tube formation in HUVEC 
and HMVEC-L 
We observed a modest but significant increase in tube formation in HUVEC 
stimulated with the selective TNFR2 mutein D143N (figure 3.14). A trend towards this 
effect was observed in HMVEC-L but this was non-significant (figure 3.3.8) probably due 
to lower sample numbers in the HMVEC-L group. Further experiments to increase the 
size of this dataset (currently on-going) may delineate any pro-angiogenic effect of 
selective TNFR2 agonism in HMVEC-L.  Of note, TNF at 1ng/mL and 10ng/mL had no 
significant effect.  
The role of TNF in angiogenesis is controversial with numerous studies showing 
that it is either pro- or anti-angiogenic, with the preponderance of published studies 
suggesting that TNF has inconsistent effects in vitro, but enhances angiogenesis in vivo. 
Hence, TNF (2.5ng/ml) failed to induce dermal HMVEC tube formation in a fibrin matrix 
(Koolwijk et al., 1996), while TNF (1ng/ml) induced HUVEC tube formation in a 
proprietary angiogenesis system (Zhu et al., 2007). Using growth factor reduced-Matrigel, 
similar to that used in our study, TNF induced an angiogenic effect in dermal HMVEC at 
0.1ng/ml (Shu et al., 2012). These data were in agreement with previous studies, in which 
TNF induced tube formation at low concentrations of TNF (Pan et al., 2002) but the effect 
was lost at higher concentrations of TNF (Leibovich et al., 1987). Thus, the lowest dose of 
TNF used in our studies may have been a log fold too high to demonstrate an effect. 
177 
 
 
Alternatively, these differing reports suggest that in vitro tube formation may rely on cell 
type, and the different matrixes and/or methods employed.  
TNFR2 activates Etk, a member of the Bruton’s tyrosine kinase non-receptor 
tyrosine kinase family involved in TNF-induced angiogenic events (Pan et al., 2002; 
Zhang et al., 2003) in vascular endothelial cells. Etk signalling involves tyrosine 
phosphorylation of the intracellular regions of vascular endothelial growth factor receptor 
2 (VEGFR2), resulting in a VEGF-independent pro-angiogenic response mediated 
through a signalling cascade including phosphatidylinositol 3-kinase and Akt (Zhang et 
al., 2003). In vivo, loss of TNFR1 (p55 receptor) leads to enhanced angiogenesis in both 
retina (Sainson et al., 2008) and wounded skin (Mori et al., 2002). Furthermore, TNFR1 
knockout mice demonstrated enhanced hind limb angiogenesis after temporary ischaemia 
compared to TNFR2 knockout animals (Luo et al., 2006). The same authors went on to 
demonstrate that, in a femoral artery ligation model, TNFR2 transgenic mice had 
enhanced ischemia-mediated arteriogenesis and angiogenesis (Luo et al., 2010). 
Endothelial cell specific expression of TNFR2 in TNFR2-deficient mice was sufficient to 
augment ischemia-induced Etk induced VEGFR2 signalling and functional flow recovery, 
thus further substantiating the concept that TNFR2 in endothelial cells uses Etk to trans-
activate VEGFR2 and promote angiogenesis. 
In our in vitro assay, we failed to observe a reproducible effect with respect to tube 
formation across different endothelial cell types with TNFR2 specific agonism (figure 
3.14). This may relate to a combination of factors. First, differences in cell type, and 
possibly quantitative TNFR expression, may influence tube formation in vitro. Second, 
we have failed to demonstrate conclusive evidence of downstream signalling by Etk 
following TNFR2 agonism in HMVEC-L (Appendix A). Third, whilst a modest effect 
was observed in HUVEC, the use of TNFR2 agonistic antibody to enhance effects of 
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D143N may have amplified any potential effect; hence in KYM-1 and HeLa cells the 
agonistic TNFR2-specific anti-serum MR2-1 had an additive effect on TNFR2 stimulation 
of JNK activity when combined with a TNFR2 specific mutein. The mechanism of this 
effect remains elusive (Jupp et al., 2001).  Finally, owing to limited cell numbers, we were 
unable to replicate the experimental numbers in HMVEC-L compared to HUVEC. The 
trend towards an effect of TNFR2 signalling was observed in HMVEC-L but this failed to 
reach significance owing to a small treatment effect and low experimental numbers (n=4). 
Efforts to increase the dataset are underway. Furthermore, in neither tube formation assay 
were we able to confirm any treatment effect of selective TNFR agonism with TNFR1 
antagonism owing to technical difficulties of the assay protocol. 
 
3.3.17 TNF induced permeability in HMVEC-L was TNFR1 dependent 
TNF increased HMVEC-L permeability as measured by changes in TER (figure 
3.15).  TNF increases endothelial permeability by a variety of mechanisms including 
microtubule rearrangement and adherens junction disassembly via p38 MAPK activation 
(Kiemer et al., 2002; Nwariaku et al., 2002; Petrache et al., 2003), increasing tyrosine 
phosphorylation of inter-endothelial junction proteins, actin stress fiber formation, and 
Ca2+ influx by a Src-dependent mechanism (Tiruppathi et al., 2001), by promoting Ca2+ 
influx via transient receptor potential channel 1 (Paria et al., 2003) and  via protein kinase 
C activation of RhoA (Wojciak-Stothard et al., 1998). All of these data, however, were 
generated in HUVEC, representative of post-capillary venules in the systemic circulation, 
which are known not to be representative of pulmonary microvascular endothelium. 
Indeed, myosin light-chain kinase (MLCK) phosphorylation causing actinomyosin-based 
cell contraction and the formation of micrometer-scale gaps is proposed as one of the 
main effector pathways in systemic vascular bed hyperpermeability (Dudek and Garcia, 
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2001). The role of this mechanism in pulmonary oedema formation however, was 
questioned by a study demonstrating that LPS induced lung injury was not attenuated in 
mice with MLCK selectively deleted from endothelial cells (Yu et al., 2012). 
TNF induced changes in trans-endothelial resistance appeared to be mediated by 
TNFR1 signalling as GSK1995057 abrogated the effect (figure 3.15). These data are 
concordant with a study that measured the TNFR dependency of transendothelial 125I 
albumin flux across HUVEC monolayers (Ferrero et al., 2001). TNF induced increases in 
albumin flux were abrogated by a monoclonal anti-TNFR1 antibody and replicated by the 
anti-TNFR1 monoclonal antibody htr-9 and the TNFR1 selective mutein R32W-S86T. 
Moreover, TNF induced hyper-permeability was unaffected by anti-TNFR2, rabbit 
polyclonal anti-TNFR2 antiserum or the TNFR2 mutein D143N-A154R. These effects 
were mediated by p38 MAP kinase dependent TNFR1 induced cytoskeletal 
reorganization.  
One potential mechanism of TNFR1 mediated pulmonary hyper-permeability, 
independent of the action of MLCK, is disruption of vascular endothelial cadherin (VE-
cadherin). VE-cadherin, an endothelium-specific member of the cadherin family of 
adhesion proteins that binds to several cytosolic protein partners, including α, β- and 
p120-catenins, is a major component of adherens junctions. Endothelial permeability is 
regulated, in part, by the dynamic opening and closure of cell-cell adherens junctions. 
Thus, disruption in function and organisation of VE-cadherin increases vascular 
permeability. In HMVEC-L, TNF induced junctional instability by Src-family tyrosine 
kinase-mediated phosphorylation of adherens junction proteins including VE-cadherin 
(Angelini et al., 2006).  These changes were associated with intercellular gap formation in 
HMVEC-L monolayers and increased trans-endothelial flux of [14C] bovine serum 
albumin in the absence of endothelial cell injury or apoptosis. Of note, further data have 
180 
 
 
demonstrated a reduction in expression of VE-cadherin in post-mortem biopsies of 
patients with ALI compared to control tissue from cancer-free lobectomy specimens 
(Herwig et al., 2013); these changes were most marked in the pulmonary capillaries. 
A further explanation for these data would be TNFR2 induced death signalling. 
Whilst we did not specifically investigate HMVEC-L viability or apoptosis in this assay, 
both TNF and GSK1995057 treated cells demonstrated no evidence of loss of viability as 
measured by MTT assay in previous experiments (figure 3.4).  
 
3.3.18 The effect of selective TNFR1 antagonism on markers of injury in TNF 
stimulated HMVEC-L 
 Injury and activation of the pulmonary endothelium are recognized as inciting 
events in the pathogenesis of ALI (chapter 1.1.2.2). TNF stimulation of HMVEC-L 
increased release of soluble forms of ICAM-1 (sICAM-1), VCAM-1 (sVCAM-1) and E-
selectin (sE-selectin), markers of endothelial injury, into cell supernatants (figure 3.16). 
TNF induced HMVEC-L injury was mediated predominantly by TNFR1 as selective 
TNFR1 antagonism reduced adhesion molecule release to basal levels, although these data 
failed to reach statistical significance owing to small numbers (figure 3.16). 
 Elevated levels of circulating adhesion molecules are associated with sepsis (the 
commonest cause of ALI). Hence both sICAM-1 and sVCAM-1 were elevated in septic 
patients, their levels correlating with multi-organ failure and death (Gearing and Newman, 
1993; Tsokos and Fehlauer, 2001), whilst circulating levels of sE-selectin were elevated in 
patients with sepsis and shock (Kayal et al., 1998; Reinhart et al., 2002) 
 Moreover, elevated levels of sICAM-1 and sE-selectin have been associated with 
poor outcomes in clinical ALI. In 67 patients with hydrostatic oedema or ALI, both 
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plasma and BALF ICAM-1 levels were significantly higher in those with ALI and 
increasing levels of ICAM-1 over time were associated with subsequent death after 
controlling for clinical variables (Calfee et al., 2009). Similarly, a threefold increase in 
BALF levels of ICAM-1 was observed in ALI patients compared to those with hydrostatic 
pulmonary oedema and levels of sICAM-1 correlated with the duration of mechanical 
ventilation (Conner et al., 1999). Finally, in a study of 83 paediatric patients with ALI, 
plasma ICAM-1 levels greater than 1,000ng/mL were associated with an 82% specificity 
for predicting non-survivors (Flori et al., 2003). In a study of 50 patients admitted with the 
systemic inflammatory response syndrome, elevated plasma E-selectin on admission 
predicted the development of ALI (and other organ failures). Mortality was also higher in 
patients with elevated plasma E-selectin (27.3%vs 0%) (Okajima et al., 2006). 
Furthermore, sE-selectin (and ICAM-1) levels were greater in the plasma of patients with 
sepsis than those who had sustained trauma not only when the patients were at risk for 
ALI but also at the time they had established ALI (Moss et al., 1996). In 27 patients with 
pneumonia, sE-selectin demonstrated utility in predicting those patients who would 
develop ALI (Osaka et al., 2011).  
 The biological function of soluble adhesion molecules remains unclear. In the 
alveolar compartment sICAM-1 has been reported to bind alveolar macrophages and 
enhance inflammatory cytokine production by alveolar macrophages in response to 
injurious stimuli (Schmal et al., 1998). Similarly, sVCAM-1 has been shown to either 
limit leukocyte integrin binding to endothelial VCAM-1 by binding to leukocytes or 
stimulate leukocyte (eosinophil) chemotaxis (Kitani et al., 1998; Ueki et al., 2009). 
Nonetheless, our in vitro data support the observation in a human in vivo inhaled LPS 
model that selective TNFR1 antagonism reduced endothelial cell injury/activation 
(O'Kane et al., 2013); reduced levels of endothelial injury may have contributed to the 
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31% reduction in BALF neutrophils with selective TNFR1 antagonism observed in this 
study. 
3.3.19 Future directions 
The respective roles of TNFR1 and TNFR2 signalling in promoting / preventing 
pulmonary oedema require further investigation. We have demonstrated that TNFR1 
signalling mediates lung microvascular permeability and study of VE-cadherin expression 
in TNF treated HMVEC-L pre-incubated with GSK1995057 and controls is currently on-
going in our laboratory.  
A further understanding of the cues for epithelial repair is undoubtedly one of the 
major challenges in the field. Whilst the scratch assay yielded equivocal results regarding 
the role of differential TNFR signalling in hAT2 repair, further investigation in tissue 
precision cut lung slice models (under development in our laboratory) may offer a more 
robust and longer-term (up to 5 days) model to define these mechanisms.  Moreover, 
identification of specific downstream signalling events in both hAT2 and HMVEC 
requires further investigation. These experiments may be optimized by the use of MR2-1 
to enhance TNFR2 signalling. 
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4 Chapter 4: The role of TNFR signalling in neutrophil priming and 
neutrophil migration into the alveolar space 
4.1 Introduction 
Numerous experimental and clinical studies suggest that neutrophils are key cells in 
the pathogenesis of ALI (reviewed in chapter 1.3.4).  Indeed, neutrophilic alveolitis is a 
histological hallmark of ALI (Lee and Downey, 2001). It is also evident that the presence 
of neutrophils per se is not necessarily damaging, and that the activation status of these 
cells was a major determinant of their role in modulating injury (Chollet-Martin et al., 
1992). 
The pleiotropism of TNF is central to the processes by which neutrophils interact 
with the endothelium.  First, TNF primes neutrophils in readiness for firm adhesion to 
pulmonary endothelium and subsequent neutrophil-mediated tissue injury through the 
enhancement of the expression of CD11b/CD18, triggering adherent neutrophils to release 
reactive oxygen species (ROS) and by promoting neutrophil degranulation and 
phagocytosis (Condliffe et al., 1996; Drost and MacNee, 2002; Dri et al., 1991; Nathan, 
1987; Gamble et al., 1985; Richter et al., 1989; Shalaby et al., 1987). Second, TNF 
regulates the expression of key neutrophil adhesion molecules on activated endothelial 
cells, including ICAM-1, VCAM- 1 and E-selectin. (Mackay et al., 1993; Slowik et al., 
1993; Neumann et al., 1996; Eriksson et al., 2005). Finally, TNF modulates neutrophil 
lifespan, and thus the potential duration of neutrophil-mediated tissue injury (Murray et 
al., 1997; Salamone et al., 2001).  
The complexity of TNF directed neutrophil-endothelial interactions was highlighted 
in experiments using TNFR-/- mice injected with either wild-type neutrophils or TNFR 
deficient neutrophils (Woodfin et al., 2009). TNF mediated endothelial activation was 
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essential for both neutrophil adhesion and trans-endothelial migration, whilst neutrophil 
priming / activation was required for adhesion but not full neutrophil migration.  
Furthermore, dissecting the distinct roles of TNFR1 and TNFR2 in each phase of 
neutrophil priming / activation, adhesion and trans-endothelial migration has to date been 
complicated by the use of a range of monoclonal and polyclonal blocking antibodies, or 
specific agonist mutant proteins (chapter 1.3.7). Monoclonal antibodies in particular have 
a tendency to induce receptor cross-linking, thereby inducing partial agonism rather than 
inhibiting signalling, whilst many receptor specific muteins lack specificity. 
Much data establishing potential mechanisms of TNF directed neutrophil-
endothelial interactions occurring within the systemic circulation has been reported. 
Murine in vivo models of systemic post-capillary venules, or in vitro studies using 
endothelial cells derived from large veins eg. HUVEC are often used. However, as 
outlined in chapter 1.4.4, neutrophil trafficking to the lung entails several structural, 
functional and mechanistic differences to that observed in the systemic circulation. The 
development of live lung imaging microscopy techniques in animals has unquestionably 
informed, and will continue to progress, the field of neutrophil-endothelial interactions in 
the lung (Looney and Bhattacharya, 2013). Nonetheless, validation and translation of such 
data in relevant human models remains central to the progression of our understanding of 
human ALI and the development of therapies and therapeutic targets. 
The work in the preceding chapter demonstrated that TNFR1 antagonsim abrogated 
selected cytokine and neutrophil chemokine release from TNF-stimulated hAT2 and 
HMVEC-L in vitro. The aim of the work in this chapter was to investigate the hypothesis 
that human pulmonary neutrophil trafficking is TNFR1 dependent. Therefore, human 
neutrophils and HMVEC-L were used, along with a highly selective TNFR1 antagonist 
and TNFR specific muteins. Specifically, the aims were: 
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a. To establish whether TNFR1 signalling directs TNF induced neutrophil priming 
and activation 
b. To determine the TNFR1 dependency of TNF induced pro-apoptotic and pro-
survival effects in human neutrophils, and 
c. To investigate the functional effects of selective TNFR1 antagonism on 
expression of neutrophil adhesion molecules by HMVEC-L and neutrophil 
migration through HMVEC monolayers in response to IL-8 
 
4.2 Specific methods 
4.2.1 Granulocyte experiments 
Human granulocytes were isolated according to the protocol outlined in chapter 2.2.5.5 
and re-suspended at a concentration of 5x106/mL. In experiments using inhibitors, 
granulocytes were pre-incubated with GSK1995057 (10nM), dummy domain antibody 
(10nM) and Adalimumab (1nM) for 60 minutes then treated with TNF (10ng/mL) or 
vehicle control for time periods specific to the experimental conditions. These 
concentrations were established from experiments in chapter 3.3.3; it was decided that a 
single dose of GSK1995057 and controls would be used throughout all in vitro 
experiments. In experiments using the TNFR specific muteins granulocytes were treated 
with R32W (TNFR1 specific mutein, 100ng/mL) and D143N (TNFR2 specific mutein, 
100ng/mL), TNF (10ng/mL) or vehicle control. The concentration of 100ng/mL for 
mutein experiments was based on published data in organ culture where a dose range of 
10-100ng/mL was used (Al-Lamki et al., 2010; Al-Lamki et al., 2005; Tchorzewski et al., 
1993). 
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4.2.2  HMVEC-L experiments 
HMVEC-L were used between passages 3 and 6. Following growth to confluence, cells 
were exposed to GSK1995057 (10nM), dummy domain antibody (10nM) and 
Adalimumab (1nM) for 60 minutes then treated with TNF (10ng/mL) or vehicle control 
for 4 hours. For analysis of neutrophil adhesion molecule expression, cells were washed 
and resuspended following gentle trypsinisation (2 minutes, trypsin 0.04% / EDTA 
0.03%, Promocell, Germany) prior to staining. 
 
4.3 Results 
4.3.1 Effect of TNF on granulocyte priming status 
Shape change, CD11b up-regulation and cell surface CD62L loss could be induced by 
TNF, suggesting that cells were minimally primed at baseline, retained normal 
granulocyte function and that TNF induced priming in vitro (figures 4.1 & 4.2).  
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Figure 4.1 TNF induced shape change in granulocytes in vitro 
Human granulocytes (5x106/mL) treated with TNF (10ng/mL) or vehicle control were analysed by 
flow cytometry. Shape change was assessed by mean forward scatter. Panel A shows a 
representative density plot of the entire population; the boxed area contains the granulocyte 
population used for subsequent analysis of forward scatter. Panels B & C show representative 
density plots of Control and TNF treated granulocytes respectively. Panel D demonstrates data 
obtained from 5 separate experiments. Data are presented as mean ± SEM analysed by Mann 
Whitney U test **p<0.01 
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Figure 4.2 TNF induced CD11b up-regulation and CD62L shedding from granulcoytes 
Human granulocytes (5x106/mL) were treated with TNF (10ng/mL) or vehicle control for 45 
minutes then stained with anti-human CD11b Pacific Blue and anti-human CD62L APC and 
before being analysed by flow cytometry. Panel A shows CD62L expression and panel B CD11b 
expression in control and TNF treated cells (n=3). Staining with the respective antibody (solid 
line) and isotype control (shaded fill) is shown in the inserted histograms. Panel C is a 
representative scatter plot of control cells (CD62 high, CD11b low), while panel D shows TNF 
treated cells (CD62 low, CD11b high). Data are presented as mean ± SEM and analysed by Mann 
Whitney U test * p<0.05, ** p<0.01 MFI; median fluorescence intensity 
 
4.3.2 Differential TNFR signalling and granulocyte priming 
Having demonstrated that TNF primes granulocytes in vitro, the aim of subsequent 
experiments was to determine which TNFR regulates mediates this effect. The TNFR1 
mutein R32W induced shape change, CD62L loss and CD11b upregulation in a similar 
manner to TNF, whilst D143N, a TNFR2 specific mutein had no effect on these 
parameters compared to vehicle treated cells (figure 4.3). 
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Figure 4.3 TNFR1 signalling induced granulocyte priming  
Human granulocytes (5x106/mL), treated with TNF (10ng/mL), the TNFR1 specific mutein R32W 
(100ng/mL), the TNFR2 specific mutein D143N (100ng/mL) or vehicle control for 45 minutes 
were stained with anti-human CD11b Pacific Blue and anti-human CD62L APC then analysed by 
flow cytometry. Panel A shows mean forward scatter, Panel B CD62L expression and Panel C 
CD11b expression in treated granulocytes (n=5). Data are presented as mean ± SEM and analysed 
by Kruskal-Wallis (Dunns) *p<0.05. MFI; median fluorescence intensity 
 
Having shown TNFR1 was likely be the dominant effector with respect to granulocyte 
priming, we examined whether TNF-induced priming could be abrogated by selective 
TNFR1 antagonism. Pre-incubation with a TNFR1 specific antagonist (GSK1995057, 
10nM) abrogated TNF-induced granulocyte priming to control levels (figure 4.4 A-C). A 
TNFR1/2 monoclonal antibody (Adalimumab, 1nM) only partially inhibited this effect 
(figure 4.4 A-C) as demonstrated by 40% of cells remaining CD11b high, CD62 low 
(figure 4.4 H). A dummy domain antibody (10nM) had no effect on CD62L and CD11B 
expression paralleling that of TNF treated granulocytes (figure 4.4 E & G). 
R32W D143N
0
20000
40000
60000
80000
100000
M
ea
n0
Fo
rw
ar
d0
Sc
a8
er
0(A
U
)
TNF$$$$$$$$$$$% $$$$$$$$$$+ $$$$$$$$$$$$$$$% $$$$%
R32W D143N
0
10000
20000
30000
40000
50000
M
FI
0(A
U
)
TNF$$$$$$$$$$$% $$$$$$$$$$+ $$$$$$$$$$$$$$$% $$$$%
*
*
R32W D143N
0
20000
40000
60000
80000
100000
0M
FI
0(A
U
)
TNF$$$$$$$$$$$% $$$$$$$$$$+ $$$$$$$$$$$$$$$% $$$$%
*
*
A
B C
190 
 
 
 
 
Figure 4.4 TNFR1 antagonsim abrogated TNF induced priming of granulocytes 
Human granulocytes (5x106/mL) were pre-incubated with GSK1995057 (10nM), Adalimumab 
(1nM), Dummy domain antibody (10nM) or vehicle for 60 minutes then treated with TNF 
(10ng/mL) or vehicle control for 45 minutes. Cells were stained with anti-human CD11b Pacific 
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Blue, anti-human CD62L APC or isotype controls then analysed by flow cytometry. Panel A 
shows mean forward scatter, Panel B CD62L expression and Panel C CD11b expression in treated 
granulocytes (n=3). Panels D-H are representative scatter plots of CD62L and CD11b in control 
(D), TNF (E), GSK1995057 (F), dummy dAb (H) and Adalimumab (G) treated granulocytes. The 
numbers in each corner of the dot plot represent the percentage of cells in each quadrant. Data are 
presented as mean ± SEM and analysed by MFI; median fluorescence intensity 
 
4.3.3 The role of TNFR signalling in superoxide burst from TNF primed 
granulocytes  
Having demonstrated that TNFR1 antagonism maintained granulocyte priming at 
(non TNF primed) basal levels, the question of whether TNFR1 antagonism could inhibit 
effector functions in TNF primed granulocytes was addressed. Using luminol-dependent 
chemiluminescence, we examined superoxide burst from TNF and TNFR mutein primed, 
fMLP-stimulated granulocytes pre-incubated with GSK1995057 and controls. Consistent 
with the priming data, R32W significantly enhanced respiratory burst in parallel with TNF 
whereas TNFR1 antagonism by both GSK1995057 and Adalimumab reduced superoxide 
release towards basal levels (figure 4.5). Priming with D143N induced peak luminescence 
values that paralleled GSK1995057 suggesting that TNFR1 may be fully competent to 
induce superoxide generation, although further study is required.  
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Figure 4.5 Selective TNFR1 antagonism inhibited superoxide release from TNF primed 
granulocytes  
Human granulocytes (5x106/mL) were pre-incubated with GSK1995057 or controls before 
priming with TNF (10ng/mL) or TNFR selective muteins (100ng/mL). Following fMLP 
stimulation superoxide release was measured by luminol-dependent chemiluminescence as 
assessed by the change in optical density of the supernatants at 550 nm over 10 minutes. Panel A 
shows a representative luminescence time course. Panel B demonstrates the cumulative fold 
change in peak height of luminescence compared to unprimed cells (n=4).  The dotted line in 
panel B represents the peak luminescence value of vehicle treated cells. Data are presented as 
mean ± SEM and analysed by Kruskal-Wallis (Dunns) *p<0.05, **P<0.01 
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4.3.4 TNFR expression and shedding from TNF stimulated granulocytes – 
the role of differential TNFR signalling 
In view of the data suggesting that TNFR1 may modulate granulocyte priming, it 
was important to establish that the observed effect was not a consequence of alterations in 
expression of TNFR, in particular loss of cell surface TNFR2.  Using flow cytometry, 
expression of both TNFR was confirmed in granulocytes (figure 4.6). TNFR expression, 
particularly TNFR 2 expression varied between donors; median fluorescence intensity 
(MFI) of TNFR1 expression of 5 donors was 31 (interquartile range 21.5-46, figure 4.6A) 
and the MFI of TNFR2 expression was 384 (IQR 213-3413 figure 4.6B). 
 
Figure 4.6 Human granulocytes expressed both TNFR1 and TNFR2  
Purified human granulocytes (5x106/mL) were stained with anti-human TNFR1 PE and antihuman 
TNFR2 FITC or isotype controls and analysed by flow cytometry. Panels A and B are 
representative of 3 separate experiments and demonstrate TNFR1 expression (Panel A) and 
TNFR2 expression (Panel B). IgG isotype controls are shown with the dotted line 
 
TNF stimulation (10ng/mL) of granulocytes induced a significant reduction in TNFR1 
cell surface expression (figure 4.7A). ELISA analysis of harvested supernatants suggested 
concentration-dependent shedding of TNFR1 maximal at 60 minutes and at lower TNF 
concentrations (figure 4.7B - 15 minute data not shown as sTNFR1 levels were below the 
lower detection limit of the ELISA). Both the expression and shedding of TNFR1 
A" B"
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appeared to be induced via TNFR1 signalling as evidenced by parallel experiments 
stimulating granulocytes with TNFR selective muteins (figure 4.7 C&D). R32W induced 
down-modulation of TNFR1 expression and receptor shedding comparable to TNF 
whereas D143N had no effect on expression or shedding of TNFR1. 
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Figure 4.7 TNF receptor dependency on TNFR1 expression and shedding from human 
granulocytes was TNFR1 dependent  
Human granulocytes (5x106/mL) were exposed to TNF (2.5, 10, 50 or 100ng/mL) or vehicle 
control for 1 hour. The cell suspension from triplicate wells were collected every 15 minutes over 
1 hour, spun at 4oC and the supernatant frozen at -80oC for sTNFR1 ELISA. The cell pellet at the 
45 minute time point was stained with anti-human TNFR1 PE for 30 minutes, washed twice then 
analysed by flow cytometry. Panel A shows TNFR1 expression in control and TNF treated 
granulocytes (n=5). Panel B shows the time course and concentration response of sTNFR1 in 
harvested supernatants (n=3). In parallel experiments, TNFR1 expression (panel C) and sTNFR1 
release (panel D) was measured in TNF (10ng/mL), R32W, D143N (both 100ng/mL) and vehicle 
treated granulocytes over 45 minutes (n=2-3). Data are presented as mean ± SEM, analysed by 
Mann Whitney U test **p<0.01 MFI; median fluorescence intensity 
 
Conversely, TNFR2 expression was increased with TNF stimulation; the observed lack of 
priming response to D143N observed in figure 4.3 cannot, therefore, be ascribed to low 
expression of TNFR2. TNFR2 shedding was time but not concentration dependent in 
response to TNF (figure 4.8 A&B). TNFR2 expression increased approximately 3-fold in 
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response to TNFR1 signalling (figure 4.8C) but there was no clear response to either 
TNFR mutein with regards to TNFR2 shedding. 
 
 
Figure 4.8 Effect of TNF and TNFR specific muteins on TNFR2 expression and shedding 
from human granulocytes 
Human granulocytes (5x106/mL) were exposed to TNF (2.5, 10, 50 or 100ng/mL) or vehicle 
control for 1 hour. The cell suspension from triplicate wells was collected every 15 minutes over 1 
hour, spun at 4oC and the supernatant frozen at -80oC for sTNFR2 ELISA. The cell pellet at the 45 
minute time point was stained with anti-human TNFR2 FITC for 30 minutes, washed twice then 
analysed by flow cytometry. Panel A shows TNFR2 expression in control and TNF treated 
granulocytes (n=5). Panel B shows the time course and concentration response of sTNFR2 in 
harvested supernatants (n=3). In parallel experiments, TNFR2 expression (panel C) and sTNFR2 
release (panel D) was measured in TNF (10ng/mL), R32W, D143N (both 100ng/mL) and vehicle 
treated granulocytes over 45 minutes (n=2-3). Data are presented as mean ± SEM. MFI; median 
fluorescence intensity 
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4.3.5 TNFR2 agonism does not “de-prime” TNF primed granulocytes in vitro  
Further to determining the role of TNFR signalling in granulocyte priming, the 
possibility that TNFR2 signalling could “de-prime’ granulocytes was investigated. As 
outlined in chapter 1.3.4, emerging data suggest that TNFR2 signalling may be anti-
inflammatory and contribute to organ repair. We speculated that de-priming of 
neutrophils, as a mechanism to dampen the inflammatory response, may be a component 
of these putative TNFR2 mediated processes. Granulocytes primed with TNF over 45 
minutes were incubated with GSK1995057 (10nM) to ‘force’ TNFR2 signalling, the 
selective TNFR2 mutein D143N (100ng/mL) or Adalimumab (1nM) as a negative control 
for 1 hour before analysis by flow cytometry. Neither GSK1995057 nor D143N had any 
discernable effect on granulocyte shape change, CD11b or CD62L expression (figure 4.9). 
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Figure 4.9 Selective TNFR2 signalling did not de-prime TNF primed granulocytes  
Human granulocytes (5x106/mL) treated with TNF (10ng/mL) then exposed to GSK1995057 
(10nM), Adalumimab (1nM) or D143N (100ng/mL) were stained with anti-human CD11b Pacific 
Blue and anti-human CD62L APC and analysed by flow cytometry. Panel A shows mean forward 
scatter, Panel B CD62L expression and Panel C CD11b expression in treated granulocytes (n=3). 
Data are presented as mean ± SEM MFI; median fluorescence intensity 
 
4.3.1 Differential TNFR signalling and modulation of neutrophil lifespan  
TNF significantly induced granulocyte apoptosis at 6 hours whilst TNF induced a 
modest 10% pro-survival effect at 20 hours (vehicle treated granulocyte 20 hour survival 
64.4% ±8.8%, TNF treated 54.1% ±10.2%) (figures 4.10A and 4.11A respectively). The 
potential role of TNFR1 signalling in determining these effects was therefore investigated. 
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Granulocyte-macrophage colony stimulating factor (GM-CSF, 10ng/mL), a potent 
inhibitor of apoptosis was used as a positive control. 
Neither the TNFR1 mutein (R32W) nor the TNFR1 antagonist (GSK1995057) 
affected basal, or in the latter case, TNF stimulated apoptosis at 6 hours (figure 4.10A). 
The lack of discernable effect on apoptosis by R32W and GSK1995057 could not be 
explained by a lack of functional activity as previous experiments had demonstrated their 
ability to regulate TNF induced priming. These data therefore imply that activation of 
both TNFRs may be required to mediate the early TNF mediated death signal in 
granulocytes. To confirm this, both R32W and D143N were added in combination. 
However, the combination of both TNFR1 and TNFR2 muteins failed to replicate the 
level of apoptosis seen with TNF (figure 4.10A). Of note, pre-exposure with the non-
functional dummy domain antibody, unexpectedly inhibited TNF induced apoptosis. 
The involvement of TNFR1 in mediating the 20 hour pro-survival effect of TNF 
was evaluated in similar experiments. R32W (100ng/mL) replicated the modest pro-
survival effect of TNF at 20 hours (R32W apoptosis 50.1% ±12.3% vs TNF apoptosis 
54.1 ±10.2%, figure 4.11A), suggesting a possible role for TNFR1 signalling although 
these data did not reach statistical significance. This was further investigated by TNFR1 
antagonism with GSK1995057 (10nM); cells pre-incubated with GSK1995057 
demonstrated levels of apoptosis similar to control treated cells.  
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Figure 4.10 Early granulocyte apoptosis required activation of both TNFR  
Granulocyte apoptosis was assessed by annexin-V-FITC / propidium iodide (PI) staining analysed 
by flow cytometry following 6 hour incubation with GSK1995057 (10nM, n=5), Adalimumab 
(1nM, n=5), dummy dAb (10nM, n=6), TNF (10ng/mL n=6), vehicle control (n=6) or the TNFR 
specific muteins R32W and D143N alone (100ng/mL, n=5) or in combination (100ng/mL each, 
n=2). Panel A shows cumulative apoptosis represented as % annexin V positive cells (PI negative 
plus PI positive). Panels B-E show representative morphological images and dot plots of vehicle 
(B), TNF (C), GSK1995057 (D) and GMCSF (E) treated cells. Values shown in each corner of the 
dot plots represent the percentage of cell within each quadrant. Data are presented as mean ± SEM 
analysed by one way ANOVA (Dunnett’s) *** p<0.001  
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Figure 4.11 The effect of differential TNFR1 signalling directed on late granulocyte survival  
Granulocyte apoptosis was assessed by annexin-V-FITC / propidium iodide (PI) staining analyzed 
by flow cytometry following 20 hour incubation with GSK1995057 (10nM), Adalimumab (1nM), 
dummy dAb (10nM), TNF (10ng/mL), vehicle control or the TNFR specific muteins R32W and 
D143N (100ng/mL) Panel A shows cumulative apoptosis; data are represented as % annexin V 
positive cells (PI negative plus PI positive) (n=6). Panels B-E show representative morphological 
images and dot plots of vehicle (B), TNF (C), GSK1995057 (D) and GMCSF (E) treated cells. 
Values shown in each corner of the dot plots represent the percentage of cell within each quadrant. 
Data are presented as mean ± SEM  
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4.3.2 Granulocyte migration through HMVEC and effect TNFR antagonism 
 The work in this chapter has so far focused on TNFR signalling and granulocyte 
activation and lifespan. Subsequent experiments were designed to interrogate the role of 
differential TNFR signalling on endothelial activation and the functional consequences 
thereof on granulocyte migration. Having optimised baseline conditions (chapter 
2.2.6.5.1), granulocyte migration through TNF-stimulated HMVEC-L monolayers in the 
presence of GSK1995057 or controls was assessed. TNF (10ng/mL) increased 
granulocyte migration  (figure 4.12) whilst pre-exposure of cells to GSK1995057 reduced 
migration to near basal levels (p=0.17), suggesting that TNFR1 may play a role in 
neutrophil-endothelial interactions.  
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Figure 4.12 TNFR1 antagonism ameliorated granulocyte migration through TNF stimulated 
HMVEC-L 
Leukotracker™ labelled granulocytes (1x106/mL, 200µL) were added to the upper chamber of a 
Transwell filter containing confluent HMVEC-L (5x104) treated with TNF (10ng/mL) in the 
presence of GSK1995057 (10nM, n=5), Adalimumab (1nM, n=4), a dummy dAb (10nM, n=5) 
and vehicle control (n=5) for 4 hours. IL-8 (100ng/mL, 700µL) was added to the lower chamber. 
Migration was assessed by measurement of fluorescence accumulated in the lower chamber after 3 
hours read at 480nm on a fluorescent plate reader. The dotted line represents granulocyte 
migration in vehicle treated HMVEC-L. Data are presented as mean ± SEM, *p<0.05.  
 
 
4.3.3 TNFR signalling and granulocyte receptor expression on HMVEC 
To investigate a possible mechanism to explain the effects of differential TNFR 
activation on granulocyte migration through HMVEC-L monolayers, we analysed the 
expression of adhesion molecules known to direct neutrophil migration in TNF activated 
HMVEC-L pre-incubated with GSK1995057 and controls. Time course analysis of 
expression of adhesion molecules known to direct neutrophil migration was undertaken in 
TNF (10ng/mL) stimulated HMVEC-L monolayers over 24 hours. Neither JAM1, nor 
ICAM-2 were induced by TNF (Figure 4.13) whilst, P-selectin could neither be detected 
at baseline nor after TNF stimulation (data not shown). By contrast, ICAM-1 and VCAM-
1 were constitutively expressed (54.4% ICAM-1 positive ±10.2%, 20.7% VCAM-1 
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positive ±6%) and up-regulated in a time dependent fashion (Figures 45.137 & 45.148). 
Low-level expression of E-selectin (6.54% cells E-selectin positive ±1.94) was detected at 
baseline with expression peaking at 4 hours (Figures 4.13 & 4.14).  ICAM-1, VCAM-1 
and E-selectin were therefore chosen to investigate the effects of differential TNFR 
signalling in modulating neutrophil adhesion molecule expression further experiments. 
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Figure 4.13 Time course of adhesion molecule expression in TNF stimulated HMVEC-L  
HMVEC-L treated with TNF (10ng/mL) for 1,2,4,8 and 24 hours were exposed to anti-human 
ICAM-1 Pacific Blue, anti-human VCAM-1 APC, anti-human E-Selectin APC, anti-human JAM-
1 PE, and anti-human ICAM-2 FITC and analysed in duplicate by flow cytometry.  (n=1) 
  
Figure 4.14 Induction of neutrophil adhesion molecule expression in TNF stimulated 
HMVEC-L  
HMVEC-L (1x105) treated with TNF (10ng/mL) or vehicle control, were resuspended and 
exposed to anti-human ICAM-1 Pacific Blue, anti human VCAM-1 APC, anti-human E-Selectin 
APC, anti-human JAM-1 PE, and anti-human ICAM-2 FITC and analysed in duplicate by flow 
cytometry (n=4). Data are expressed as mean ± SEM analysed by Mann Whitney U test *p<0.05 
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 The effect of selective TNFR1 antagonism on neutrophil adhesion molecule 
expression by HMVEC-L was analysed following 1 hour pre-incubation with 
GSK1995057 followed by TNF (10ng/mL) stimulation over 4 hours. Selective TNFR1 
antagonism abrogated TNF induced expression of ICAM-1, 1 and VCAM-1 and E-
selectin to constitutive levels (Figure 4.15). Treatment of HMVEC-L with the TNFR1 
mutein R32W induced expression of all 3 neutrophil ligands in parallel with TNF but 
these preliminary data failed to reach significance owing to low experimental numbers.  
Dual TNFR receptor antagonism (Adalimumab) only partially blocked VCAM-1 
expression (figure 4.15B) implying additional regulatory mechanisms for regulation of 
TNF induced VCAM-1 expression. Cumulatively, these data suggest a role for TNFR1 in 
the expression of neutrophil adhesion molecules by HMVEC-L.  
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Figure 4.15 Selective TNFR1 antagonism abrogated ICAM-1 and VCAM-1 expression in 
TNF stimulated HMVEC-L  
HMVEC-L (1x105) were pre-exposed to GSK1995057 (10nM), Adalumimab (1nM), a dummy 
dAb (10nM) or vehicle for 1 hour then treated with TNF (10ng/mL), R32W (TNFR1 mutein, 
100ng/mL) or vehicle control for 4 hours. Resuspended cells were exposed to anti-human ICAM-
1 Pacific Blue, anti human VCAM-1 APC, anti-human E-selectin PE and analysed in duplicate by 
flow cytometry (n=2-53). Panels show fold-change in proportion of cells expressing ICAM-1 (A), 
VCAM-1 (B) and E-selectin (C) for each condition. The dotted line represents expression levels in 
vehicle treated cells. Data are presented as mean ± SEM analysed by Kruskal Wallis (Dunns) 
*p<0.05, **p<0.01  
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4.4 Discussion 
4.4.1 Summary of important findings 
 TNFR1 signalling has a pivotal role in TNF induced priming and respiratory burst 
activity in human neutrophils. Selective TNFR1 agonism induced alterations in classical 
priming markers (shape change, CD11b up-regulation and CD62L shedding) and 
augmented respiratory burst in fMLP-stimulated neutrophils that paralleled the effect of 
TNF. Selective TNFR2 agonism had no effect compared to PBS control treated cells. 
These data were further confirmed by selective TNFR1 antagonism, which abrogated 
neutrophil priming and reduced respiratory burst 2-fold in TNF stimulated cells. Analysis 
of TNFR expression and shedding suggested that TNFR1 expression was under the 
dominant control of TNFR1 signalling.  
 TNF stimulated early-apoptosis but this effect was not specific to either TNFR 
suggesting that engagement of both TNFR is required to induce early apoptosis. TNFR1 
agonism replicated the modest (10% reduction in apoptosis) late pro-survival effect of 
TNF, but this effect was not statistically significant. TNFR1 antagonism of TNF 
stimulated neutrophils, rescued apoptosis to control levels at 20 hours, but again this was 
not statistically significant.  
Selective TNFR1 antagonism ameliorated neutrophil migration through HMVEC-
L monolayers. Our data suggest that this may be due to blockade of up-regulation of the 
neutrophil adhesion molecules ICAM-1, VCAM-1 and E-selectin on HMVEC-L although 
further functional studies using blocking antibodies to adhesion molecules or adhesion 
molecule knockout mice are required. 
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4.4.2 The role of differential TNFR signalling in neutrophil priming and 
activation 
 A number of studies have attempted to examine define the role of differential 
TNFR signalling in neutrophil priming using a range of selective monoclonal and 
polyclonal blocking antibodies allied with specific agonist mutant proteins. In agreement 
with our data (figures 4.3 and 4.4), the majority of these suggest a pivotal role for TNFR1 
in priming of respiratory burst activity. Using agonistic anti-TNFR antibodies, TNFR1 
was shown to be exclusively involved in TNF induced up regulation of CD11b expression 
and priming of superoxide release (Abe et al., 1995). Similarly, in adherent neutrophils 
where TNF functions as a full secretagogue (Dri et al., 1991; Nathan, 1987; Nathan, 1989; 
Richter et al., 1989), TNFR1 was fully competent to induce superoxide generation and, 
CD11b up-regulation with redundancy of TNFR2 (Menegazzi et al., 1994).  
In contrast, it has been suggested that TNFR1 and TNFR2 cooperate to induce the 
respiratory burst (Barbara et al., 1994; Richter et al., 1989). In both studies, TNFR1 was 
identified as the major mediator of intracellular signalling but both authors suggested a 
requirement for TNFR2 to potentiate TNFR1 signalling. Others have suggested that, 
whilst TNFR1 alone is responsible for the priming effect of TNF induced phagocytosis in 
human neutrophils, TNFR2 regulates binding of TNF to TNFR1 (Della Bianca et al., 
1995). Whilst our data did not support these findings, these data are in keeping with the 
ligand-passing model proposed by Tartaglia and Goeddel (Tartaglia et al., 1993; Tartaglia 
et al., 1993) discussed in chapter 1.3.3. 
The mechanisms underlying TNF-induced neutrophil priming remain elusive. 
Both ERK and p38 MAPK mediated serine phosphorylation of p47phox, leading to 
assembly of the NADPH oxidase and generation of ROS, have been identified as key 
events in TNF-induced priming (Dang et al., 2006; Kilpatrick et al., 2010). In experiments 
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using human neutrophils in suspension and neutralizing TNFR antibodies, 
phosphorylation of serine345 on p47phox was mediated exclusively by TNFR1 via 
p38MAPK (Dewas et al., 2003).  Moreover, in a series of articles by Kilpatrick, binding 
of TNF to TNFR1, in cooperation with ligation of integrins, has been postulated to 
activate PI3K, thereby modifying δ-PKC and promoting p47phox phosphorylation 
(Kilpatrick et al., 2002; Kilpatrick et al., 2004; Kilpatrick et al., 2010; Kilpatrick et al., 
2006; Korchak and Kilpatrick, 2001). These conclusions are supported by the observation 
that inhibition of class IA PI3K and p38MAPK abolished TNFR1 induced ROS 
generation (Geering et al., 2011).  
In this study changes in CD11b and CD62L expression were used as markers of 
neutrophil priming (figures 4.3 and 4.4). Shape change, CD62L, and CD11b expression, 
as well as chemotaxis, have been shown previously to be affected during neutrophil 
isolation, with primed cells being less able to migrate in response to chemotactic stimuli, 
having less CD62L expression, greater CD11b expression, and a blunted response to 
neutrophil agonists (Haslett et al., 1985). It is however, intriguing to speculate on the 
functional implications of alterations in the expression of these neutrophil adhesion 
molecules. Consistent with the quiescent, non-adherent state of circulating neutrophils, 
constitutively expressed CD11b/CD18 cannot mediate efficient adhesion or effector 
functions (Hynes, 1992). Stimulus-induced up-regulation of CD11b, as observed in our in 
vitro data (figures 4.2-4.4), does not augment CD11b/CD18 mediated neutrophil adhesion 
(Vedder and Harlan, 1988; Schleiffenbaum et al., 1989). Thus, despite clinical data 
suggesting that CD11b up-regulation correlates with adverse clinical outcomes (Rinder et 
al., 2003; Orr et al., 2007), qualitative or conformational changes may be more relevant to 
CD11b function than total cell surface expression (Diamond and Springer, 1993; Oxvig et 
al., 1999). Indeed, conformational activation of CD11b has been demonstrated in critical 
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illness (Rosenbloom et al., 1999) and occurred in the absence of CD11b up-regulation 
(Orr et al., 2007). Moreover, interrogation of the respective roles of the CD11b/CD18 sub-
units, demonstrated that CD11b mediated cell adhesion and spreading in response to a 
range of ligands but was unable to support cell migration (Solovjov et al., 2005).  
Pharmacological blockade and genetically modified mouse experiments have 
provided contradictory data regarding the functional implications of CD62L shedding. 
Initial studies suggested that shedding allowed neutrophils to migrate normally after 
extravasation (Venturi et al., 2003) and that blockade of shedding did not affect neutrophil 
rolling, adherence or transmigration in TNF activated HUVEC monolayers under flow 
(Allport et al., 1997). Conversely, the Doerschuk group demonstrated in knockout mice 
that initial neutrophil retention in the lung following complement fragment injection was 
CD62L independent, however, neutrophil sequestration after 5 minutes was CD62L 
dependent (Doyle et al., 1997) suggesting an essential role in retention of sequestered 
neutrophils within pulmonary capillaries. Recent murine data has also demonstrated that 
CD62L is required for PSGL-1–dependent integrin activation, slow rolling, and leukocyte 
recruitment in vitro and in vivo (Stadtmann et al., 2013). Moreover, pharmacological 
blockade of CD62L shedding increased CD62L expression on the surface of neutrophils 
and augmented signal input through CD62L (Hafezi-Moghadam et al., 2001). These 
changes were associated with reduced rolling velocity (Hafezi-Moghadam and Ley, 
1999), increased ‘‘smoothness’’ of rolling, enhanced arrest, and transmigration (Hafezi-
Moghadam et al., 2001). Finally, CD62L is cleaved from the cell surface by ADAM17 
(and other sheddases) (Smalley and Ley, 2005). Thus, compared to wild-type, ADAM17-/- 
mice exhibited higher CD62L expression associated with slower neutrophil rolling with 
improved adherence with or without TNF activation (Tang et al., 2011) and mice 
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expressing non-cleavable CD62L had enhanced neutrophil infiltration in response to intra-
peritoneal E. coli . (Long et al., 2012)  
 Collectively, these data suggest that that blockade of CD11b up-regulation and 
CD62L shedding, for example by GSK1995057, may augment neutrophil adhesion and 
arrest at least in the systemic circulation. The implications for pulmonary capillary 
leukocyte infiltration are, however, unclear as none of these studies investigated 
functional effects in the lung microvasculature, where, owing to spatial constraints, 
neutrophil arrest is independent of CD62L mediated rolling and neutrophil migration 
occurs by both CD11b/CD18 dependent and independent mechanisms, depending on 
stimulus (Doerschuk, 2001). Recent but highly novel data from Summers et al suggest 
that priming neutrophils with GM-CSF or platelet activating factor (PAF) ex vivo 
prolongs pulmonary transit kinetics compared to control cells (Summers et al 2014). 
Autologous 99m Technetium labelled cells were injected into healthy volunteers and the 
peak signal from selected anatomical regions of interest was measured by gamma 
scintigraphy over 40 minutes. In addition to prolonged transit times, imaging 
demonstrated a significant retention of GM-CSF primed neutrophils in the lung compared 
to control cells. These data are in concordance with earlier experiments by Haslett et al in 
which formyl-norleucyl-leucyl-phenylalanine (FNLP) primed radiolabelled neutrophils 
were shown to be significantly retained within the lungs of rabbits, compared to control 
cells (Worthen et al., 1987). 
Given that TNFR2 signalling has immunomodulatory functions (Cabal-Hierro and 
Lazo, 2012) and that our data suggested up-regulation of TNFR2 following priming 
(figure 4.8), we considered the hypothesis that TNFR2 signalling de-primed neutrophils in 
vitro. Neutrophils challenged with PAF displayed a spontaneous return to baseline values 
of ROS production, cell polarisation and CD11b activity within 120 min (Kitchen et al., 
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1996). The mechanisms underlying neutrophil de-priming are unknown, although it has 
been postulated that the healthy lung microvasculature may play a role (Singh et al., 
2012). TNF, D143N and GSK1995057 were unable to de-prime TNF-primed neutrophils 
(figure 4.9), suggesting that differential TNFR signalling does not participate in neutrophil 
de-priming mechanisms, at least in vitro. 
4.4.3 The role of differential TNFR signalling in receptor expression and 
shedding in human neutrophils 
 TNF induced down-modulation of TNFR1 in human neutrophils was associated 
with shedding of TNFR1 and was mediated by TNFR1 signalling (figure 4.7). 
Additionally, TNFR2 was shed, but intriguingly expression of TNFR2 increased (figure 
4.8). This effect was not clearly mediated by either TNFR. 
Previous data regarding the mechanism of surface TNFR loss has been discordant. 
TNF stimulation of human neutrophils decreased expression of both TNFR (Dri et al., 
2000). Using TNFR specific and competing antibodies, these effects were shown to be 
mediated exclusively via TNFR1 and involved shedding of both receptors. A further study 
demonstrated loss of TNFR expression in TNF stimulated neutrophils. Owing to low 
levels of sTNFR1 in harvested supernatants, the authors concluded that the down-
modulation of TNFR1 was due to receptor internalisation, while TNFR2 was shed (Porteu 
and Hieblot, 1994). It has been argued that the observed discrepancy in TNFR1 shedding 
in this study owed to the low sensitivity of the ELISA employed. Accordingly our data 
were generated with an identical proprietary ELISA kit used in the study by Dri which 
demonstrated no cross reactivity with R32W or D143N.  
Proteolytic cleavage (shedding) is the principal mechanism of TNF receptor down-
modulation that may on the one hand reduce sensitivity to TNF, and on the other hand 
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limit bioavailability of TNF by providing soluble forms TNFR that could compete for the 
cytokine with the cellular receptors. The clinical significance of this effect is highlighted 
by TNFR1-associated periodic syndromes (McDermott et al., 1999); missense mutations 
of the human TNFR1 gene impair receptor shedding and patients present with increased 
inflammatory responses and concomitant fever. TNFR shedding appears to be regulated at 
least in part by the cell surface metalloproteinase TNF converting enzyme (TACE or 
ADAM17) (Bell et al., 2007; Black et al., 1997). Whilst definitive data to confirm the role 
of TACE in human neutrophils is lacking, TACE is expressed by human neutrophils at 
levels comparable to that of TNF receptors (Dri et al., 2000). In irradiated mice 
reconstituted with blood cells deficient in functional ADAM17 (ADAM 17 gene knockout 
is lethal), LPS stimulated shedding of TNFR1 and TNFR2 from neutrophils was 
incompletely abrogated (Bell et al., 2007). These data suggest a primary but not exclusive 
role for ADAM17 in TNFR shedding in murine neutrophils. Interestingly, resting 
neutrophils from ADAM17 chimeric mice expressed higher levels of surface TNFR1 and 
TNFR2 compared with resting neutrophils from wild-type mice.  
Interference with TNFR shedding therefore represents an alternative mechanism of 
modulating TNF induced inflammation. Indeed, a protective role of TNFR1 shedding by 
ADAM17 was reported in TNF sensitisation of hepatocytes to Fas-mediated death 
(Murthy et al., 2010). TNF signalling promoted hepatotoxicity, whilst excessive TNFR1 
shedding was protective. Interestingly, TNFR1 shedding induced protection via 
dampening of JNK phosphorylation and NF-κB activation. This effect was further 
confirmed in a recent study from the Bhattacharya laboratory applying confocal 
microscopy to ADAM17 knockout mice and the TNFR1 blocking antibody E20. In lung 
microvessels, TNF induced TNFR1 shedding was entirely ADAM17 dependent and was 
regulated by endothelial mitochondrial Ca2+ and ROS production (Rowlands et al., 2011). 
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Blockade of TNFR1 shedding by inhibition of mitochondrial Ca2+ and ROS production, 
propagated inflammation, as evidenced by enhanced (TNF dependent) E-selectin 
expression and leukocyte adhesion.  
Despite contrasting the majority of published data, the finding that TNF up-
regulated TNFR2 expression is not without precedent. TNF has been shown to induce 
increased TNFR2 expression in human malignant epithelial cell lines (Kalthoff et al., 
1993) and fibroblasts (Winzen et al., 1993). However, TNF incubations over 20 to 48 
hours were used in these experiments. Moreover, in LPS treated mice, whilst TNFR1 
expression in lung microvascular cells was down-regulated, TNFR2 expression remained 
unchanged. Alternatively, the discrepancy may be explained by differences in TNF 
concentration (2.5ng/mL) and duration of TNF exposure (15 minutes) employed in others’ 
work (Dri et al., 2000).  
4.4.4 The role of differential TNFR signalling in modulating neutrophil 
lifespan 
 In parallel with TNFR shedding, TNF mediated neutrophil apoptosis contributes to 
the regulation of duration and intensity during inflammatory responses (Jonsson et al., 
2005). In the work presented in this chapter, and consistent with published data (Murray 
et al., 1997; Salamone et al., 2001), we have demonstrated that TNF has a bimodal effect 
on apoptosis; inducing apoptosis at 6 hours whilst affecting a modest pro-survival 
response at 20 hours in vitro (figures 4.10 and 4.11). Selective TNFR agonism alone did 
not replicate this effect suggesting that that dual activation of both TNFR is required for 
the early apoptotic effect of TNF, whilst our data demonstrated no clear effect of 
differential TNFR signalling upon late survival. 
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The finding that engagement of TNFR2 may be required for early apoptosis, was 
somewhat surprising; TNFR2 lacks a cytoplasmic death domain and is unable to recruit 
FADD (chapter 1.3.3.2). TNFR2 can specifically enhance TNFR1-mediated apoptosis by 
depletion of the NFκB-promoting/caspase-8 inhibitory TRAF2-cIAP1/2 complex from 
TNFR1 via competitive recruitment to TNFR2 and subsequent proteasomal degradation 
(Declercq et al., 1998; Weiss et al., 1998). However, our data showing that R32W was 
unable to induce apoptosis despite maintaining full agonistic activity in priming of fMLP-
stimulated ROS release would suggest that this is not the mechanism, at least in 
neutrophils. A number of studies have demonstrated apoptosis induction after selective 
stimulation of TNFR2. In most of these reports, apoptosis was not directly triggered by 
TNFR2, but was mediated indirectly by up-regulation of transmembrane TNF, which then 
secondarily stimulated TNFR1 (Grell et al., 1999; Vercammen et al., 1995). The absence 
of effect with D143N in our study would contradict this, although again, we cannot 
exclude that firstly the mutein is non-functional and secondly that TNFR2 was 
unresponsive to soluble TNF (Rauert et al., 2010). Data from the rat-mouse cytotoxic T-
cell hybridoma PC60 suggest that TNFR2 can induce cell death independently from 
TNFR1, but the underlying signalling mechanisms are unknown (Vandenabeele et al., 
1995).  
The failure of the combination of both TNFR muteins to replicate TNF induced 
apoptosis (figure 4.10) is not unprecedented (Chilvers group, unpublished data) and may 
reflect either lack of specificity of D143N or an inability to initiate downstream 
signalling. The ability of R32W to induce neutrophil priming and ROS release would 
suggest functionality of the TNFR1 mutein used. However, as outlined previously we 
have been unable to demonstrate specific functional responses to D143N in a range of 
models. Interestingly, in a study using pre-exposure to anti-TNFR antibodies followed by 
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TNF (100u/106 neutrophils), neither antibody alone enhanced neutrophil apoptosis at 3 
hours, whilst a combination of the two also failed to enhance apoptosis (Gon et al., 1996).  
TNF induced a moderate anti-apoptotic effect in neutrophils after 20 hours in 
vitro. Data demonstrating that inhibition of NF-κB increased constitutive apoptosis (Ward 
et al., 1999; Choi et al., 2003) would suggest that NF-κB, probably via transcription of 
survival proteins is the probable signalling pathway for this pro-survival effect. NF-κB is 
regulated via TRAF2 and IκB kinase (IKK) suggesting that these effects are under 
dominant control of TNFR1. That R32W mirrored the effects of TNF (10% reduction in 
apoptosis from baseline), and TNFR1 antagonism returned apoptosis to constitutive levels 
supports a possible role for TNFR1 signalling. 
Kilpatrick and colleagues further added to the field with data proposing an 
additional regulatory role for ERK1/2 as a downstream regulator of TNFR1 induced anti-
apoptosis. Using an indirect measurement of apoptosis, Caspase 3 activity, TNF induced 
anti-apoptotic signalling was increased six-fold at 20 hours compared to freshly isolated 
cells (Kilpatrick et al., 2006);. TNF reduced Caspase-3 activity by almost 50%, an effect 
mediated by phosphorylation of ERK1/2. In parallel with priming mechanisms outlined 
previously (chapter 5.2.2), δPKC was required for TNF-triggered activation of ERK1/2. 
Both of these effects are mediated by TNFR1, further supporting a putative role for 
TNFR1 signalling in the pro-survival effect. 
Other experimental nuances may impact upon constitutive and induced rates of 
apoptosis. In our experiments, we used a standard dose of TNF throughout (10ng/mL). 
This dose reflects TNF concentrations in the BALF of ALI patients (Meduri et al., 1995). 
In the study by Murray et al, a dose of 25ng/mL was anti-apoptotic at 20 hours, however, 
a concentration-dependent effect has also been observed; low doses (<1ng/mL) were anti-
apoptotic, whereas higher doses (10-100ng/mL) were pro-apoptotic (van den Berg et al., 
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2001). The authors concluded that at higher doses, the production of respiratory burst may 
induce apoptosis. This effect was recently investigated by a Swiss group, who reported 
that TNFR1 stimulation induced p38 MAPK and class IA PI3Ks, which are usually 
involved in survival pathways, as proximal death players (Geering et al., 2011).  These 
kinases were shown to be essential for the generation of ROS, which furthermore 
triggered caspase-3 activation resulting in neutrophil apoptosis. We observed a pro-
apoptotic effect with GSK1995057 treatment; assuming ROS production modulated 
apoptosis in our assay, it would be anticipated that TNFR1 antagonsim would reduce ROS 
production, thus promoting survival. We cannot exclude the previously observed effect of 
contaminating mononuclear cells in propagating this effect (Walmsley et al., 2004); in the 
data presented here, neutrophils were routinely >95% pure and the conditions were 
matched for each treatment.  
4.4.5 Selective TNFR1 antagonism ameliorates neutrophil migration through 
HMVEC-L monolayers 
 The observation that, in murine cremaster vessels, endothelial TNFR were an 
absolute requirement for neutrophil adherence and migration (Woodfin et al., 2009) 
suggests a specific role for TNF induced modulation and activation of the endothelium in 
this process. Thus we sought to investigate these findings in human in vitro models. TNF 
stimulation of HMVEC-L monolayers enhanced neutrophil migration towards IL-8 (figure 
4.12). This effect was ameliorated by both TNFR1 antagonism and dual TNFR1/2 
blockade suggesting a role for TNFR1 signalling in monolayer activation. The 
experimental set-up was designed such that treated monolayers were washed extensively 
prior to the addition of neutrophils, reducing the possibility of priming or activation of 
neutrophils by cytokines released from stimulated monolayers. Thus, any treatment effect 
could be attributed to activation of endothelial cells alone. Moreover, we sought extensive 
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evidence of monolayer integrity to ensure that neutrophils did not preferentially migrate 
through endothelial gaps. 
We used a simple, static, Transwell filter based method to analyse migration. The 
major criticism of such assays (compared to dynamic flow-based assays) is that they 
essentially assess neutrophil migration down a chemotactic gradient with endothelial cells 
“in the way” as opposed to endothelial-driven migration (McGettrick et al., 2007). In 
addition, the location of non-migrated cells in the filter is ambiguous and the kinetics of 
static transmigration differ from flow-based migration (Rainger et al., 1999; Rainger et 
al., 1995). By removing adherent cells in the upper chamber and placing the filter itself in 
lysis buffer along with migrated cells we attempted to overcome some of these issues 
(chapter 2.2.6.6) In preliminary experiments we attempted to create a bilayer model of 
static migration using HMVEC-L on the apical surface and hAT2 on the basolateral 
surface. This work is ongoing but presents challenges particularly in the seeding of hAT2 
on the basolateral surface. Future work should address experiments in both a flow based 
assay system and LPS injured ex vivo lung to validate our findings. 
Having demonstrated a potential role for TNFR1 signalling in neutrophil 
migration, through endothelial monolayers, we hypothesised that this may be mediated via 
alterations in the expression of neutrophil ligands by TNF activated HMVEC-L. A range 
of in vitro and in vivo data suggest that ICAM-1, VCAM-1, E-selectin, Junctional 
Adhesion Molecule 1 (JAM1), ICAM-2 and P-selectin are critical adhesion molecules 
regulating trans-endothelial neutrophil migration in the systemic circulation. Initial 
experiments determined that only ICAM-1, VCAM-1 and E-selectin were TNF responsive 
(figure 4.14). Time course data for TNF induced ICAM-1, VCAM-1 and E-selectin 
expression (figure 4.13) are comparable with in vitro data from HUVEC (Mackay et al., 
1993) and murine in vivo data (Neumann et al., 1996; Bertok et al., 2011). Contrary to 
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reports in HUVEC and in vivo, both VCAM-1 and ICAM-1 were expressed at baseline in 
HMVEC-L and increased in a time dependent manner in response to TNF; basal 
expression of ICAM-1 was significantly higher than VCAM-1 (figure 4.14). 
ICAM-1, VCAM-1 and E-selectin all contain consensus sites for NF-kB in their 
promoter regions, suggesting a central role for TNFR1 acting via this route. Consistent 
with our data demonstrating that TNFR1 antagonism abrogated adhesion molecule 
expression, several authors have demonstrated TNFR1 dependency in adhesion molecule 
expression in both in vivo and in vitro (Bertok et al., 2011; Chandrasekharan et al., 2007; 
Neumann et al., 1996; Mackay et al., 1993; Slowik et al., 1993; Kneilling et al., 2009). 
Perhaps the most compelling data to suggest a definitive role for TNFR1 in adhesion 
molecule expression comes from experiments in HUVEC using the same clones of 
muteins employed in this work and a TNFR2 agonsitic antibody in combination with 
small molecule inhibitors of JNK, p38MAPK and MEK1. (Zhou et al., 2007).  TNF 
induced ICAM-1 and VCAM-1 expression and mRNA expression were found to be NF-
κB but not ERK, p38MAPK or JNK dependent. This effect was mediated exclusively by 
TNFR1, measured by protein, mRNA and cell surface expression levels of ICAM-1 and 
VCAM-1. Of note, using an NF-κB inhibitor and NF-κB reporter construct, this effect 
was found to be entirely NF-κB dependent, an effect similarly reported in A549 cells 
(Holden et al., 2004).  
Conversely, both an exclusive and regulatory role for TNFR2 have been proposed. 
Chandrasekharan et al. suggested that both TNFR were critical for TNF induced E-
selectin and VCAM-1 expression while TNFR2 signalling was sufficient for ICAM-1 
expression in murine aortic endothelial cells (Chandrasekharan et al., 2007). An additional 
regulatory role for TNFR2 signalling in murine lung endothelial cells stimulated with 
TNF was further shown; both TNFR1 knockout mice and lung microvascular cells treated 
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with a TNFR2 antagonist demonstrated reductions in VCAM and E-selectin (Bertok et al., 
2011). Moreover, in a TNFR-knockout mouse model of cerebral malaria, TNFR2 was 
critical for ICAM-1 induced up-regulation of leukocyte sequestration in brain 
microvessels (Lucas et al., 1997).  
It should be highlighted that none of these studies were undertaken with a focus on 
the human lung microvasculature. Heterogeneity in both the parent species and vascular 
bed of endothelial cells employed in these studies and the phenotypic differences thereof 
(King et al., 2004; Aird, 2007) may account for the conflicting data observed. To our 
knowledge, this is the first study investigating TNFR dependency on neutrophil migration 
and adhesion molecule expression in human cells.  
Recent data have suggested additional key roles for ICAM-2 and JAM1 in 
transcellular neutrophil migration. These effects, however, have been shown to be 
stimulus specific. For example, in receptor knockout mice, IL-1β induced neutrophil 
migration via recruitment of pathways involving ICAM-2 and JAM1, whereas TNF 
induced migration was independent of these adhesion molecules (Huang et al., 2006; 
Woodfin et al., 2007; Thompson et al., 2001). One possible explanation for these findings 
is that TNF regulated neutrophil migration via neutrophil activation as opposed to 
exerting effects on vascular endothelium (TNF was administered systemically to mice in 
these experiments). Our data showing that JAM and ICAM-2 expression was not 
inducible in HMVEC-L over 24 hours TNF exposure (figure 4.13) would suggest that in 
human lung microvasculature, TNF induced neutrophil migration is probably independent 
of these molecules.     
 Inducible expression of P-selectin has been proposed as a key regulator of 
inflammation (McEver and Zhu, 2010), and P-selectin knockout mice exhibit absent 
leukocyte rolling and impaired recruitment to sites of systemic inflammation (Mayadas et 
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al., 1993). In HUVEC P-selectin expression is inducible within minutes following 
treatment with histamine (Hattori et al., 1989). In HMVEC-L P-selectin cell surface 
expression was neither constitutive nor inducible in response to TNF stimulation (data not 
shown). These data confirm previous animal studies demonstrating that P-selectin was not 
expressed on pulmonary capillary endothelium of normal rats, mice, and rabbits (Mulligan 
et al., 1992). Moreover, whilst TNF induces P-selectin expression in murine endothelium 
(Hahne et al., 1993; Liu et al., 2010) increasing slow rolling and adhesion (Liu et al., 
2010), in HUVEC, TNF has been shown to have no effect, or even decrease P-selectin 
mRNA (Burns et al., 1995; Yao et al., 1996). Hence, P-selectin expression appears to be 
stimulus, species and vascular bed specific and its role as a neutrophil ligand in the 
pulmonary microvasculature, at least in response to TNF, is questionable. 
 The finding that selective TNFR1 antagonism ameliorated neutrophil migration 
could alternatively be explained by effects on the endothelial surface layer (ESL) or 
glycocalyx.  Emerging data suggest that ESL loss induces neutrophil adhesion to 
endothelial cells. Potential mechanisms include the release of pro-adhesion mediators 
previously sequestered by the glycocalyx, exposure of previously hidden endothelial 
surface adhesion molecules, and/or the activation via proteoglycans of pro-adhesion 
endothelial signalling pathways (Schmidt et al., 2011). The TNFR specificity of this loss 
was investigated by the Downey group, using pulmonary intra-vital microscopy (Schmidt 
et al., 2012). In the pulmonary microvasculature, LPS induced degradation of the ESL, 
specifically heparan sulfate (HS), via TNF. This effect was abolished in mice lacking 
TNFR1 suggesting a central role for TNFR1 signalling in HS homeostasis. LPS induced 
ESL loss exposed ICAM-1 and was associated with increased adherence of neutrophils in 
vivo.  
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4.4.6 Future directions 
 Using the combination of human neutrophils, human lung microvascular cells and 
a highly selective TNFR1 mutein, reassuringly, we have validated much of the published 
literature in models relevant to human ALI. Future work should address further the 
functional effects of differential TNFR induced priming and activation of neutrophils on 
neutrophil migration in the lung. These experiments could be repeated using in vivo 
imaging techniques in combination with an ex vivo ALI model. Ex vivo modeling would 
additionally allow interrogation of the hypothesis that primed neutrophils preferentially 
migrate to injured lung. Further mechanistic data defining the role of TNFR1 antagonism 
in modulating neutrophil-endothelial interactions allied with emerging in vivo data may 
encourage early phase trials of selective TNFR1 antagonists, in the prevention of ALI.   
Given the persistent failure of animal models of ALI to translate to therapeutic 
benefit, the parallel development and application of human in vitro, in vivo and ex vivo 
models (with relevance to the lung microvasculature) to investigate these mechanisms is 
essential.   
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5 Chapter 5: Development & characterisation of human ex vivo 
perfused lung models of ALI 
5.1 Introduction 
Animal models have been invaluable in the study of complex diseases such as ALI, 
allowing testing of hypotheses in complex biological systems. Rodent ALI models, in 
particular, have revealed important biologic mechanisms underlying the temporal 
sequence of injury, inflammation and dysregulated repair. However, despite over 30 years 
of promising experimental and preclinical studies, no pharmacological intervention 
developed thus far (including anti-TNF therapy) has reduced mortality in ALI. This fact 
alone highlights the limitations of current models of ALI and the urgent need for tractable 
human models of ALI to develop and test novel therapeutic targets and provide more 
relevant data to inform subsequent larger clinical trials. In particular, the development of 
ex vivo human lung models of ALI could offer a new paradigm in ALI translational 
research allowing recapitulation of moderate to severe ALI, experimental manipulation 
and temporal analysis of distal lung tissue, which are not achievable using current in vivo 
human models (chapter 1.2.2.1).  
Several recent studies by the Matthay group at University of California San 
Francisco (UCSF) have shown the potential of ex vivo models for studying the 
pathophysiology of ALI. In 20 human lungs rejected for transplantation, the investigators 
demonstrated that firstly changes in alveolar fluid clearance (AFC, as a marker of 
epithelial barrier function) could be measured in their model and that AFC was preserved 
in perfused compared to non-perfused ex vivo lung tissue (Frank et al., 2007). Secondly, 
β2 agonist terbutaline increased rates of AFC compared to basal levels (Frank et al., 
2007). Finally, levels of soluble receptor for advanced glycation end products (RAGE, a 
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marker of alveolar type I epithelial cell injury) correlated inversely with AFC (Briot et al., 
2009). Thus, human data regarding a therapeutic intervention for pulmonary oedema and 
a putative biomarker for alveolar epithelial cell injury were generated highlighting the 
potential translational impact of such models.  
The same investigators then established an injury model in ex vivo human lung (Lee 
et al., 2009). The right middle lobe or left lower lobe was injured with an intra-bronchial 
instillation of E. coli endotoxin. A contra-lateral lobe was used as the control. Instillation 
of endotoxin into the distal airspaces resulted in acute pulmonary oedema, an increase in 
lung vascular permeability and an almost complete loss of AFC. These effects were 
associated with a significant increase in BALF neutrophils and levels pro-inflammatory 
cytokines implicated in the pathogenesis of ALI (IL-1β, TNFα and IL-8). The 
translational potential of the model was realised through studying the effect of 
mesenchymal stem cells on AFC in the injured lobe over 4 hours: MSCs reduced 
endotoxin-induced injury and inflammation, and augmented AFC compared to controls. 
Thus, ex vivo ALI modelling allowed assessment of the effect of a therapeutic 
intervention in abrogating some of the key physiological, immunological and pathological 
features of clinical ALI. 
Most recently, the UCSF group have developed an ex vivo live bacteria pneumonia 
model (Lee et al., 2013). Escherichia coli (109 to 1010 colony forming units) was instilled 
into the right middle lobe or left lower lobe. In parallel with the LPS model, this induced 
cytokine release, neutrophil infiltration and impaired AFC in the injured lobe compared to 
control. Of note, this model was extended to 10 hours perfusion to induce a bacteraemia in 
the perfusate. Injured lungs remained stable throughout the experimental period with only 
a modest decline in AFC in the control lobe at 10 hours compared to that measured 6 
hours after injury. Thus, this study demonstrated firstly that alternative injury modalities 
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can induce injury and secondly that longer-term perfusion is feasible without progressive 
lung injury.  
In the previous chapters we have demonstrated the pleiotropic roles of differential 
TNFR signalling in a range of in vitro models of ALI.  The aim of this chapter was to 
translate these data in the UK’s first ex vivo human lung injury model. The specific aims 
of experiments in this chapter were: 
a. To establish the ex vivo lung perfusion technique to produce stable physiology 
and long-term viability 
b. To characterise our own LPS induced human ex vivo ALI model 
c. To establish a method of performing pharmacological study in ex vivo lung 
d. To investigate the effects of selective TNFR1 antagonism on neutrophil 
infiltration into the alveolar space in an ex vivo model 
5.2 Specific Methods 
5.2.1 BAL protocol 
 The control lobe was cannulated under direct vision with a bronchoscope 
(Olympus, Japan). 25mL of sterile 0.15M saline was injected via the working channel and 
then aspirated into two sterile collection pots. The collected bronchoalveolar lavage fluid 
(BALF) was filtered through 4 layers of sterile surgical guaze and then centrifuged at 
200rcf for 5 minutes at 4oC to pellet any cells present in the BALF. The supernatant was 
aliquoted and stored at -80oC for analysis at a later date. The cell pellet was then re-
suspended in 500uL of ice cold PBS.  
 20µL of the original BALF was removed and mixed with 180µl of red cell lysis 
buffer (Sigma-Aldrich) and left to stand for 5 minutes at room temperature. 10µL of this 
solution was then mixed and added to 10µL trypan blue stain and left to stand for 2 
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minutes. 10µL of this stained mix was then withdrawn and added to a haemocytometer 
and a total cell count made.  
 A further 120µL of the original BALF was added to 480µL of red cell lysis buffer 
and incubated for 5 minutes at room temperature. This solution was then centrifuged at 
1500rpm for 5 minutes. Following re-suspension of the cell pellet in 600µL of PBS 100 
and 200µL of this solution was added in duplicate to funnel clips in a cytospin (Cytospin 
2, Thermo Scientific) and centrifuged at 300rpm for 3 minutes, high acceleration. Slides 
were removed and allowed to air dry before being placed in methanol for 4 minutes. 
Slides were then sequentially placed in DiffQuick stain; orange/red for 1 minute then blue 
for 2 minutes with excess stain being rinsed off in between with distilled water. Stained 
slides were allowed to air dry for 30 minutes before being coverslip mounted using DPX 
(Sigma Aldrich). Cells were examined by light microscopy, magnification x20, 300 cells 
per slide in triplicate and the neutrophil count calculated per condition.  
5.2.2 Protein collection 
 Sections of control and LPS injured lung (weighing 50-100mg) were immediately 
snap frozen in liquid nitrogen and stored at -80oC for later analysis of protein content.  
Frozen tissue samples were crushed in liquid nitrogen using a pestle and mortar and 
scraped into a 2mL Eppendorf. 200-400µL of ice-cold Hardie lysis buffer (50 mM Trizma 
base, 250 mM sucrose, 50 mM sodium fluoride, 1 mM sodium pyrophosphate, 1 mM 
EDTA, 1 mM DTT, 1% Triton X-100, 0.05 mg/mL soybean trypsin inhibitor, 0.1 mM 
PMSF, 1 mM benzamidine in dH20) was added to the Eppendorf and left on ice. The 
tissue in Hardie lysis buffer was then homogenised using an ultra-turrax (small probe, 
IKA, Germany) for 20 seconds on ice. The probe was cleaned with clean ice-cold distilled 
water and a paper towel between homogenisations. Samples were then centrifuged at 
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15000g for 20 minutes at 4oC and the resulting supernatant removed, placed in a fresh 
eppendorf and stored at -80oC until analysis by Western Blotting or ELISA. 
5.2.3 Wet:dry weight ratio 
 Following injection of LPS or vehicle control, the injectate area in peripheral lung 
was marked with a pen (figure 5.7D). After 4 hours, a tissue sample from the demarcated 
area was harvested and the sample immediately homogenised in a 7mL bijou. After 
homogenisation the sample was weighed (wet weight) snap frozen in liquid nitrogen and 
placed in the freeze dryer for 24 hours, after which a dry weight was recorded. A wet dry 
weight ratio was calculated: 
   
5.2.4 Measurement of lung “dynamics” 
 Lung physiologic parameters including pulmonary artery pressure, perfusate flow 
rate, dynamic compliance and peak airway pressure were measured throughout EVLP at 1 
hourly intervals. Pressures were measured with standard pressure monitoring equipment 
(Edwards Lifesciences, USA). Flow rate was measured with an ultrasonic flow probe 
(Maquet, USA). Compliance and airway pressure measurements were recorded 
continuously from the ventilator (Evita XL, Drager, Germany). Pulmonary vascular 
resistance (dyn·s·cm-5) was calculated: 
   
5.2.5 Lung injury scoring of human ex vivo lung 
 Sections of control and LPS injured lung (weighing 50-100mg) were gently 
inflated with 10% formalin solution (1-2mL, Sigma Aldrich, UK), placed in a bijou 
Wet:dry weight = (Wet weight/dry weight) *1000 
80 x (pulmonary artery pressure – left atrial pressure) 
Perfusate Flow 
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containing 10% formalin (7mL) for 24 hours and then embedded in wax. Sections cut at 
5µm were stained with haematoxylin and eosin and then examined by light microscope 
for pathological changes by a pulmonary pathologist who was unaware of the 
experimental groups. Semi-quantitative assessment of acute lung injury was performed 
using interstitial, alveolar and septal oedema, vascular thrombosis, haemorrhage, 
interstitial and alveolar inflammation and alveolar fibrin accumulation/hyaline membrane. 
Five regions from each specimen were examined, and each parameter was scored for 
severity using a 4 point scale; 0 = absent, 1 = mild, 2 = moderate, 3 = severe (Vaschetto et 
al., 2008). The sum of scores for each parameter gave the Lung Injury Score with a value 
of 0 to 24.  
5.3 Results 
5.3.1 Optimisation of the ex vivo lung perfusion circuit for future 
experimentation 
 Early experiments used a ‘closed’ system whereby both the left atrium and PA 
were cannulated and the lungs were placed in a specially designed dome which supported 
both inflow and outflow tubing (figure 5.1 A & B). This system, however, mandated that 
donor lungs had an intact left atrial cuff.  
 With the development of alternative clinical equipment, we changed to an ‘open’ 
system where the PA was cannulated but the left atrium or pulmonary veins were left 
open to air (figure 5.1 C & D). This system reduced the cold ischaemic time (CIT) as the 
technical demands of suturing the left atrial cannula often took over 30 minutes and 
avoided the need for an intact left atrial cuff, thus markedly increasing our potential donor 
pool. 
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 In both systems, we initially used a centrifugal pump and a membrane oxygenator 
(without gas) to heat the perfusate and hence the lungs. This was based on equipment 
applied in the clinical setting (Cypel et al., 2011) (figure 5.2A). However, changing to a 
roller pump system with a simple heat exchange device (figure 5.2 B) offered 
physiological advantage by generating pulsatile flow and technical advantage of reducing 
the hardware costs and the dead-space in the system; hence less perfusate per experiment 
was required. Both circuits were fitted with ‘quick-release’ connectors to allow the circuit 
to be clamped, flow temporarily ceased and the lung container taken to the computed 
tomography (CT) scanner for baseline imaging. Both systems also allowed continuous 
measurement of PA pressure via a PA transducer in the PA cannula and both were 
connected to a clinical grade ventilator (figure 5.2 C). The most recent iteration of our 
model is outlined in figure 5.2D. 
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Figure 5.1 Arterial and venous cannulation in the ex vivo lung perfusion system 
Initial models employed a clinical grade XVIVO™ dome (Image A). A conical XVIVO™ cannula 
(arrow panel B) was sewn into the left atrium and a straight XVIVO™ cannula was tied into the 
pulmonary artery thus creating a ‘closed’ perfusion system. Latterly, we have used an open system 
(panel C) whereby the left atrium is open to air, draining into a specially designed hardshell 
reservoir. A customised, bevelled cannula was tied into the pulmonary artery (panel D).  
 
 
A" B"
C" D"
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Figure 5.2 Ex vivo lung perfusion circuit hardware  
Initial models employed a centrifugal pump to generate flow and membrane oxygenator 
(connected to a heat exchanger) to allow heating of the perfusate and lungs (panel A). Recent 
models have used a roller pump and a clinical grade heat exchange device (panel B). A standard 
ICU ventilator was connected via an endotracheal tube secured in the trachea thus providing a 
breath-by-breath read-out of lung compliance and resistance and a pressure transducer was 
inserted into the pulmonary artery to allow continuous measurement of pulmonary artery 
pressures and hence pulmonary vascular resistance (panel C). An overall outline of the current ex 
vivo circuit is demonstrated in the schematic (panel D). 
 
A" B" C"
Ventilator !
Pulmonary Vein !
Reservoir!
Roller pump !
Heat-exchange device !
Pulmonary Artery!
Heater Cooler!
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5.3.2 Clinical characteristics of donor human lungs 
 Lungs were accepted based on the criteria outlined in table 5.1. Referrals were 
received on average once per fortnight but only about 25% of lung offers were accepted. 
The majority of lungs were declined on the basis of radiological and gas-exchange 
criteria. Alternatively acceptable donor lungs could not reach us within the pre-
determined CIT limit. The characteristics of the accepted lungs are outlined in table 5.2. 
The CIT in some cases was as high as 39 hours; despite the projected CIT being within 
our limit, logistical delays contributed to a prolonged CIT. In 2 cases of young donors 
with normal radiology, the PaO2:FiO2 ratio did not fall strictly within our criteria but the 
lungs were used. 
Table 5.1 Clinical characteristics of donor lungs  
Clinical Characteristics Results (n=10) 
Age (years) 54±13 
Male/Female (%) 60/40 
PaO2:FiO2 ratio on acceptance of lungs 370±221 
Total cold ischaemic time (hrs) 34±4 
 
5.3.3 Human lungs ventilated and perfused ex vivo for 8 hours demonstrated 
no signs of injury  
 Pulmonary vascular resistance and lung compliance remained stable for the 
duration of prolonged ex vivo lung perfusion in our model set-up (figure 5.3). Biopsies 
taken before EVLP and after 8 hours EVLP demonstrated no histological evidence of lung 
injury when examined by a pulmonary pathologist blinded to experimental conditions 
(figure 5.4). 
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Figure 5.3 Human lungs maintained stable pulmonary vascular resistance (PVR) and 
compliance throughout ex vivo perfusion.  
The ventilator gave a breath-by-breath read-out of lung compliance while PVR (dyn·s·cm-5) was 
calculated:  (80 x (pulmonary artery pressure – left atrial pressure) / perfusate flow rate. 
Pulmonary artery pressure was measured continuously via a built in pressure transducer n=8. Data 
are presented as mean ± SEM 
 
Figure 5.4 Human lungs maintained for 8 hours ex vivo demonstrated no histological 
evidence of injury  
Human lungs were rewarmed on the ex vivo circuit, perfused and ventilated and maintained for 8 
hours. A biopsy from the right lower lobe was taken after rewarming and again after 8 hours 
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normothermic perfusion and ventilation. Samples stained with haematoxylin and eosin were 
examined by a pulmonary pathologist blinded to experimental conditions. The above demonstrates 
representative images at 2 different magnifications before and after 8 hours EVLP of both the 
bronchovascular bundle and lung parenchyma 
 
5.3.4 Cytokine release into BALF in LPS injured ex vivo human lungs  
 Compared to control, human ex vivo lung injured with LPS (0.1mg/kg predicted 
body weight of donor) demonstrated increased release of the pro-inflammatory cytokines 
IL-1β, TNF, IL-6 and IL-8 in BALF (figure 5.5, panels A-D). This effect was evident at 8 
hours following injury. After 4 hours, only IL-1β and TNF showed significant increase 
compared to vehicle treated lung. Release of soluble TNF receptors type 1 and 2 in the 
BALF demonstrated no significant difference between vehicle treated lung at both 2 and 4 
hours (figure 5.5 panels E & D). 
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Figure 5.5 LPS injured ex vivo human lung demonstrated evidence of alveolar inflammation  
LPS (0.1mg/kg, 10mL) or vehicle control (10mL) were instilled into the right middle lobe or left 
lower lobe respectively of human lungs on the EVLP circuit. After 2, 4 and 8 hours, the injury and 
control lobes were lavaged with 5% human albumin solution (50mL). Interleukin 1-beta (IL-1β, 
panel A), Tumour Necrosis Factor alpha (TNFα, panel B), Interleukin-6 (IL-6, panel C), 
Interleukin-8 (IL-8, panel D), soluble TNF receptor-1 (TNFR-1, panel E) and soluble TNF 
receptor-2 (TNFR-2, panel F) were measured by sandwich enzyme linked immunsorbent assay 
(ELISA) n=3-6. Data are presented as mean ± SEM analysed using Mann Whitney U test 
*p<0.05, **p<0.01 
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5.3.5 The effect of LPS injury on pulmonary oedema, histological lung injury 
scores and neutrophilic infiltration into the alveolar space 
 LPS injury induced an elevation in lung tissue wet:dry ratio suggestive of 
pulmonary oedema in LPS injured segments (figure 5.6A). This effect was not translated 
into a significant elevation of histological lung injury scores, which included alveolar and 
septal oedema as part of the scoring system, although there was a trend towards increased 
injury in LPS treated lung tissue (figure 5.6B) 
 
Figure 5.6 The effect of LPS injury on wet:dry ratio and lung injury scores in human ex vivo 
lung 
Wet:Dry ratio (panel A) was determined by weighing a homogenised segment of injured or 
control lung (wet weight) and then re-weighing after 24 hours of freeze-drying (dry weight) and 
dividing the wet by the dry weight for each sample n=4. Lung Injury Scores were assessed by 
blinded pulmonary pathologist. Based on established scorings systems, a lung injury score 
between 0 and 24 was given to each sample analysed in duplicate n=4. Data are presented as mean 
±SEM analysed by Mann Whitney U test, *p<0.05 
  
 LPS injured lung demonstrated significant influx of neutrophils into the alveolar 
space as evidenced by elevated neutrophil counts in the BALF (figure 5.7 A & C) as well 
as histological evidence of intravascular neutrophils in LPS injured lung (figure 5.7D). 
The tissue myeloperoxidase level in LPS treated lung tissue increased 2 fold although this 
failed to reach statistical significance (figure 5.10B).  
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Figure 5.7 BALF of LPS injured ex vivo human lung demonstrated neutrophilic infiltration 
Human lungs were injured with LPS (0.6mg/mL, 10mL) or vehicle control, After 4 hours the 
respective lobes were lavaged and representative tissue sections harvested. Panel A represents the 
neutrophil count in cytospins of BALF from LPS and control treated lung n=5. Panel B represents 
the myeloperoxidase levels in protein extracted from harvested tissue n=4-5. Panel C is a 
representative cytospin of LPS injured ex vivo lung. Data are presented as mean ±SEM analysed 
by Mann Whitney U test *p<0.05 
 
5.3.6 LPS injury did not activate the STAT pathway in human ex vivo lung 
 LPS injury had no effect on activation of the signal transducers and activators 
of transcription (STAT) pathway as evidenced by STAT1/STAT3 phosphorylation 
measured by western blotting (figure 5.8 panels B & C). There was, however, significant 
variation in STAT1 phosphorylation; 3 of the samples demonstrated a doubling of STAT1 
phosphorylation whilst 3 samples demonstrated no effect beyond basal conditions or 
vehicle treated tissue. p38 mitogen activated protein (MAP) kinase, an putative upstream 
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signalling regulator of the STAT pathway (Bode et al., 2012), similarly showed no 
difference between vehicle and LPS treated tissue (figure 5.8A). 
 
Figure 5.8 LPS did not activate p38MAPK or STAT pathways in ex vivo human lung 
Human lungs were injured with LPS (0.1mg/kg, 10mL) or vehicle control. After 4 hours 
representative tissue sections were harvested and snap frozen for later processing. Protein was 
extracted from the defrosted lung tissue specimens and analysed for p38MAP kinase (ELISA, 
panel A) or STAT1 and STAT3 phosphorylation (Western blotting, panels B & C) n=5. Data are 
expressed as mean ±SEM. The dotted line represents mean fluorescence or intensity at 0 hours. 
 
5.3.7 Methods to administer therapeutic intervention in ex vivo lung models 
 In preparation for experiments investigating the effect of GSK1995057 on LPS 
induced human lung injury we investigated whether discrete doses of Evans blue could be 
injected into areas of lung to facilitate a dose-response experiment. Using log fold 
dilutions of Evans blue we were able to demonstrate that this resulted in a sigmoidal-type 
dose response effect when harvested tissue was analysed (figure 5.9) 
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Figure 
5.9 Evans blue dose response in ex vivo porcine lung  
Porcine lungs were harvested from abattoir culled male pigs, placed on the ex vivo circuit and 
ventilated and perfused. Following rewarming, Evans blue was injected via a 23 gauge cannula 
into discrete areas of the right lower lobe at log fold dilutions of neat solution (100mg/mL). 
Representative tissue specimens were resected at 4 hours and placed in formamide for 24 hours. 
The supernatant was collected at absorbance measured at 610nm via a fluorescent plate reader 
n=3. Data are presented as mean ± SEM  
 
 We then repeated this experiment using UO126 (Cell Signalling, USA), a selective 
inhibitor of the extracellular signal-regulated kinase (Erk1/2) pathway (MEK1). At 
concentrations of 100µM there was a trend towards inhibition of Erk phosphorylation, 
however, this was non-significant (figure 5.10) reflecting both low sample numbers and 
probable sampling error as in previous LPS experiments. 
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Figure 5.10 Dose response of UO126 a selective Erk1/2 MAP kinase inhibitor in ex vivo 
porcine lung  
Porcine lungs were harvested from abattoir culled male pigs, placed on the ex vivo circuit and 
ventilated and perfused. Following rewarming, UO126 was injected into discrete areas of the right 
lower lobe at log fold dilutions. Representative tissue specimens were resected at 4 hours and snap 
frozen. Intracellular protein was then extracted and total and phosphorylated Erk measured in 
20µg of protein by Western blotting (panel A). The developed blots were analysed using Image J 
software to quantitate the density of the bands and the relative values of phosphorylated MAPK to 
total MAPK (panel B p42 Erk, panel C p44 Erk) n=3. Data are presented as mean ± SEM 
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5.4 Summary of important findings in this chapter 
 We have established a method for obtaining human lungs declined for transplant 
and re-animating them ex vivo. Despite prolonged CITs (up to 39 hours in individual 
cases) these lungs do not demonstrate evidence of physiological deterioration or 
histological injury after 8 hours of normothermic EVLP. 
 We have refined our method of LPS administration such that we are able reliably 
to induce release of pro-inflammatory cytokines in the alveolar space. This is associated 
with influx of donor neutrophils and pulmonary oedema, as evidence by elevated wet:dry 
ratios in LPS treated lungs. However, there was no histological evidence of ALI.  
 Method development designed to facilitate pharmacological study in ex vivo lungs 
demonstrated that dose-response-experiments in single lobes are limited by sampling error 
 
5.5 Discussion 
5.5.1 Model Development 
 We used group-specific healthy volunteer whole blood added at a ratio of 1:10 to 
the perfusate based on published methodology from the UCSF group.  Autologous whole 
blood was not available due to logistical and ethical considerations. The addition of whole 
blood was critical to induce impaired AFC (Lee et al., 2009) and it would seem likely, that 
neutrophil infiltration into the alveolar space is dependent on the presence of circulating 
neutrophils (and possibly monocytes and platelets, chapter1.4.4.4) (Abraham et al., 2000; 
Folkesson et al., 1995; Folz et al., 1999; Kawabata et al., 2000; Looney et al., 2006; 
Shimizu et al., 2009). In the study by Lee et al, the majority of experiments were 
performed using blood donated by AB, Rh+ volunteers. Despite this, no adverse changes 
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in lung physiology or endothelial permeability in control lung lobes were observed 
suggesting that, for short term study at least, non-matched whole blood can be used.  
 Currently, there exist 2 clinical methods of EVLP; the ‘Toronto’ method using a 
closed system and an acellular perfusate (Cypel et al., 2011; Cypel et al., 2008) and the 
‘Lund’ method applying an open system with the addition of matched red cells to the 
perfusate (Ingemansson et al., 2009).  We prioritised technical simplicity and were 
discouraged from using the closed system by initial experiences suggesting that the need 
for an intact left atrial cuff added a premium to the number of available lungs. 
Maintenance of a positive left atrial (LA) pressure of 3-5mmHg may, however, be vital. 
This small, but positive LA pressure may prevent collapse of distal veins during 
inspiration (Petak et al., 2002), whilst stabilizing alveolar geometry and lung compliance 
(Broccard et al., 2002). In the only published series of prolonged EVLP, application of a 
closed system with protective ventilation maintained stable lung function over 12 hours in 
human lungs and demonstrated good lung function and low levels of oedema in porcine 
lungs perfused for 12 hours subsequently transplanted into recipient pigs (Cypel et al., 
2008). Despite employing an open system, we demonstrated stable physiology with no 
evidence of injury over 8 hours EVLP (figures 5.3 and 5.4). Nonetheless, for future 
experiments requiring longer durations of EVLP, for example investigation of the kinetics 
of cytokine release in LPS injured lungs, reverting to a closed system may be optimal.  
5.5.2 The impact of prolonged cold ischaemia 
 Prolonged CITs have variably been associated with poor outcomes. Whilst 
some studies concluded that graft CIT was not an independent predictor of increased 
adverse outcomes (Gammie et al., 1999; Fiser et al., 2001) except with donors over 50 
years (Meyer et al., 2000) other clinical and experimental studies have suggested that 
CITs beyond periods as short as 5 hours are detrimental (Snell et al., 1996; Fischer et al., 
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2000). Moreover, in patients with reperfusion oedema after lung transplantation, a 
correlation was found between CIT and capillary-alveolar protein permeability (Ware et 
al., 1999) and in a human EVLP model, prolonged CIT was associated with alveolar 
epithelial injury as evidenced by submaximal alveolar fluid clearance and higher levels of 
RAGE (Briot et al., 2009). We adopted a pragmatic approach to CIT in our model. Our 
protocol targeted a CIT of less than 36 hours, as this seemed a practical compromise that 
increased the potential donor pool such that we could select lungs in younger donors and 
with better baseline gas exchange that might have prolonged CITs.  
Our lungs did not demonstrate histological evidence of injury (figure 5.4) nor 
baseline inflammation (figures 5.5 and 5.6) despite a mean CIT of 34 hours (table 5.1). 
However, previous data has suggested that many lungs rejected for transplantation based 
on conventional clinical criteria did not demonstrate significant histological abnormalities 
nor did they demonstrate abnormal alveolar epithelial fluid transport capacity (Ware et al., 
2002). We were also unable to definitively confirm that our lungs, despite the presence of 
structural integrity, were biologically viable. Previous data suggest that, at least in porcine 
lung, 12 hours of EVLP allows successful transplantation with good organ function(Cypel 
et al., 2008). Such categorical proof is clearly not logistically feasible in experimental 
human lungs. Nonetheless, as surrogate markers of viability, we have been able to culture 
hAT2 after 8 hours EVLP and have maintained precision cut lung slices (PCLS) from 
EVLP in vitro for a further 3-4 days with no loss of viability as measured by lactate 
dehydrogenase release and synthesis of surfactant lipids (data not shown).  
Previous studies by the group at UCSF have used baseline AFC as both a marker 
of suitability for experimentation and as an outcome measure in interventional studies 
(Lee et al., 2009; Briot et al., 2009; Lee et al., 2013). They were able to demonstrate 
firstly that perfusion per se increased AFC 4-fold and that the basal AFC rate (Frank et 
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al., 2007) was comparable to that measured in other species (Matthay et al., 2002). 
Moreover, the AFC determined in their model was comparable to estimated AFC rates in 
patients with pulmonary oedema (Ware and Matthay, 2001; Verghese et al., 1999). It is 
notable that AFC was preserved, despite the absence of a pulmonary flush with 
preservation solution prior to cold storage; this has been developed to both cool the lungs 
(to reduce metabolic activity during transport) and provide endothelial protection in the 
immediate post-transplantation phase (de Perrot and Keshavjee, 2003). In initial 
experiments, we attempted to use AFC as a baseline measure of suitability for 
experimentation and baseline injury. However, we were unable to reliably reproduce the 
published methodology (Lee et al., 2009; Frank et al., 2007). We therefore used computed 
tomography assessment of interstitial oedema as a clinically relevant index of baseline 
injury and ‘leak’ (data not shown) prior to our interventional studies. 
5.5.3 Endotoxin induced acute lung injury 
 We developed a reproducible E. coli endotoxin-induced ALI model in human ex 
vivo lung preparation perfused partially with group matched donor whole blood. 
Instillation of LPS into the distal airspaces of the right lower lobe increased lung water 
(figure 5.6A) and induced an acute neutrophilic inflammatory response within the injured 
alveolus (figure 5.7) associated with elevated levels of IL-1β, TNF, and IL-8 (figure 5.5), 
the most biologically active cytokines found in ALI pulmonary edema fluid (Ware and 
Matthay, 2000).  
  In the only comparative ex vivo model, Lee et al (Lee et al., 2009) demonstrated 
similar trends in cytokine release and an associated neutrophilic alveolitis but at an 
approximately 10-fold higher magnitude in both control and LPS injured lungs; in their 
analysis, both the cytokine concentrations and neutrophil counts were multiplied by the 
volume of BAL injectate (125mL). In parallel with our findings (figure 5.4), they did not 
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demonstrate significant histological injury other than neutrophil infiltration into the 
alveolar space, suggesting that whilst sufficient to induce a neutrophilic alveolitis both the 
concentration of endotoxin and the duration of assessment may be insufficient to induce 
classical histological changes of ALI such as a denuded basement membrane and hyaline 
membrane formation (chapter 1.1.2.1). Absence of loss of alveolar type 1 cells or 
proliferation of alveolar type 2 cells was further confirmed in tissue sections examined by 
transmission electron microscopy (data not shown). The absence of significant alveolar 
epithelial damage is similarly demonstrated in currently available animal models of ALI 
(Bastarache and Blackwell, 2009; Matute-Bello et al., 2008; Ware, 2008) and represents 
one of the major failings and indeed criticisms of current ALI modeling (Matute-Bello et 
al., 2008).    
 In vivo human data using intra-tracheal administration of LPS at doses ranging 
from 1 to 4 ng/kg similarly demonstrated increases in BALF neutrophils and IL-1β, TNF, 
and IL-8 (as well as other neutrophil chemokines) (O'Grady et al., 2001). This effect 
peaked at 6-8 hours and was associated with increased permeability to protein and 
albumin. Interestingly, the authors also noticed an increase in both TNFR1 and TNFR2 in 
the BALF, an effect which was sustained for 24 hours; whilst we noticed a trend towards 
elevated TNFR release at 2 hours, this was not sustained at 4 hours (figure 5.5). CMS and 
TNF treated hAT2 in vitro did not release significant TNFR (figure 3.8) suggesting that 
TNFR release into the BALF may originate from the systemic circulation as opposed to 
direct epithelial injury.   
 We could not demonstrate activation of the STAT pathway or upstream signalling 
kinases such as p38 MAP kinase in LPS injured lungs (figure 5.10). The STAT family of 
transcription factors (as well as NF-κB, MAPK, and phosphotidylinositol 3-kinase 
pathways) have been shown to participate in mediating lung inflammatory responses 
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(Severgnini et al., 2004; Rahman and MacNee, 1998), in particular the host response to 
LPS (Kovarik et al., 1998). Indeed in 3 different murine models of ALI including intra-
peritoneal LPS, STAT activation was demonstrated throughout the lung in resident cells 
as well as recruited inflammatory cells (Severgnini et al., 2004). Moreover, this effect 
occurred before evidence of histological lung injury or release of TNF in the BALF. 
Therefore, in the absence of demonstrable histological injury (figure 5.8B), we used 
activation of the STAT pathway as an early injury marker in our model.  
Potential reasons for the observed lack of STAT activation are multiple. First, this 
may represent sampling error. These samples in these experiments were collected using 
blind endobronchial instillation of endotoxin. The wide variation in STAT1 activation in 
our dataset (figure 5.8B) may indicate that the LPS exposure of the samples was variable 
owing to sampling error. This represents a current limitation of the model as discussed 
above. Second, HMVEC-L and murine epithelial cells treated with LPS did not 
demonstrate evidence of STAT activation (Severgnini et al., 2004) suggesting that STAT 
activation requires resident phagocytic cells, via LPS driven production of cytokines or 
ROS; LPS induced STAT activation was ROS dependent in mice and IL-6 but not TNF or 
IL-1β induced STAT activation in vitro (Severgnini et al., 2004). We did not demonstrate 
significant release of IL-6 in our model (figure 5.5). Finally, in mice, maximal pulmonary 
STAT activation was observed after that seen in the liver (Severgnini et al., 2004) 
suggesting that a hepatic acute phase response may propagate lung inflammation. Whilst 
the EVLP model affords an opportunity to investigate the lungs in isolation, the absence 
of other organs does not allow for analysis of the role of the systemic inflammatory 
response. 
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5.5.4 The ex vivo lung model as a platform for pharmacological study 
 We undertook dose response experiments (figures 5.9 & 5.10) to establish a 
method of performing dose-response studies in ex vivo lung. By virtue of the scarcity of 
resource and the current cost of obtaining human lung tissue (£1800 per set of lungs), it 
would be optimal to investigate multiple doses of a therapeutic compound in a single lung. 
Our preliminary data (figures 2.26) suggested that nebulised solutions administered to ex 
vivo lung result in homogenous distribution to distal lung. In a pilot gene transfer 
experiment, nebulisation of the combination of the cationic liposome (GL67A) and 
plasmid DNA expressing CFTR (pGM169) in porcine ex vivo lung demonstrated protein 
expression in distal lung and perfusate (data not shown) implying that nebulised 
therapeutics successfully penetrate the alveolar space in ex vivo lung models. The use of a 
double lumen endotracheal tube or bronchial blocker to obstruct specific lobes may 
facilitate analysis of a nebulised compound compared to control but nebulisation, as a 
means of drug delivery, does not generally allow for multiple dosing schedules. 
Nonetheless, the nebulised Evans blue data and these gene transfer data suggest that the 
model, in principal, holds promise for assessment of nebulised therapies.  
 Our data (figures 5.9 & 5.10) suggested that peripheral administration of 
compounds is not sufficiently sensitive to be a viable future methodology; this probably 
relates to sampling error. Moreover, for ALI models in particular, the most robust markers 
of injury appear to be BALF inflammatory cytokines and neutrophil infiltration into the 
alveolar space. Systemic administration of either an injurious agent or novel therapeutic 
into the perfusate does not allow for an internal control, one of the strong advantages of 
the current set-up. Hence, endobronchial administration of experimental therapies is the 
more promising technique for pharmacological experiments.  
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 Our current experimental design for investigation of selective TNFR1 antagonism 
in a human ex vivo ALI model is outlined in figure 5.11. We have established this model 
on 2 occasions, suggesting that the method is feasible, however, on both occasions we 
were unable to complete the protocol due to early (2 hours after LPS administration) 
pulmonary oedema affecting both lungs. Whilst a dose response is not technically 
possible, the experimental design has an internal control for both the intervention 
(GSK1995057 vs dummy domain antibody) and the injury (LPS vs vehicle), allowing a 
large volume of data to be generated from a single experiment. Furthermore, despite the 
dilution factor of the BALF and elevated levels of soluble TNFR (figure 5.5), TNF 
bioactivity was detectable during the first 4-8 hours suggesting high local lung 
concentrations of TNF. Thus, in parallel with our in vitro data, we speculate that selective 
TNFR antagonism may modulate the local inflammatory response in human ex vivo LPS 
induced ALI models.  
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Figure 5.11 Protocol for investigation of effect of selective TNFR1 antagonism in LPS 
injured ex vivo human lung 
Human lungs are rewarmed on the EVLP circuit and group-specific whole blood (150mL) added 
to the perfusate. GSK1995057 (0.2µg/mL, 10mL) or dummy domain antibody (0.2µg/mL, 10mL) 
is injected via catheters positioned in distal lung segments. After 1 hour, LPS (0.1mg/kg, 10mL) 
or vehicle control (10mL) is injected via the same catheters. Sampling of BAL and tissue is 
undertaken at 4 hours post-LPS injury. BAL: broncho-alveolar lavage, DMEM: Dulbecco’s 
modified eagle medium, HAS: human albumin solution, LPS: lipopolysaccharide, PA: pulmonary 
artery, PAP: pulmonary artery pressure, PEEP: positive end expiratory pressure, Vt: tidal volume 
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5.5.5 Harnessing the potential of ex vivo ALI models 
 The applications of our model are currently limited by the quality of lung substrate 
and the availability of lung tissue. We have now completed a total of 16 human ex vivo 
lung perfusion experiments ie. ventilation and perfusion were established, with or without 
ALI modelling, for at least 4 hours. Around 25% of our experiments were abandoned 
because the lungs developed pulmonary oedema at an early stage. This probably reflects 
the prolonged CIT in our lung substrate allied to donor factors. Furthermore, the 
frequency of lung offers was sporadic. As a result, our cumulative understanding and 
experience of the model has been hindered; by comparison, the UCSF group gain access 
to around 1 ex vivo lung per week albeit that only 10-20% of their lungs generate 
meaningful data (personal communication JW Lee, UCSF). Nonetheless, the potential of 
the model to facilitate investigation of a range of pathological processes in ALI is 
significant.  
 Our model and others’ undoubtedly recapitulate some of the key features of in vivo 
ALI in a humanized model that is highly tractable and allows temporal sampling of distal 
lung tissue.  Moreover, such models have already generated novel translational data (Lee 
et al., 2009; Lee et al., 2013), which have formed a considerable component of the 
preclinical evidence base for a phase 1 trial investigating the role of mesenchymal stem 
cells in the treatment of ALI (clinical trials number NCT01775774). It is clear that no 
model, animal or human, can replicate a multi-faceted syndrome. Nonetheless, the 
refinement of LPS human models allied with the development of alternative injury models 
(eg. acid induced injury) and data from in vivo human models such as post-
oesophagectomy or inhaled LPS, has the potential to generate meaningful data to inform 
future clinical trials in ALI. 
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 Hence a mechanism to gain access to increased numbers of donor lungs with 
shorter CITs would be desirable. To this end, we have submitted an ethics application 
with NHS Blood & Transplant to allow us to gain access to lungs from brain-dead donors 
in UK hospitals who have consented for donation of their organs for research purposes, if 
rejected for solid organ transplantation.  The resulting increase in tissue availability and 
significantly shorter CITs would enable us to adopt a more rigorous approach to assessing 
and characterising organs, such that the best lungs will be used for complex functional 
experiments.  
5.6  Future directions 
 The immediate aim is to complete experiments investigating selective TNFR1 
antagonism in LPS injured ex vivo human lung to complement much of the in vitro data 
generated from work in this thesis. In particular, the effect of GSK1995057 on neutrophil 
migration into the alveolar space in an ex vivo model merits further study.  
 Subsequently, we plan to extend our own in vitro and others’ animal in vivo 
observations regarding cellular trafficking in pulmonary inflammation into an ex vivo 
human model. For example, recruitment of neutrophils to the pulmonary interstitium in 
animal models is both platelet and monocyte dependent (Pitchford et al., 2003; Kreisel et 
al., 2010; Kornerup et al., 2010). Combining our ALI model with collaborators’ 
experience with ex vivo radiolabelling techniques, nuclear imaging and two-photon 
intravital microscopy may allow novel mechanistic insights into inflammatory cell 
trafficking in human lung.  
 We have based our model almost entirely on published methodology from the 
UCSF group, using LPS as the injurious stimulus. With increasing experience of the 
technique, ideally in the context of greater throughput of human lungs, there exists the 
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potential to develop alternative injury models such as human gastric acid aspiration and 
live bacteria to broaden the translational potential of the platform. 
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6 Chapter 6: General Discussions 
6.1 Summary of important results 
 TNF induced release of IL-8, IL-6 and GM-CSF from lung alveolar epithelial cells 
and lung microvascular endothelial cells, was predominantly controlled by TNFR1 
signalling. Pre-treatment of lung microvascular cells with the selective TNFR1 antagonist 
GSK1995057 had no effect on IL-10 release from TNF stimulated cells, whereas dual 
TNFR blockade reduced IL-10 release to basal levels, suggesting that IL-10 release may 
be predominantly controlled by TNFR2 signalling.  
Cyclic mechanical strain induced release of IL-8, IL-6, and IL-1β from hAT2 but 
this effect did not appear to be mediated by either TNFR. There was no effect of CMS on 
either sTNR1 or sTNFR2 release, suggesting that sTNFR release in clinical studies (of 
high versus low tidal volume ventilation) does not originate directly from the effect of 
mechanical stimulation of the alveolar epithelium. 
Neither TNF alone nor differential TNFR signalling affected wound healing in 
hAT2. In human umbilical vein endothelial cells, TNFR2 signalling promoted tube 
formation but this effect was not paralleled in cells from the lung microvascular 
endothelium. 
The TNFR1 signalling pathway mediated lung microvascular cell injury, measured 
as decreased in trans-endothelial resistance in HMVEC-L and shedding of sICAM-1, 
sVCAM-1 and sE-selectin. Similarly, up-regulation of the neutrophil adhesion molecules 
ICAM-1, VCAM-1 and E-selectin (indicative of endothelial cell activation) was TNFR1 
signalling-dependent. Accordingly, selective TNFR1 antagonism ameliorated neutrophil 
migration through HMVEC-L monolayers, an effect that may be due to blockade of up-
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regulation of these neutrophil adhesion molecules although further functional studies, 
(discussed in chapter 6.4), are required. 
 TNFR1 signalling played key roles in neutrophil priming, activation, and cell fate.  
Hence, TNFR1 was the main receptor mediating TNF-induced alterations in neutrophil 
cell surface molecule expression, modulating changes in CD11b, CD62L, TNFR1 and 
TNFR2. TNFR1 was also the dominant receptor mediating TNF-induced reactive oxygen 
species production.  The role of TNF receptors in modulating neutrophil apoptosis was 
examined; whilst engagement of both receptors was required to induce early neutrophil 
apoptosis, TNFR1 antagonism reversed TNF induced late survival to constitutive levels of 
apoptosis. In contrast to previous animal studies, we found no evidence that TNFR2 
signalling modulated neutrophil priming (measured by ROS generation and cell surface 
molecule expression). 
 In an attempt to generate translational data investigating the effects of differential 
TNFR1 signalling, we established a human ex vivo model of ALI. Using human lungs 
declined for transplant, we used an LPS method of injury based on previously published 
methods. We were able reliably to induce release of the pro-inflammatory cytokines TNF, 
IL-8, IL-6 and IL-1β in the alveolar space. This was associated with a significant influx of 
healthy donor neutrophils and pulmonary oedema in LPS injured lung compared to 
control treated contralateral lung, despite the absence of histological evidence of ALI. 
Unfortunately our attempts to investigate the effects of TNFR1 antagonism on neutrophil 
migration into the alveolar space in this model have been unsuccessful to date but study is 
on-going. 
 In summary, these data suggest that TNFR1 has a central role in multiple phases of 
neutrophil transmigration from the lung microvasculature into the alveolar space. 
Additionally, TNFR1 signalling may play key roles in TNF mediated neutrophil priming, 
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activation, and cell fate (summarised in figure 6.1). Hence, neutrophils are attracted to 
sites of injured microvascular endothelium down a chemotactic gradient in both the 
vascular and alveolar compartments; chemokine production appears to be regulated via 
TNFR1 signalling. Owing to priming induced shape-change and TNFR1 induced changes 
in cell surface adhesion molecules on both neutrophils and lung endothelial cells, 
neutrophils arrest in the pulmonary circulation before transmigrating to the alveolar space. 
TNFR1 signalling may promote neutrophil transmigration through the lung microvascular 
endothelium through endothelial cell activation and TNFR1 induced gap junction 
formation. Once in the alveolar space, neutrophils further propagate injury via TNFR1 
driven respiratory burst. Neutrophilic alveolitis is perpetuated by TNF induced survival 
signalling, a process, which is also probably TNFR1 mediated.  
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Figure 6.1 Summary of important results of this thesis and potential effects of selective 
TNFR1 antagonism on neutrophilic alveolitis in ALI 
The annotation in red highlight processes that may potentially be modulated by selective TNFR1 
antagonsim 
ICAM-1 – intracellular adhesion molecule 1; JAMs – junctional adhesion molecules; PECAM - 
Platelet endothelial cell adhesion molecule; VCAM-1 - vascular cell adhesion molecule 1 
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6.2 Experimental models 
6.2.1 Co-culture experiments  
 For simplicity, we investigated differential TNFR signalling in cell monolayers 
and suspensions of purified neutrophils. Lung injury, however, is increasingly recognized 
to result from a complex interplay between cells of the alveolar capillary membrane, 
alveolar macrophages, neutrophils, monocytes and platelets.  For example, numerous 
studies have demonstrated that activated neutrophils induce inter-endothelial gap 
formation via secreted neutrophil products, through adhesion dependent mechanisms and 
by alterations in the balance between ROS and nitric oxide (Wang and Doerschuk, 2002). 
Hence, total neutrophil depletion and disruption of surface integrins or oxidant 
production, blunted lung vascular permeability increases (Gao et al., 2005; Gao et al., 
2002; Xu et al., 2002). Intriguingly, neutrophil migration has also been shown to trigger 
repair of alveolar epithelial cells after transmigration induced injury (Zemans et al., 2011). 
Whilst we have demonstrated that differential TNFR signalling may affect neutrophil 
migration through TNF stimulated HMVEC-L (figure 4.12), further investigation of 
neutrophil-endothelial and neutrophil-epithelial interactions in co-culture experiments 
would further delineate the role of differential TNFR signalling in these processes. Similar 
co-culture experiments could be undertaken with platelet and neutrophil co-cultures as 
well as monocyte-neutrophil co-cultures, in particular examining the role of TNF 
signalling in platelet and monocyte adhesion molecule expression and their subsequent 
interactions with both neutrophils and the lung microvascular endothelium.  Significant in 
vitro findings, in principle, could then be translated in human ex vivo lung experiments. 
 In addition the relative role of alveolar macrophages in inflammation induced by 
mechanical ventilation could be assessed. Alveolar macrophages from the same lung 
specimens would be added to the culture medium immediately before CMS is performed 
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in hAT2 cells. Such experiments could shed light on the relative contribution of alveolar 
macrophages to cytokine and chemokine production in high stretch ventilation. 
 Alveolar epithelial permeability is critical in alveolar flooding (Wiener-Kronish et 
al., 1991) and implicated in intra-alveolar fibrin deposition and hyaline membrane 
formation (Bastarache et al., 2009), whilst preserved epithelial barrier function is 
inversely associated with patient mortality (Ware and Matthay, 2001). A dichotomous role 
for TNF in regulating alveolar permeability has been suggested. Hence, TNF inhibited 
epithelial sodium uptake, which is crucial for alveolar liquid clearance, by means of 
reducing the expression of subunits of the epithelial sodium channel ENaC (Dagenais et 
al., 2004). This effect was probably mediated by a TNFR1 and ceramide-dependent 
mechanism (Bao et al., 2007). By contrast, TNF increased alveolar fluid clearance in a rat 
pneumonia model (Rezaiguia et al., 1997). Experiments investigating the role of 
differential TNFR signalling in mediating epithelial permeability are currently on-going.  
6.2.2 siRNA knockdown of TNFR in endothelial and epithelial cells 
 Despite the large number of studies investigating TNF as a potential therapeutic 
agent, the complexity of TNF biology in ALI and in general is poorly appreciated. This 
work has confirmed that many of the potentially injurious events in TNF mediated lung 
inflammation occur through TNFR1 mediated signalling. As such, TNFR1 antagonism 
represents a potentially attractive therapeutic target. Nonetheless, we have failed to 
convincingly answer the hypothesis, based on animal studies of TNFR signalling (Bertok 
et al., 2012; Wilson et al., 2007), that selective antagonism of TNFR1 may also potentiate 
the protective effects of TNFR2 signalling. Hence, based on the data presented in this 
thesis, it is difficult to argue the putative benefits of selective TNFR1 antagonism 
compared to dual blockade of both receptors. Whilst we endeavoured to interrogate 
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TNFR2 signalling using a TNFR2 specific mutein, the results from these experiments 
were unconvincing and we could not demonstrate a TNFR2 specific signalling event.  
 The use of selective siRNA knockdown of TNFR in alveolar epithelial and lung 
microvascular endothelial cells may allow interrogation of the hypotheses that TNFR2 
signalling plays a central role in arteriogenesis (Luo et al., 2010), endothelial and 
epithelial cell apoptosis (Fontaine et al., 2002) and maintenance of the alveolar capillary 
membrane through cytoskeletal rearrangements (Hamm-Alvarez et al., 2001; Pan et al., 
2002). Whilst technically challenging, this methodology has been successfully used in 
non-pulmonary endothelial cells (Perrot-Applanat et al., 2011) and these data may more 
definitively outline the role of TNFR2 signalling in human models of ALI. 
6.3 Clinical Importance 
 Despite 40 years of investigation no pharmacotherapy can be recommended as 
standard management of ALI. Deficiencies in the translation of promising experimental 
data into clinically effective therapies may be partly explained by limitations of the 
currently available pre-clinical animal models of ALI (Matute-Bello et al., 2008; 
Bastarache and Blackwell, 2009). Failed clinical trials in ALI also probably result from 
delayed recognition of patients at risk and the subsequent development of the full-blown 
syndrome.  
 Recognising these limitations, the work in this thesis was designed to target both 
these short-comings. Hence, we have developed a tractable human ex vivo ALI model and 
translational in vitro human data underpinned by extensive animal pharmacodynamic and 
pharmacokinetic data from a novel domain antibody from GSK. Moreover, the data using 
the selective TNFR1 antagonist GSK1995057 in this thesis were generated exclusively by 
exposure of cells to GSK1995057, prior to TNF stimulation. This experimental strategy 
was employed for 3 reasons. First, data regarding the kinetics of TNF release and anti-
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TNF strategies in sepsis models (Beutler et al., 1985; DeForge et al., 1990; Tracey et al., 
1987) suggest that anti-TNF therapy in ALI (to demonstrate clinical efficacy) would need 
to be given within hours of onset of lung injury. Second, there is a growing recognition 
within the ALI scientific community that treatment of established ALI has thus far been 
unsuccessful (Kor et al., 2012; Levitt and Matthay, 2012). Contemporary clinical trials 
have largely targeted a patient population within 48 hours of meeting ARDS criteria, who 
are already requiring mechanical ventilatory support for established gas exchange 
abnormalities. The administration of preventative ALI therapies may therefore be a more 
effective treatment strategy. The application of risk stratification scoring, for example the 
Lung Injury Prevention Study (LIPS) score (Gajic et al., 2011) or informatics technology 
to identify high-risk patients (Herasevich et al., 2009) may provide an opportunity for the 
administration of therapies such as selective TNFR1 antagonism prior to the onset of the 
full-blown ARDS. Those patients undergoing elective cardiothoracic surgery who are at 
high risk of developing ALI (chapter 1.2.2.1) may represent a further cohort of patients 
that may benefit, although the safety of this approach would need to be established. Using 
this paradigm, and similarly targeting neutrophil activation and leukocyte adhesion, a 
recent multi-centre, placebo controlled, phase II trial of aspirin in patients at high risk of 
ALI (defined by LIPS scoring) has recently commenced in the USA (Kor et al., 2012).  
Third, in established ALI owing to loss of surfactant, a large volume of dependent lung 
becomes collapsed and consolidated (chapter 1.1.2) thus reducing the likelihood of 
inhaled compounds accessing the most severely injured lung units. This observation was 
cited as one of the reasons that inhaled albuterol failed to improve outcomes (ventilator-
free days) in a recent clinical trial, despite protocol design to ensure optimal alveolar drug 
delivery (Matthay et al., 2011). Indeed, in this trial, albuterol could be measured 
systemically, suggesting that the majority of drug was delivered to non-injured alveoli 
allowing systemic absorption. Our own data (chapter 2.2.12.7) demonstrated that 
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nebulization of dye to normal lung resulted in homogenous distribution throughout distal 
lung ex vivo, suggesting that administration of prophylactic inhaled GSK1995057 
(assuming droplet size and administration method were optimized) would reach distal 
lung prior to the onset of injury.  Not only would this possibly confer protection to the 
alveolar capillary epithelium, but any compound absorbed systemically would be at 
maximal concentration in the lung microvasculature where the putative benefits outlined 
in figure 6.1 could be realised. 
 Hence, the effect in vivo of selective TNFR1 antagonism as a preventative therapy 
to modulate neutrophil migration in the lung was recently highlighted in an inhaled LPS 
model of ALI (O'Kane et al., 2013; Proudfoot et al., 2014). Healthy volunteers were 
randomised to nebulized GSK1995057 or placebo, 1 hour prior to administration of 
inhaled LPS. Inhalation of GSK1995057 was associated with a trend towards reduced 
BAL neutrophilia with significant reductions in BAL cytokines and chemokines. 
Interestingly, and in parallel with our in vitro data, inhaled GSK1995057 appeared to 
reduce endothelial activation as evidenced by reduced BALF levels of the endothelial 
injury marker von Willebrand factor. This study also demonstrated that single doses of 
inhaled GSK1995057 in healthy subjects had an acceptable safety profile, was well 
tolerated, and demonstrated reproducible pharmacokinetic and pharmacodynamics data 
(Proudfoot et al., 2014; O'Kane et al., 2013). 
6.4 Future Directions 
  Given the absence of available pharmacological interventions, there is a clear and 
urgent need for novel therapies in ARDS. The work from this thesis, combined with 
extensive animal data from GSK (unpublished data) and in vivo human data from the 
McAuley group in Belfast (O'Kane et al., 2013) suggest that leukocyte-endothelial 
interactions and endothelial activation are potential targets for selective TNFR1 inhibition 
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in clinical trials. Accordingly a multi-centre phase II trial of selective TNFR1 inhibition as 
prophylaxis against ALI in oesophagectomy patients will commence in October 2014. 
Further mechanistic insight is nonetheless required.  
 Our collaborators at Cambridge University have established a neutrophil-
endothelial flow chamber system whereby neutrophils are passed over monolayers of 
HMVEC-L at variable flow rates and video-microscopy used to quantify neutrophil 
migration. This assay would allow interrogation of the effects of selective TNFR1 
antagonism (and TNFR1 agonism) on leukocyte migration under flow conditions, and 
may be more representative of in vivo neutrophil-endothelial interactions.  The 
mechanism of any TNFR1-mediated effect in the flow-based assay could be further 
explored using selective TNFR knockout mice, or mice treated with GSK1995057 
combined with two-photon intra-vital lung microscopy techniques. Expertise with these 
techniques is currently being developed with our collaborators. 
 Moreover, whilst the putative benefits of GSK1995057 induced disruption of 
TNFR1 signalling have been outlined in this thesis, the impact of preservation of TNFR2 
signalling, in our own models and others, has been limited. TNF signalling through 
TNFR2 was recently shown to be indispensably required for the protection of the skin 
against oxidative stress-induced inflammation in the zebrafish. The absence of TNFR2 
signalling in zebrafish triggered the local production of H2O2, which activated NF-κB to 
induce up-regulation of genes encoding pro-inflammatory mediators and neutrophil 
infiltration (Candel et al., 2014). Our own data suggest that IL-10 release and possibly 
tube formation are TNFR2 specific signalling events. Genomic analysis using DNA 
microarray technology of HMVEC-L treated with either GSK1995057 or the TNFR 
specific muteins may help identify candidate genes specific to the TNFR2 signalling 
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cascade, adding further insight into the potential effects (clinically appealing or indeed 
harmful) of selective TNFR1 antagonism in human cells.  
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Appendix A  
 
Figure A.1 Representative western blot for phosphorylated AKT in TNF treated human 
precision cut lung slices 
Human precision cut lung slices ∼400µm in12-well tissue culture plates containing 1ml of RPMI 
were treated with TNF (10ng/mL) in the presence of GSK057 (10nM), Adalimumab (1nM), a 
dummy dAb (10nM) and vehicle control for 30 minutes. Intracellular protein was then extracted 
and phosphorylated Akt measured in 20µg of protein by Western blotting. βActin was used as a 
loading control The above image is representative of n=2 
 
 
 
Figure A.2 Representative western blot for phosphorylated AKT in TNF treated HMVEC-L  
HMVEC-L were grown to confluenceover 72hours then treated with TNF (10ng/mL) in the 
presence of GSK057 (10nM), Adalimumab (1nM) and vehicle control or D143N (100ng/mL) 
alone for 30 minutes. Intracellular protein was then extracted and phosphorylated Akt measured in 
20µg of protein by Western blotting. βActin was used as a loading control. The above image is 
representative of n=2 
 
   D143N  Adalimumab      GSK057        TNF              Control
  
pAKT%
β'Ac)n%
   D143N  Adalimumab      GSK057         TNF             Control
  
pAKT%
β'Ac)n%
266 
 
 
 
Figure A.3 Representative western blot for phosphorylated Etk in TNF treated HMVEC-L  
HMVEC-L were grown to confluenceover 72hours then treated with TNF (10ng/mL) in the 
presence of GSK057 (10nM, n=2), Adalimumab (1nM) and vehicle control or R32W (100ng/mL) 
and D143N (100ng/mL, n=2) alone for 30 minutes. Intracellular protein was then extracted and 
phosphorylated Etk measured in 20µg of protein by Western blotting. The above image is 
representative of n=3 
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Appendix B  
 
Lung Recovery Protocol (21) 
Background	  
The	  purpose	  of	  our	  research	  is	  to	  take	  whole	  human	  lungs	  and	  re-­‐animate	  them	  ex	  vivo	  
by	   ventilating	   and	   perfusing	   both	   lungs	   on	   a	   specially	   designed	   ex-­‐vivo	   circuit.	   We	  
therefore	   require	   specific	   anatomy	  and	  hence	  a	   tight	  harvesting	  protocol	   to	  enable	  us	  
insert	  a	  large	  pulmonary	  artery	  cannula	  and	  endotracheal	  tube.	  	  
Surgical	  Recovery	  Instructions	  	  
• Administer systemic heparin 25000iu IV 
• Flush lungs (via pulmonary trunk) in situ with 1 litre of cold preservation solution (ideal – perfadex but 
alternatives eg. UW satisfactory)  
• Harvest en bloc lungs as per double lung transplant methodology 
• It is absolutely mandatory that we have at least 3-4cm of intact pulmonary trunk (see images 
below)  
• Dissect as close to pulmonary valve as possible  
o This will require dissection of pulmonary trunk from aorta 
• The pulmonary venous circulation can be incomplete 
• Minimum  3cm trachea  
• The lungs must be free of contusions or air leaks 
o We ventilate the lungs on arrival in the UK  
• The en bloc lungs should be placed in a bag on ice 
	  
Special	  Instructions	  
• Please	   leave	  out	  any	  type	  of	   identifying	  donor	   information	   including,	  donor	  chart	  
and	  labelling	  stickers.	  
• Fax	  donor	  chart	  to	  IIAM	  at	  (732)	  661-­‐2527	  within	  24	  hours	  of	  cross	  clamp	  time.	  	  
Researcher	  Synopsis	  
268 
 
 
The	  researcher	  will	  utilize	  the	  lung	  to	  enhance	  their	  understanding	  of	  the	  pathogenisis	  of	  
lung	  diseases	  with	  the	  hopes	  of	  revealing	  novel	  therapeutic	  targets.	  
Images	  for	  Reference	  
We	  require	   the	  pulmonary	   trunk	  not	   the	  right	  or	   left	  PA	  as	  we	  need	  to	  homogenously	  
perfuse	  both	  lungs	  simultaneously	  via	  a	  single	  cannula	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Appendix C  
 
International Institute for the Advancement of Medicine (IIAM) 
Research Biomaterials Policy 
I. PURPOSE 
To provide non-transplantable, human biomaterials for medical research, education and      
development, and other uses demonstrating scientific merit. 
II. AVAILABILITY 
All requests for biomaterials will be considered. Availability will be contingent on donor referrals 
and criteria. 
III. PROCEDURE 
All applicants must complete and submit the IIAM Application/Biomaterials Transfer Agreement 
(BMTA), and Exhibits A-C. 
IV. BIOMATERIALS USE 
Biomaterials shall be used only for the purposes cited in the Application, and may not be 
transferred to a 3rd party without prior written authorization from IIAM. 
V. RESEARCH PRECAUTIONS 
IIAM will provide documentation of serological test results, and other donor demographic 
information. Researcher is responsible for using appropriate precautions in handling human 
biomaterials. 
VI. RECORD KEEPING 
Applicant agrees to maintain and provide upon request by IIAM a timely and complete accounting 
of biomaterials received. This information shall be used in part to ensure adequate tracking of 
biomaterials, and can be made available for inspection by any regulatory agency. Upon approval 
of IIAM’s Application Review Committee, an executed copy of the BMTA will be returned to the 
applicant/researcher, and biomaterial placement will commence. 
VII. ACKNOWLEDGEMENT  
All researchers must acknowledge IIAM in any presentations or publications. A copy of any 
published material should be forwarded to IIAM. 
I.   APPLICANT DATA  
Name of Researcher: Dr Mark Griffiths    Phone (day): 0044 (0)2073518523 
Ext 2030 
Edison Corporate 
Center 
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Institution Name or Corporation Name: Royal Brompton Hospital (Nights/weekends):  
0044(0)7875999126 
Is institution a non-profit organization?     Yes      No  Fax:  
n/a___________________________________ 
Name and mailing address: c/o AICU____________________  E-mail address: 
m.griffiths@imperial.ac.uk___ 
Royal Brompton Hospital  Addt’l contact: Dr Alastair 
Proudfoot_____________ 
Sydney Street   Phone 
(day): 0044 (0)2073518523 Ext 8528______ 
London SW3 6NP, United Kingdom  (Nights/weekends): 0044 
(0)7779011194________ 
II. HUMAN BIOMATERIALS 
 
Description of Biomaterials requested:  Whole human lungs with intact trachea, bronchi, 
pulmonary arteries and cuff of left atrium sufficient to attach a perfusion cannula (as large as 
possible). Intact vagus nerve. 1 unit (250mL) of autologous whole blood.   
          
 
Specimen size or weight:   Any suitable adult lungs (>16 years of age), donor weight >30kg 
    
Number of samples, frequency & duration, proposed start date: As required – we are likely to 
request around one per week, maximally two per week. During academic holiday periods eg 
Christmas, Easter etc. Depending on the success of our study, we will use lungs for a minimum 
of 18 months. We plan to start as soon as possible – ideally mid September (13th) if possible.
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Preferred Source(s) of Specimens and Condition of Biomaterials Requested: 
 Organ donor (from IIAM’s Organ Division only): non-transplantable organs recovered under 
sterile conditions within  
         0-60 minutes of cessation of cardiovascular circulation, and typically delivered to researcher 
within 12-48 hours from aortic cross-clamp. Please indicate acceptable time from cross-clamp to 
delivery; up to ____ hours 
 Deceased donor (from IIAM’s Anatomical Division only): biomaterials are typically recovered 
under clean, non-sterile  
         conditions within 24-96 hours post-mortem. Please indicate acceptable period of post-mortem 
time; up to ____ hours 
 
Disease Screening: 
IIAM requires that all biomaterials provided for research are obtained from donors after receiving appropriate 
consent or authorization for donation, a detailed medical/social history screening and serological testing. 
Serological testing is included as part of IIAM’s service, and is administered for:  
Organ Division: Anti-HIV I-II, HBsAg, HBcAb, Anti-HCV, Anti-HTLV I-II, RPR, Anti-CMV and EBV  
Anatomical Division: Anti-HIV I-II, HBsAg, Anti-HCV, RPR, and HB core Antibody IgM  
These test results can be provided to Applicant if desired but should never be considered conclusive. 
Biomaterials from a donor testing positive for any of the infectious diseases (e.g. Anti-HCV) in the standard 
panel will not be shipped unless specific written authorization is obtained from the Applicant at that time.  
Please check all that apply: 
  Standard infectious disease screening panel (listed above) 
  Please include the following tests in addition to the standard panel (extra charge): 
_________________________ 
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  Biomaterials from donors testing positive for the presence of one or more infectious agents are 
acceptable because:  
III.   PRESERVATION METHODS 
 Fresh; stored in preservation solution and shipped on wet ice. (UW and HTK are considered 
industry-standard for preservation and are the primary preservation solutions used in IIAM’s Organ 
Division. 
 Passive freezing at -20˚ C and shipped on dry ice (the primary mode of preservation used in 
IIAM’s Anatomical Division). 
*Fixative, Medium, or Other Requirements (if other than those listed above. * Researcher may 
be required to 
 supply any non-standard preservation media or fixatives):IV. RESEARCH PROJECT 
Title: Development of a Human Ex Vivo Lung Research Model 
Use of biomaterials (complete attached Exhibit A for detailed summary): Study of whole human 
lung ex vivo 
Funding Source (and identification number, if applicable): Host Institutional Funding +/- competitive 
grant (Wellcome Trust) 
Institutional Review Board (IRB) approval: If required by APPLICANT’S institution, please attach 
letter of approval or exemption from your IRB.  
IRB Alternative: If IRB approval is not required by APPLICANT’S institution, it is incumbent on the 
researcher to obtain approval from his/her supervisor or the authority designated to undertake and 
review the proposed research, whose signature is required on page 6 of the Biological Materials 
Transfer Agreement. 
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IIAM 
INTERNATIONAL INSTITUTE FOR THE ADVANCEMENT OF MEDICINE 
APPLICATION AND AGREEMENT FOR HUMAN BIOLOGICAL MATERIALS FOR 
RESEARCH USE 
 
BIOLOGICAL MATERIALS TRANSFER AGREEMENT 
 This BIOLOGICAL MATERIALS TRANSFER AGREEMENT (the Agreement) is made this 2nd 
day of ____September________(Year) _2010_______ by and between  The Royal Brompton 
Hospital_____________,  hereinafter referred to as “APPLICANT”, and the Musculoskeletal 
Transplant Foundation, a District of Columbia non-profit organization (“MTF”) acting by and through the 
International Institute for the Advancement of Medicine, an unincorporated division of MTF (“IIAM”). 
 
WHEREAS MTF, acting by and through IIAM, acquires or procures and distributes non-transplantable 
human biomaterials (hereinafter “biomaterials”) for the advancement of medical research, education, 
and development, and other approved uses; 
 
WHEREAS, APPLICANT desires IIAM’s services in obtaining such biomaterials; and 
 
WHEREAS, the parties desire to cooperate for the purposes of providing APPLICANT with such 
biomaterials, 
NOW, THEREFORE, in consideration of the premises and the mutual covenants and agreements 
hereinafter set forth and other good and valuable consideration, the receipt of which is hereby 
acknowledged, the parties hereby agree as follows: 
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1) During the term of this Agreement, IIAM will use reasonable efforts to provide biomaterials 
suitable, in its sole judgment, and that meet criteria provided by the APPLICANT in the Biomaterials 
Request Form, which is attached hereto as Exhibit B, for APPLICANT’s requirements and in the 
amounts requested.  IIAM acknowledges that APPLICANT’s needs are subject to change; such 
changes will be communicated via an updated Exhibit B. This Agreement and any transfer of 
biomaterials made pursuant hereto constitutes a limited and conditional license to APPLICANT for use 
of the biomaterials or biomaterial progeny (cells, cell lines, subcellular fractions, isolates, or 
recombinant materials, DNA, RNA, or any derivatives thereof), and use thereof shall be limited to the 
specific use set forth in APPLICANT’s Application and Agreement for Human Biological Materials for 
Research Use to which this Agreement is attached.  Uses of immortalized or cloned material are 
prohibited unless prior written consent is obtained from IIAM.  Use of human biomaterials as a therapy 
is strictly prohibited without prior written authorization from IIAM.  In addition, the APPLICANT’s use of 
biomaterials shall not be subject to any licensing, contractual, or consulting obligation to another party 
without IIAM’s prior written consent, which may be withheld in IIAM’s sole discretion, except that 
APPLICANT may share the data and results with third parties. 
2) a) APPLICANT agrees to pay service fees (“Service Fees”) to IIAM for its biomaterials 
acquisition, processing, preservation, storage and delivery charges as set forth on Exhibit C attached 
hereto, and which may be amended by IIAM from time to time, provided that any such changes in the 
Service Fees shall only be effective on 30 day written notice. 
b)  Payment terms are net thirty (30) days. 
c) APPLICANT will receive a 100% credit for the Service Fee of IIAM biomaterials if the biomaterials fall 
outside of the APPLICANT’S approved protocol, provided that the Applicant notify IIAM within 24 hours 
of receiving the biomaterials. In the event that IIAM is not notified within 24 hours of biomaterial receipt, 
the credit may be reduced by at least 50% subject to IIAM’s sole judgment.  APPLICANT shall either 
destroy the biomaterials at its facility in accordance with local, state and federal regulations or, if 
APPLICANT is unable to destroy the biomaterials, APPLICANT may return the biomaterials to IIAM, 
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with prior permission from IIAM, within five business days of delivery to APPLICANT. IIAM is 
responsible for the costs of transportation and tissue destruction in such cases 
3)       IIAM represents and warrants that it has reviewed consent or authorization for research from the 
donor or next- of-kin which was obtained, to the best of IIAM’s knowledge, in accordance with all 
applicable state and federal laws and regulations prior to recovery and distribution. IIAM will maintain 
approved protocols, consent or authorization forms for biomaterial acquisition for research. 
4)      APPLICANT hereby makes the following representations and warranties to IIAM: 
a) APPLICANT will not transfer any biomaterials or biomaterial progeny (as defined in Section 1 of the     
Agreement) received from IIAM to any third party without prior written authorization from IIAM. 
b) APPLICANT agrees to maintain and provide upon request by IIAM a timely and complete accounting 
of biomaterials being used.  This information shall be used in part to ensure adequate tracking of 
biomaterials, and may be made available for inspection by any regulatory agency. 
  c) APPLICANT or anyone on its behalf will not intentionally contact or acquire human biomaterials 
from IIAM's sources, which are available upon request, during the term of the Agreement or any 
extension thereof and for a period of three (3) years thereafter.  This restriction does not apply to those 
IIAM sources with whom the APPLICANT previously had a biomaterials acquisition or procurement 
agreement prior to the execution date of this Agreement.  Furthermore, this restriction shall not apply if 
during such period IIAM ceases to exist or ceases to engage in the supply of human biomaterials. 
 d) APPLICANT’S employees, representatives, and agents shall handle human biomaterials obtained 
under this Agreement using universal precautions, as mandated by the U.S. Occupational Safety and 
Health Administration Bloodborne Pathogens Final Standard (OSHA).  APPLICANT and its employees, 
representatives and agents shall use, handle, store and dispose of all human biomaterials supplied to 
APPLICANT pursuant to this Agreement in compliance with all applicable local, state, and federal 
statutes, laws, rules and regulations including but not limited to OSHA. 
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 e) During the term of this Agreement, APPLICANT will utilize the services of an entity authorized under 
applicable law to dispose of the biological materials provided by IIAM.  APPLICANT agrees to use the 
entity listed on the attached Biomaterials Request Form to dispose of all biological materials provided 
by IIAM to APPLICANT pursuant to this Agreement. 
 f) APPLICANT shall not use or store any biological materials in any facility other than one primarily 
used as a medical facility or laboratory (a “Medical Facility”), unless prior to utilizing such biological 
materials: (i) APPLICANT requests in writing that IIAM permit the use of such biological materials in a 
facility other than a Medical Facility (a “Non-Medical Facility”), and indicates the proposed use of such 
biological materials as well as how they will be disposed, and (ii) the owner or operator of said Non-
Medical Facility provides to IIAM a written certification that (X) such owner or operator is aware of the 
proposed use of such biological materials in said Non-Medical Facility, (Y) such owner or operator 
consents to such use in the Non-Medical Facility, and (Z) the proposed use of such biological materials 
in said Non-Medical Facility is permitted under applicable law. 
 g) APPLICANT may request that IIAM and IIAM, at its sole discretion, may agree to dispose of 
biological material provided by IIAM to APPLICANT pursuant to this Agreement.  In the event IIAM 
agrees to dispose of any such biological materials, APPLICANT shall arrange for the shipment of such 
biological materials to IIAM or an IIAM designated facility (as directed by IIAM) in accordance with all 
applicable laws, including proper wrapping and containment of all such biological materials to ensure 
their safe shipment.  APPLICANT agrees to pay all shipping costs and IIAM’s fees related to the 
disposal of any such biological materials. 
 h) APPLICANT shall not identify or attempt to identify the donor of any biomaterials provided by IIAM. 
i) All statements in the Application are complete and correct. 
5)     All shipments of biomaterials shall be made on the following terms: 
a) Shipments will be made in the best possible manner so as to preserve the quality 
of the biomaterials.   The parties hereto understand that the fragility of human biomaterials is such that 
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damage may occur during shipment; nevertheless, IIAM shall use its best efforts to comply with the 
handling and shipping protocols provided by APPLICANT. 
b) Except as otherwise expressly stated herein, all biomaterials are provided by IIAM 
“as is” and without additional warranty. ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, 
INCLUDING BUT NOT LIMITED TO WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A 
PARTICULAR PURPOSE, ARE DISCLAIMED. 
6)    APPLICANT will acknowledge IIAM as a provider of human biomaterials and agrees to provide 
IIAM with a copy of any non-confidential publication that makes reference to IIAM.  
7)     a)APPLICANT will indemnify and save harmless IIAM and their respective officers, directors, 
agents,   employees, consultants and/or IIAM's human biomaterials sources from any actual loss or 
damage resulting from the use by APPLICANT of human biomaterials specimens provided by IIAM or 
IIAM's human biomaterials sources, except for loss or damage resulting from any breach of warranties 
or representations made by IIAM in this Agreement or as a result of IIAM's gross negligence or willful 
misconduct in performing its obligations hereunder. 
b)  IIAM will indemnify and save harmless APPLICANT and its respective officers, 
directors, agents, employees,  and/or consultants from any actual loss or damage arising from IIAM's 
performance of this  
 Agreement except for loss or damage resulting from any breach of warranties or representations made 
by APPLICANT in this Agreement or as a result of APPLICANT’S gross negligence or willful 
misconduct in performing its obligations hereunder. 
8)      a) All medical or other information relating to a donor shall be treated as Confidential Information 
of each party, and notwithstanding any provision to the contrary continued herein, shall not be 
disclosed except to the extent otherwise required or permitted by law.  Both parties to this Agreement 
shall act, and shall take reasonable measures to cause their respective agents, contractors, 
employees, officers and directors to act, in accordance with all applicable laws, rules and regulations 
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regarding the confidentiality of donor specific medical information.  This obligation shall expressly 
survive termination of this Agreement. 
b) Each party understands that the other party and its agents, contractors, employees, officers and 
directors will or may be provided valuable technical and non-technical information and trade secrets 
relating to, among other things, the referral, recovery and use of biomaterials and/or medical or other 
information relating to donors (“Confidential Information”) that is proprietary and valuable to the 
disclosing party (the “Disclosing Party”) and that to protect the Disclosing Party’s legitimate interests, 
the Disclosing Party must protect such Confidential Information.  Therefore, the receiving party (the 
“Receiving Party”) will hold in confidence and not disclose to third parties or use any such Confidential 
Information except in connection with the performance of its obligations hereunder, and will take 
reasonable steps to cause its agents, contractors, employees, officers and directors to hold in 
confidence and not disclose to third parties or use any Confidential Information except in connection 
with the performance of the Receiving Party’s obligations hereunder.  The Receiving Party agrees that 
the Disclosing Party’s failure to mark any such information as “Confidential Information” shall not relieve 
the Receiving Party of its obligation to treat such information as Confidential Information.   
c) The Receiving Party shall cause each of its agents, contractors, employees and officers who 
Confidential Information to enter into a confidentiality agreement that contain confidentiality provisions 
comparable to those set forth herein. The provisions of this paragraph shall not apply to any information 
that is in the public domain, is known to the Receiving Party at the time of its disclosure, is acquired or 
developed by the Receiving Party following disclosure without violation of this Agreement or is 
disclosed by the Disclosing Party to any third party without similar non-disclosure restrictions. 
d) The Receiving Party shall promptly notify the Disclosing Party if the Receiving Party receives a 
subpoena seeking any Confidential Information so that the Disclosing Party has an opportunity to take 
appropriate action with the entity issuing the subpoena before any such Confidential Information is 
released. The parties agree that the terms and conditions of this Agreement will be considered 
Confidential Information. 
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9)    The term of this Agreement shall be one (1) year beginning on the date of execution and 
automatically continuing for further successive terms of one (1) year thereafter, unless either of the 
parties hereto shall have given to the other thirty (30) days prior written notice (by certified mail at their 
respective addresses listed at the end hereof, return receipt requested) of its intention to terminate this 
Agreement, whereupon this Agreement shall terminate thirty (30) days after receipt of such notice.  The 
Agreement may also be terminated by either party before the end of an annual term by giving the other 
thirty (30) days prior written notice of its intention to terminate this Agreement, whereupon this 
Agreement shall terminate thirty (30) days after receipt of such notice.  Termination shall not relieve the 
parties hereto of any of their obligations by the nature thereof extending past such termination. 
10)  a)    This Agreement may not be amended without the prior written consent of both parties hereto. 
b)  This Agreement and the Application attached hereto constitutes the entire agreement between the 
parties hereto relating to the subject matter hereof, and supersedes any prior agreements, written or 
oral, regarding the subject matter hereof. 
c)  This Agreement will be binding upon and inure to the benefit of the parties hereto and their 
respective heirs, successors and assignees; provided, however, that neither party shall transfer or 
assign this Agreement or their rights and obligations hereunder, including by merger or operation of 
law, with a change of control of APPLICANT constituting an assignment for purposes of this 
Agreement, without the prior written consent of the other party. 
IN WITNESS WHEREOF, the parties have executed and delivered this Agreement. 
RESEARCHER:                           MUSCULOSKELETAL TRANSPLANT 
FOUNDATION: 
Print name/title:  ____________________________                         Print name/title: 
________________________________ 
Signature: ___________________ Date:  __________                     Signature:               Date: 
____________ 
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RESPONSIBLE DEPARTMENT HEAD:    
Print name/title: ________________________________ 
Signature: _______________ Date: ________________ 
Exhibit  A- Synopsis of Research 
(to be completed by Researcher/Applicant) 
SUMMARY: 
Despite technological advances and substantial investment, current respiratory drug 
development pipelines have a high attrition rate. This, in part, relates to limitations of 
current animal models of respiratory disease which fail to recreate many of the 
pathophysiological hallmarks of human disease. Novel preclinical models and preclinical 
research based on human tissues is therefore required.  
Ex vivo lung perfusion (EVLP) is a technique used successfully in human transplantation 
to evaluate and regenerate donor lungs previously thought to be unsuitable for 
transplantation. Outside the transplant arena, the potential of human ex vivo lung 
research as a novel translational model in respiratory medicine is now being realised. Ex 
vivo modelling is functionally superior to tissue and cell-based assays. It provides 
preserved physiologic functions and conditions, inherent in the tissues and organs being 
intact. Refinement and development of human ex vivo lung models and ex vivo disease 
modelling has the potential to create more relevant, robust preclinical data.  
SPECIFIC AIM: 
We aim to establish whether an ex vivo lung perfusion model is a viable, predictable and 
reproducible translational research model.   
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Our laboratory has established in vitro models of lung injury using human tissue from 
lung resection specimens. In addition, we have developed and refined an EVLP circuit 
using porcine lung, confirming structural lung viability at twelve hours.  
 
Data gained from ex vivo human study will build on the results of current in vivo animal 
and in vitro human work, enhancing our understanding of the pathogenesis of lung 
disease and hopefully reveal novel therapeutic targets 
LONG TERM OBJECTIVE:  
Establishment of an EVLP research model will facilitate pharmacodynamic and 
pharmacokinetic study of novel agents prior to phase I study.  EVLP has the potential to 
offer a new gold standard for preclinical testing of novel therapeutics in lung disease. 
 
IIAM Biomaterials Request Form-Exhibit B (Organ Division) 
 
Date of Request 02/09/10_ Requested by Dr A Proudfoot______ Application # (IIAM Use Only)  
SHIP TO: 
 Adult Intensive Care Unit room 3078,  
 Level 3 Royal Brompton Hospital,  
 Sydney Street  
City: London State: ______ Zip: _SW3 6NP_________ 
Attention: _Alastair Proudfoot (Bleep 1109 / Ext 8528)_ Phone Number:  
Courier preferred: Please circle one:    Sterling          AirNet         Freight Services 
282 
 
 
 
Accept Weekend Deliveries? Yes ___  or No __   Accept Sunday referral for Monday delivery? Yes __or 
No __ 
BIOMATERIALS REQUESTED: Whole human lungs with intact trachea, bronchi, pulmonary 
arteries and cuff of left atrium sufficient to attach a perfusion cannula (as large as possible). 
Intact vagus nerve. 1 unit (250mL) of autologous whole blood.  
Donor Criteria: (i.e. Age, Race, Gender) Age >16 yrs <50 years, no race specification, male OR 
female  
Contraindications: (i.e. IV Drug Use, ETOH abuse) _Free from communicable diseases as 
previously  
Quantity (Please note “singles” or “pairs”): whole lungs &  trachea ______________ Frequency: As 
required by researchers – likely weekly / bi-weekly________________________ 
DISPOSAL OF MEDICAL WASTE: Disposed of by Applicant’s Designated Medical Waste Agent:  
In accordance with Local Trust Guidelines and complying with Human Tissue Act (UK; 2004)  
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Exhibit C-Fee Schedule 
Whole human Lung:                    $  857 per specimen 
 
Service Fee:                                                      $ 50 per shipment (to cover costs for 
                                                                            the shipping materials and follow-
up        forms including the Donor 
Demographic Form with all 
pertinent medical info.) 
 
Shipping:                                                           Shipping costs vary depending on 
                  weight, courier and destination.  
                                                                            Estimates available upon request. 
      Agreed as roughly $800 
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